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The Wilms’ tumour suppressor gene WT1, encodes a structurally diverse and 
multifunctional protein with tightly controlled expression throughout the 
development of several organ systems. Although initially defined as a tumor 
suppressor, WT1 has been found to be overexpressed in some cancers. How WT1 
contributes to the shift from normal to aberrant development, or from normal function 
to oncogenic function, is poorly understood. Recent studies have shown an 
abundance of bidirectional transcription across metazoan genomes suggesting that 
non-coding antisense transcripts may have important roles in cell function. WT1-AS 
transcripts are capable of positively modulating WT1 protein levels in vitro, but 
relatively little is known about the functions of these antisense transcripts in vivo. 
The aim of this thesis was to characterize the role of a highly conserved region, Mcr2, 
located upstream of human and mouse WT1. Our data suggests that Mcr2 is not 
translated into protein and is transcribed in an antisense orientation. Mcr2 was found 
partially conserved in fish and well conserved in terrestrial vertebrates. By analysing 
novel mouse strains with genetically modified Mcr2 we have identified that Mcr2 
may have a role in both fertility and embryonic survival, as well as regulating liquid 
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1.1 The Wilms’ tumour 1 gene WT1 
 
The WT1 gene encodes for multifunctional zinc finger proteins and is well known for 
its complexity. This gene is mostly conserved across vertebrates and is important in 
organ development as well as tumourigenesis. Mouse models have proved WT1 to be 
essential for normal kidney function and also for the development of other organs. In 
human, the lack or malfunction of this gene is associated with Wilms’ tumour (WT), 
as well as other solid tumours and hematological diseases. It is currently a target for 
cancer immunotherapy.  
 
 1.1.1 Identification 
Characterization of the short arm of chromosome 11, while studying constitutional 
heterozygous deletions in WAGR syndrome (Wilms’ tumour, aniridia, genitourinary 
malformations, mental retardation) (Francke et al., 1979; Riccardi 1980; Shannon 
1982), enabled the identification of 11p lost of heterozygosity (LOH) in sporadic WT 
(Fearon et al., 1984; Koufos et al., 1984; Orkin et al., 1984; Reeve et al., 1984). This 
led to identification of WT1 that was mapped to chromosome 11p 13 and cloned by 
three different groups (Call et al., 1990; Gessler et al., 1990; Rose et al., 1990). 
Further pedigree analysis of families with hereditary predisposition to WT found the 
linkage to 11p genetic markers absent, uncovering the presence of more than one WT 
predisposition locus (Huff et al., 1988; Grundy et al., 1988; Lewis et al., 1988).  
However, preliminary studies confirmed WT1 to be tissue specific (Call et al., 1990) 
and highly expressed on the developing kidney (Haber, 1990; Pritchard-Jones, 1990).  
 
Identification of the WT1 homologue in the mouse (Wt1) followed a similar route. A 
deletion encompassing the small eye (Sey) locus in the mouse model called Sey
Dey
 
which resembled the phenotype cause by the human l1pl3 WAGR deletions (see 
Section 1.1.9.1.5) (Gessler et al., 1990) contributed to the isolation and 




1.1.2 WT1 gene structure 
Both human and mouse WT1 genes span about 50 kb of the genome, comprising 10 
exons (Figure 1.1). The last four exons encode a Krüppel’ type zinc finger domain 
employed by a broad array of transcription factors that play important roles in gene 
regulation. WT1 produces four major distinct isoforms due to two alternative splicing 
events. 
 
1.1.2.1 WT1 isoforms 
WT1 gives a clear example of how, due to transcriptional and post-transcriptional 
alternative mechanisms, a plethora of protein isoforms that can each display distinct 
biological properties. Differential pre-mRNA splicing of WT1 produces a diverse 
range of mRNA species (Call et al., 1990; Dallosso et al., 2003; Gessler et al., 1990; 
Gessler et al., 1992; Haber et al., 1991). In human and in mouse the gene encodes in 
theory at least 32 different 36-62 kDa protein isoforms by a combination of 
alternative mRNA splicing (Haber et al., 1991) plus RNA editing (Sharma et al., 
1994) and non-AUG translational initiations (Bruening and Pelletier, 1996; Figure 1.1 
A).  
 
Of the known alternative splicing events two are the most well studied. One leads to 
inclusion or exclusion of exon 5 (+/- exon 5) (Figure 1.1 C) which encodes 17 amino 
acids (aa) and this splice-isoform event is conserved exclusively in mammalian 
species (Miles et al., 2003), whose exact function in vivo remains unclear given that 
mice lacking this exon do not appear to have altered development or fertility (see 
Section 1.1.9.1.4) (Natoli et al., 2002). Later studies did suggest it to be involved in 
cell survival in cell culture systems (Renshaw et al., 2004). Also it has been found 
that the +/- exon 5 ratio is altered in WTs (Baudry et al., 2002) and in acute myeloid 
leukemia (AML) (Gu et al., 2010; Siehl et al., 2004).   
 
A different splicing event takes place in exon 9 (Figure 1.1 E). This isoform arises 
from the use of an alternate 5’ splice junction at exon 9 and results in the insertion or 
omission of three aa (Lysine-Threonine-Serine, KTS) between zinc fingers 3 and 4 
(+KTS/-KTS), which modulates DNA binding specificity (Rauscher et al., 1990) and 
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subnuclear localization (Larsson et al., 1995). Transfection of constructs expressing 
differential levels of either WT1 + KTS or WT1 –KTS into two different P53 
negative cells lines shows in both cell types that WT1 –KTS induced apoptosis, 
whereas WT1 +KTS isoforms did not (Menke et al., 1997). This became relevant 
because WT1 +/- KTS ratio is altered in Fraiser syndrome (FS), where a germline 
mutation in the splice consensus sequence (resulting in reduced WT1 +KTS isoform) 
produces characteristic severe kidney and gonad developmental abnormalities in vivo 
(see Section 1.1.9.1.3) (Hammes et al., 2001). In normal tissues isoforms including 
the WT1 +KTS aa account for about 80% of the cellular mRNA, while those 
encoding +/- exon 5 account for at approximately 60% (Haber et al., 1991). The WT1 
+exon 5 splicing is exclusive from mammals, whereas the WT1 +KTS isoform is 
conserved even in lower vertebrates (Kent et al., 1995; Miles et al., 1998; 2003; 
Semba et al., 1996). The WT1 –KTS isoforms appear to function as transcription 
factors (Madden et al., 1990), whereas the WT1 +KTS isoform associate with 
splicing complexes in the nucleus and might be involved in RNA metabolism (Menke 
et al., 1998). In mammals the different WT1 isoforms were initially shown to be 
present in fixed ratios of 8.3:3.8:2.5:1 (WT1 +exon 5/+KTS : -exon 5/+KTS : +exon 
5/-KTS : -exon 5/-KTS) (Haber et al., 1991). Nevertheless, the ribonuclease 
protection assay (RPA) gave multiple bands from a very long RPA probe, making it 
difficult to discern which band identifies a particular isoform. Subsequent studies 
have re-examined the isoform ratios in different species combining reverse 
transcription-PCR (RT-PCR) and RPA assays (Kent et al., 1995). Even though these 
two techniques gave consistent results they did not confirm the expression ratios 
proposed by Haber et al., 1991. Also later studies showed that there is no differences 
of isoform ratios between species and that it remains static during nephrogenesis 
(Hammes et al., 2001), giving a ratio of 1.1-1.5 for WT1 +/-KTS using the mouse 
model.Other evidence shows that ratios can change according to cell/tissue context 
(Baudry et al., 2002). It has been proposed that altered WT1 isoform ratios may be 
involved on the etiology of sporadic WT and leukemia (Baudry et al., 2002; Klamt, et 






Figure 1.1 Schematic representation of WT1 gene. Alternative start codons in exon 
1, fixed exons in black, alternative exons marked in red (A-E). Red arrows show start 
of transcription. Green boxes (I-V) represent protein functional domains described in 
the text. Figure adapted from Hohestein & Hastie, 2006. 
 
The latest splice-isoform identified was named Alternative WT1 (AWT1) (Figure 1.1 
B), and was detected in hematopoietic and renal cells. It lacks exon 1 and it arises 
through transcription from an alternative promoter located in intron 1. This protein 
has a  shorter N-terminal and smaller size, of 33 kDa, and exhibits normal 17aa and 
WT1 KTS splices as in the canonical WT1 transcripts (other isoform transcripts) 
(Dalloso et al., 2004). Although the functional consequences have not been 
elucidated, it is known that AWT1 is imprinted in the maternal allele with expression 
driven from the paternal allele. However, in WTs AWT1 is expressed on both alleles, 
an example of loss of imprinting (LOI). In addition to this alternative splicing, for the 
variety in WT1 mRNA/protein species has been reported as a result of post-
transcriptional RNA editing in exon 6 (leucine to proline at codon 280, Figure 1.1 D) 
(Sharma et al., 1994). Also the use of an upstream non-AUG (CUG) alternative 
initiation codon has been reported to happen from upstream CUG in-frame with the 
main AUG start site and (Bruening and Pelletier., 1996), producing higher molecular 
weight proteins (approximately 68 kDa). The use of alternative start codons and RNA 







1.1.3 Functional WT1 protein domains 
There are three characteristic main domains of WT1 proteins: self recognition, 
activation and repression. Self-association domains have been described within the 
first 182 aa residue (Figure 1.1 II) (Englert et al., 1995a; Reddy et al., 1995b; Holmes 
et al., 1997) although this domain is still not well understood. The amino (N) 
terminus is rich in prolines and glutamines, and resembles the transactivation or 
repression domains of other transcription factors. WT1 protein can act as an activator 
or repressor of genes. Using hybrid protein domain-mapping experiments GAL4-
fusion proteins were use to identify the transcriptional repressor domain within the N-
terminus of WT1 (Madden et al., 1993b) localized to residues 71–180 (Figure 1.1 
III). Later on, the suppression domain was further localized by cotransfection of WT1 
deletion mutants with a reporter construct to aa 92-101 (Carpenter et al., 2004). 
 
A transcriptional activation domain (residues 180-294) was characterized by transient 
cotransfection assays in a murine fibroblasts cell line (NIH3T3) of WT1 binding sites 
either side of a minimal promoter of the Platelet-derived growth factor A-chain 
(PDGF A-chain) gene (a gene transcriptionally suppressed by WT1) (Wang et al., 
1993) (Figure 1.1 IV). WT1 can activate or down-regulate transcription depending on 
cofactors present in specific cell types. Using deletion analysis revealed regions 
required for transcriptional repression (Wang et al., 1995a), although is quite 
interesting that the isoform AWT1 lacks the repression domain as well as the putative 
RNA recognition motif, self association, transcriptional repression and activation 
domains (Figure 1.1, I, II, III and IV), but the biological relevance of skipping these 
domains has not been elucidated (Dalloso et al., 2004). However, in isoforms with 
the repression domain, there occurs oligomerization which may block a repression 
domain and /or reveal an activation domain (Wang et al., 1995a). The suppression 
domain is also known to recruit a transcriptional cosuppressor, BASP1 (Carpenter et 
al., 2004). WT1 encodes a typical Krüppel-type zinc-finger protein (Figure 1.1 V) 
with affinity for GC-rich sequences that are closely related to the EGR-1 sequence. 
EGR-1 and WT1 share 67% of homology in the amino acid sequence of the zinc 
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finger domains. The N-terminal region of the WT1 zinc finger domains have been 
shown to have properties of nuclear localization signals (Englert et al., 1995a, 
Bruening et al., 1996). A potential RNA recognition motif was identified in the N-
terminus of WT1 by computer modeling by Kennedy et al., (1996), although its role 
still not proved experimentally. 
1.1.4 Transcriptional regulatory properties 
 
1.1.4.1 WT1 DNA Binding 
Interactions between proteins and DNA play an important and fundamental role in the 
regulation of gene expression. However, the mechanisms by which WT1 proteins 
select target genes to modify their expression still not fully understood. Work by 
several groups indicate that the choice of cell system, expression vector or reporter 
construct can all have an impact on the transcriptional regulators (reviewed by Menke 
et al., 1998; Little et al., 1999). This can be especially contradictory for those genes 
that are very context-dependent due to the fact that reporter constructs have shown to 
influence the activity of WT1 proteins (Reddy et al., 1995a).  So, it has been 
observed through transfection experiments that WT1 can either enhance or repress the 
expression of specific targets or gene constructs depending on where the WT1 
binding site is in relation to the transcriptional start site, as well as which cell type is 
employed and how the experiments were performed (Laity et al., 2000; Lee and 
Pelletier, 2001; Reddy et al., 1995a; Wang et al., 1995b).  
 
Studies identified specific sequences that might be hot spots of interaction between 
WT1 and DNA. By its four zinc fingers, WT1 can bind to a variety of GC-rich 
sequences, for example, the early growth reponse-1 (EGR1) DNA sequence binding 
sites (5'-GNGNGGGNG-3') (Rauscher et al., 1993), and the WT1 high affinity 10 bp 
site (5'-GCGTGGGAGT-3') or (TCC) motif (Wang et al., 1993). These sites are 
linked with WT1-dependent genes that can be up or down regulated as it has been 
found in vitro (Hamilton et al., 1995; Nakagama et al., 1995). Earlier studies 
proposed that binding sequences are likely to be isoform specific. The WT1 +KTS 
isoform binds the consensus sequence 5'-GCGGGGGCG-3', where the WT1-KTS 
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does not (Rauscher et al., 1993). More recent studies have demonstrated stronger 
binding (including both WT1+/-KTS) to a series of longer sites defined as 5′-GCG-
(T/G)GG-GG-(G/G)(A/G)(T/G)-3′ (Borel, et al., 1996; Hamilton et al., 1995), where 
this 12-base pair site defines more accurately the topological  binding of the four zinc 
fingers, with each zinc finger binding to a 3-base pair triplet (Pavletich et al., 1991).  
 
In a recent report Hartwig et al., (2010), analyzed WT1 targets in nephron progenitor 
cells in embryonic explants. A pool of 1663 candidate genes were obtained by 
looking for a EGR1 DNA consensus site under bioinformatic analyses.  Co-
immunopresipited-PCR was used to indicate biological significance together with a 
novel in vivo model, using modified WT1 morpholino loss-of-function in embryonic 
kidney explants. By this triangulation of techniques the result was a corroboration of 
genes previously identified as WT1 targets in the developing nephron such as: Bmp7, 
Pax-2 and Sall1. Additionally, other 8 novel candidates were found Cxxc5, Lsp1 , 
Pbx2, Plxdc2 ,Rps6ka3, Fgfr3, Scx , Sox11.  
 
1.1.4.2 WT1 in RNA binding 
In eukaryotic cells, numerous RNA binding proteins and small RNAs play key roles 
in the post-transcriptional regulation of gene expression, including pre-mRNA 
splicing and polyadenylation. RNA binding proteins can also form stable 
ribonucleoprotein (RNP) complexes that transport and localize RNAs. Mutations in 
RNA binding proteins are known to account for some genetic disorders and, 
potentially, malignancy (reviewed in Burd and Dreyfuss, 1994). Suggesting the 
possible participation of WT1 in RNA processing, Larsson et al., (1995), showed 
subnuclear co-localization of WT1 and small nuclear RNP (snRNP) proteins in 
“speckles” and coiled bodies inthat was splice-isoform dependent. The highest 
affinity binding was seen for the WT1 +KTS isoforms. Furthermore, computer 
modeling has identified a putative RNA recognition motif at aa 11-72 (Kennedy et 
al., 1996). In subsequent studies WT1 +KTS protein was shown to be directly 
associated with the ubiquitous splicing factor, U2AF65 which is part of the splicing 
machinery (Davies et al., 1998). Apparently this interaction does not require the first 
180 aa implying that RNA binding is not essential for interaction with U2AF65 so 
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another part of the protein might be required for this interaction. Subsequent analysis 
has shown that WT1 co-purifies by chromatography with nuclear proteins present in 
large (>2mDa) RNP complexes (Ladomery et al., 1999).  
 
Both WT1 +/- KTS protein were shown to be able to bind the IGF2 (insulin-like 
growth factor type-2) exon 2 mRNA transcript as an RNA-protein interaction 
(Caricasole et al., 1996), mediated by the zinc finger motifs that bind to a target site 
overlapping (but not identical to) that for DNA binding. Moreover, via RNA-RNA 
interaction WTl may be autoregulatory (Moorwood et al., 1999), the WT1 locus is 
complex and is characterized by antisense transcription of RNA initially called WIT-1 
(Huang et al., 1990), which is expressed in the same temporal and spatial manner as 
WT1 protein (Yeger et al., 1992; Moorwood et al., 1998). Later on the same region 
renamed as WT1 antisense (WT1-AS) was shown to be transcribed from a promoter 
located in WT1 intron 1 (Figure 1.1 B). WT1 is thought to bind a complementary 
antisense in human RNA and as this is an important topic for this thesis it will be 
discussed later on in more detail. 
   
1.1.4.3 WT1 protein-protein  interactions  
Analysis of native WT1 protein from human kidney and WTs shows WT1 present in 
homodimers (approximately 120 kDa), and association in complexes of 70kDa-
80kDa, suggesting complex formation with other proteins beside WT1 (Iben and 
Roger-Pokora, 1999). WT1 can dimerise via interactions at its N-terminal domain, 
shown by yeast two-hybrid in vitro assays, GST pull-down assays and co-
immunoprecipitation (Englert et al., 1995b; Holmes et al., 1997; Reddy et al., 
1995b). Interactions are also mediated via domains within the zinc fingers (Bruening 
et al., 1996). P53 was identified by coimmunoprecipitation as a protein that interacts 
with WT1 in baby rat kidney cells expressing WT1 and from WT specimens 
(Maheswaran, 1993). The tumour suppressor p53 can associate with the first two 
zinc-fingers of WT1. When WT1 is coexpressed with wild type p53 in (p53 null), the 
interaction of exogenous p53 and WT1 prevents apoptosis of cells after UV 
irradiation (normally mediated by p53) representing an anti-apoptotic function of 
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WT1 (Maherswaran et al., 1995). Data in the literature also suggests that these two 
proteins can reciprocally modify each other’s biological activities, in WT1 this occurs 
through the zinc fingers domain. More recent studies in mice suggest that WT1 and 
p53 can cooperate in tumourigenesis (Menke et al., 2002). WT1 also forms a 
complex with the transcription factor PAX-2, which was proposed to form a 
regulatory feedback to the expression of both the PAX-2 and the WT1 genes during 
kidney development. 
 
It has been found that the Brain Acid Soluble Protein 1 (BASP1) is a WT1 
transcriptional cosuppressor (Carpenter et al., 2004). More recent studies using cell 
model mimicking the differentiating podocyte was used to show how the interaction 
between WT1-BASP1 is required for differentiation by Green et al., (2009). Both 
proteins colocalized to regulate the expression of Bak, c-myc and podocalyxin gene 
promoters, demonstrating that BASP1 can localize to gene promoters that are 
regulated by WT1.  
 
WT1-interacting protein (WTIP) was isolated by a yeast two-hybrid screen 
experiment. In a podocyte cell line, WTIP is expressed at the cell surface, as part of 
the filtration barrier of the glomeruli where WTIP is inhibiting transcriptional 
activation of WT1. (Srichai et al., 2004). Other studies have identified interactions of 
WT1 with the prostate apoptosis response factor (Par4) (Johnstone et al., 1996), the 
p53 homologues p63 and p73 (Scharnhorst et al., 2000), ubiquitin-conjugation 
enzyme 9 (Nachtigal et al., 1998), and FHL2 (Du et al., 2002), with components of 
the splicing machinery (Larsson et l., 1995), Ciao_1 (Johnstone et al., 1999) and the 
transcriptional co-activator CBP (Wang et l., 2001). So, in addition to all this WT1 
also has other roles in gene regulation dependent on interactions with several 
different proteins (reviewed by Riviera & Haber 2005; Lee and Haber2001; Wagner 




1.1.5 WT1 targets of transcriptional regulation 
WT1 isoform (e.g. AWT1), specific WT1 DNA binding site and the cell type in 
which the experiment was performed has resulted in the identification of many 
targets, that exhibit either up or downregulation of their expression (Table 1.1). It has 
been recently demonstrated that exogenous expression of WT1 in the human breast 
cancer cell lines, MDA-MB and MCF-7 and in human leukemic cell lines, can 
activate the c-Myc promoter and stimulate cellular proliferation (Han et al., 2004). In 
contrast, studies reported in HeLa cells, with the CAT reporter assays showed 
repression of the c-Myc promoter by WT1 indicating an antiapoptotic function. A role 
for WT1 in differentiation is proved by its action on the amphiregulin gene, which 
encodes a member of the epidermal growth factor family that stimulates epithelial 
branching in organ cultures of embryonic mouse kidney (Lee et al., 1999). WT1 and 
amphiregulin mRNAs are co-expressed in the podocyte layer of developing glomeruli 
in the differentiating kidney (Lee et al., 1999).  WT1 protein containing or excluding 
the WT1 +KTS amino acids inhibit expression of cyclin E, a critical step in 
promoting initiation of S phase of the cell cycle. WT1 -KTS shows the strongest 
effect, suppressing cyclin E promoter activity by 4-5 fold (Loeb et al., 2002). This 
target gene was identified by the use of inducible WT1 expression in tissue culture, 
and was confirmed by co-transfection and electro mobility shift assays (EMSA). 
Interestingly, the inhibition appears to be cell-line specific. WT1 can downregulate 
growth factor receptors such as EGFR modifying it expression of the Early Growth 
Response (EGR) family, primarily due to similarities in the consensus sequences of 
WT1 and EGR1. This introduces the possibility that WT1 activity and/or binding to 
this target sites (consensus sites are present in the cyclin E promoter) can be also 
modified by cellular context. However, the consequences of binding are most often 
mutually opposing; EGR1 activates the transcription of genes that WT1 repress 








                   Table 1.1 Selected WT1 target genes. 

























































Loeb et al., 2002 
Madden et al 1991 
Reddy et al., 1995b 
Englert et al., 1995a 
Werner et al., 1994 
Mayo et al., 1999 
Dey et al., 1994 
Ward et al., 1995 
Lee et al., 1999 
Englert et al., 1997 
McCann et al., 1995 
Ryan et al., 1995 
Dame et al., 2006 
Martinez- Estrada et al., 2010 
Martinez- Estrada et al., 2010 
Kirschner et al., 2008 
Chang et al., 2009 
Ratelade et al., 2010 
Ratelade et al., 2010 
Kirschner et al., 2006 
Madden et al., 1991 
Norden et al., 2010 
Graham et al.,  2006 
Madden et al., 1993a 
Morison  et al., 2005 




1.1.6 The functional roles of WT1 
 
1.1.6.1 WT1 as a tumour suppressor gene 
The failure of cellular mechanisms that normally control growth can result in the 
abnormal cell proliferation characteristic of cancer. WT1 is a zinc-finger transcription 
factor which regulates the expression of multiple growth factors such as colony 
stimulating factor (Harrington et al., 1993), insulin-like growth factor I (Sarfstein et 
al., 2006). Loss of WT1 inactivation leads to upregulation of these growth factors and 
the formation of WTs, leading to its original classification as a tumour suppressor 
(Little & Wells et al., 1997). WT1 appears to show lower levels of expression during 
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differentiation of the leukemic cell line K562 (Phelan et al., 1994). Also by antisense 
experiments the inactivation of WT1 in K562 cells leads to reduced proliferation 
followed by apoptosis (Algar et al., 1996).  
 
In addition to this, the ability of WT1 to induce growth suppression in vivo in mice 
might support its role as a tumour suppressor. In vitro experiments indicated that 
ectopic expression of WT1 +KTS isoforms in murine M1 leukemic cells produced 
spontaneously monocytic differentiation. The WT1/+KTS expressing cells were 
inoculated into C.B-17 scid/scid mice. Tumours arising in these mice exhibited a loss 
of ectopic WT1 protein expression and M1 cells stably expressing WT1/+KTS 
isoforms exhibited a reduction in tumour formation (Fraizer et al., 2004; Smith et al., 
2000). 
 
1.1.6.2 WT1 as an oncogene 
Oncogenesis is an abnormal process of cell proliferation. Divergently from its initial 
characterization as a tumour suppressor gene, mounting evidence suggests that WT1 
can also act as an oncogene. It has been observed that disruption of WT1 function has 
been implicated in the formation of many different tumour types. However it has 
been found that in ovarian cancer is currently reported that nuclear undisrupted WT1 
protein is observed in most serous carcinomas and also 30% of endometrioid 
carcinomas (Mandore et al., 2010). Aberrant expression might be the mechanism by 
which suggested tumour suppressor gene (TSG) function of WT1 is disrupted. In 
contrast, it has been found without mutations and overexpressed revealing putative 
role as an oncogene. Consistently with what happen with leukemia, in which 
mutations of the WT1 gene are rare, an absence of WT1 mutations in 98 different 
cancer samples of non hematopoietic origin were found (Oji et al., 2002, 2004). Since 
it is up-regulated in a variety of human cancers such as astrocytic tumours (Oji, 
2004), breast cancer (Loeb, 2001), leukemia (Miwa, 2003) and many sporadic WTs 
(Ghanem, 2000; Grubb, 1994), which accounts for ~85% of all WTs, WT1 cannot be 
classified as a TSG. Interestingly, using immunohistochemistry analysis of WT1 




How WT1 promotes oncogenic effects remains to be established, but genes that are 
key to the control of apoptosis have been highlighted as targets of WT1, including c-
myc, Bcl2, Bcl2A1, Bak, and JunB (Han et al., 2004; Mayo et al., 1999; Morrison et 
al., 2005; Simpson et al., 2006; Kim et al., 2007; Green et al., 2009; Renshaw et al., 
2004; Udtha et al., 2003). For example, exogenous expression of WT1 in the human 
breast cancer cell lines, MDAMB-468 and MCF-7 and in human leukemic K562 cells 
can activate the c-Myc promoter and stimulate cellular proliferation.  
 
The isoform +exon 5 WT1/+KTS has been associated with a strong anti-apoptotic 
response (Ito, 2006), given that an exon 5 WT1-specific siRNA induced apoptosis in 
three WT1-expressing leukemia cell lines, but not in WT1-non-expressing lymphoma 
cell line (Ito et al., 2006). Interestingly as it has been stated earlier, mice lacking this 
exon do not have a discernable abnormal phenotype which might suggest that exon 5 
plays a role directly in disease processes rather than in development. In tumours its 
expression is highly abundant which suggesting a potential therapeutically target 
(Renshaw et al., 2004). WT1 has been proposed as a prognosis marker in AML 
(Sakamoto 2009), breast cancer (Gupta et al., 2009) and endometrian ovarian cancer 
(EOC), is a putative gynecological biomarker that is differentially expressed among 
gynecological epithelia (Shimizu et al., 2000). Nuclear WT1 protein is present in 
tubal and ovarian epithelium (Shimizu et al., 2000). In contrast, WT1 is not expressed 
in endometrial epithelium in the nucleus (Shimizu et al., 2000), therefore, WT1 is 
been a potential biomarker candidate. In ovarian cancers, it is currently reported that 
nuclear WT1 protein is observed in the majority of serous carcinomas and also 30% 
of endometrioid carcinomas (Acs et al., 2004; Cathro et al., 2005; Waldstrom et al., 
2005). However, it is unclear whether this is a reflection of the actual incidence of 
WT1 protein expression in these two histotypes, or whether WT1’s efficiency as a 





1.1.7 WT1 in disease 
 
1.1.7.1 Wilms’ Tumour  
WT also known as nephroblastoma is the commonest solid tumour in childhood 
(Bennington and Beckwith, 1975) affecting 1 in 10,000 children and accounting for 
approximately 6% of all paediatric cancers (Matsunaga et al., 1981). Wilms’ tumours 
arise from aberrant differentiation of metanephric mesenchyme before age of 5. 
Current radio therapy treatment success is achieved in about 85% of cases were 
previously were uniformly lethal. 
 
Most WTs are unilateral and most likely arise from sporadic in about 10-15% of WTs 
with inactivating mutations (Coppes et al., 1993a; Varnasi et al., 1994). Most of these 
mutations include nonsense and missense changes. Sporadic mutations may 
correspond to an early event in the etiology of WT, and such have been found in 
nephrogenic rests (Park et al., 1993). Nephrogenic rests appear to be precursor lesions 
that originate from the blastema in the developing kidney and may progress to WT 
(Beckwith et al., 1990). A multi step model of WT genesis has been proposed by 
Charles and et al., (1998). WT is believed to begin from a single cell progenitor 
already transformed within a pluripotent cell population which undergoes aberrant 
differentiation. About 10% of sporadic WTs express elevated levels of an in frame 
deletion of exon 2, they may alter the transactivational function of the encoded 
protein (Haber et al., 1993b). In most of the cases of sporadic WTs the WT1 gene is 
not mutated but WT1 is still expressed at high levels. Such tumours may have 
alterations in downstream targets of WT1 or result from genetic or epigenetic 
alterations in other cellular pathways upstream to produce over expression. In a 
minority of WTs, WT1 is truncated in the DNA-binding domain. In 70% of cases the 
wild-type allele was lost, proving that this WT1 can act as a recessive tumour 
suppressor gene. Although most cases are spontaneous, small number are associated 
with hereditary predisposition such as familial WT, BWS, Denys-Drash syndrome 
(DDS), WAGR and also Fraiser Syndrome (FS) (see Table 1.2) which will be briefly 
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described next (Beckwith et al., 1969; Francke et al., 1979; Pelletier et al., 1991b; 
Weidemann et al., 1964).  
 
 
1.1.7.2 Human syndromes associated with Wilms Tumour 
A group of syndromes which involve WT1 are found to present a set of related 
features, including urogenital abnormalities and WT predisposition (Table 1.2), some 
of them will be described next. 
 
 
1.1.7.2.1 WAGR syndrome 
WAGR syndrome comprises sporadic aniridia (lack of an iris), genitourinary 
malformation, mental retardation and a high risk of developing WT (Francke et al., 
1979). Karyotype analysis detects deletions encompassing band 11p 13 in pediatric 
patients. This chromosomal deletion includes WT1 and also a gene involved in 
aniridia PAX-6. WT1 acts recessively and therefore requires a second mutation 
described as the Knudson double hit hypothesis model (Knudson, 1971). The 
increased incidence of WT in WAGR is due to any somatic WT1 mutation in kidney 
being a 2
nd
 hit, therefore WT in WAGR is an example of the role of WT1 as a TSG. 
In contrast loss of only one allele PAX-6 is necessary to result in aniridia. 
 
1.1.7.2.2 Denys-Drash syndrome 
DDS is an infrequent syndrome in children, which is characterized by nephropathy, 
genital abnormalities and a predisposition to WT (Denys 1967; Drash, 1970) also 
characterized by a focal or diffuse mesanglial sclerosis. Nephropathy generally occurs 
during the first couple of years and progresses to renal failure due to nephrotic 
syndrome by the 4
th
 year, which results in increasing proteinurea. Cases have been 
reported where children do not exhibit the full spectrum of pathological feature. 
These patients can have a normal karyotype and generally have normal developments 
of genitals. In contrast patients may have external abnormalities while presenting an 
XY karyotype where phenotype includes ambiguous genitalia and male 
pseudohermaphroditism (Little et al., 1994; Mueller, 1994; Pelletier et al., 1991a). 
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The vast majority (90%) of patients with DDS carry constitutional mutation in the 
WT1 gene, most of which are located in exons 8 and 9, (Baird et al., 1992). Mutations 
are dominant, as patients are frequently heterozygous for WT1 mutation. In contrast 
to WAGR, most individuals with classic DDS harbours missense mutations. These 
are located in the zinc finger DNA binding region (Little et al., 1995; Roger-Pokora 
et al., 2004) affect the DNA binding capability of WT1. There is a clear contrast 
between DDS and WAGR, although both display a broad variability in the severity of 
their genital abnormalities, in DDS the presence of mutated WT1 leads to a more 
severe effect on genitourinary development and a less dramatic effect when only one 
allele is lost. In addition to these differences, WAGR patients do not get renal failure 
as a consequence of mesangial sclerosis whereas DDS patients do.   
 
1.1.7.2.3 Frasier syndrome 
The current diagnosis of Frasier syndrome is usually is based on the association of 
male pseudohermaphroditism (gonadal dysgenesis), with steroid-resistant nephritic 
syndrome due to glomerular sclerosis, which progresses to end-stage renal failure 
during adolescence or adulthood. Frasier et al., (1964) described a syndrome that 
associates nephrotic syndrome (due to focal and segmental glomerular sclerosis) with 
pseudo hermaphroditism (as a result of XY gonadal dysgenesis). One of the 
differences between this and DDS is that renal failure becomes present during 
adolescence or older and gonadoblastoma and more frequent than WT (Barbaux et 
al., 1997). In FS mutations in intron 9 affect the expression of WT1–KTS from one 
allele (Bruenin et al., 1992) which modifies the normal WT1 + and – KTS ratio. 
    
1.1.7.2.4 Beckwith-Weidemann syndrome 
Beckwith-Weidemann syndrome (BWS) occurs with a frequency of 1 in 13,700 
births and is characterized by growth abnormalities, particularly unbilical hernia, 
macroglosia and gigantism with hemihypertrophy and also in association with 
neonatal hypoglycaemia, typically ear creases and pits. This condition also 
predisposes to developmental cancer including adenocortcal carninoma, 
hepatoblatoma, rhabdomyosarcoma and most often, WT (Beckwith, 1983). The 
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localization of BWS to 11p15 follows linkage analysis and association of BWS with 
chromosomal abnormalities. Furthermore, evidence for genomic imprinting in this 
region is given by loss of heterozygosity in WTs always occurring on the maternal 
allele (Schrieder et al., 1987, Williams et al., 1989). However, there are several 
imprinted genes such as H19, L1T1 and p57, which may also play a crucial role on 
this syndrome (Brown et al., 1996; Ward, 1997). 
 
Table 1.2 Comparative of WT related syndromes. 
 
Adapted from Bong-Lee et al., (2001). 
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1.1.8 WT1 in development 
The WT1 gene is important not only in cell proliferation or cancer but also in cell 
differentiation, in developmental morphogenesis and in subsequent physiological 
organ maintenance (Hastie, 1994). Indeed it expression pattern suggested for the 
normal development and homeostasis of several organs and tissues through the 
modulation of proliferation and differentiation in a cell-specific manner (reviewed by 
Dizcensa 2005; Scholz and Kirschner 2005). WT1 protein products act as 
transcriptional and post-transcriptional regulators and in consequence it shows 
fundamental roles in nephrogenesis, haematopoiesis, cardiogenesis and sex 
determination (Scharnhorst et al., 2001; Roberts 2005).   
 
In varied cell organogenic contexts WT1 expression pattern indicates that the function 
of the gene can have either negative or positive effect on proliferation and/or 
differentiation. Wt1 KO mouse proved to be essential for the normal development of 
kidney. Also in the urogenital system as gonads (Kreidberg et al., 1993), but also 
other mesothelium-derived organs such as epicardium, spleen (Herzer et al., 1999), 
adrenal glands (Moore et al., 1999), as well as in olfactory system (Wagner et al., 
2005) and neuronal tissues specifically retinal ganglia (Wagner et al., 2002). 
However, WT1 function in the kidney has received the most attention because of its 
functional role in development. 
 
1.1.8.1 Kidney Morphogenesis and function 
In Mammals and birds kidney development is characterized by induction of a 
mesenchymal to epithelial transition where three different systems are formed at 
different developmental stages. The earliest is the pronephros, with excretory 
function in larval stages in amphibians and fish and with unknown function in higher 
vertebrates. The next is the mesonephros (the excretory gland of the mammalian 
embryo), and the last metanephros (which becomes the permanent kidney). These 
correspond to three main different developmental stages, the first two stages: onset of 
nephrogenesis and the progression of nephrogenesis are both transitory, and the third  
establishment and the maintenance of normal podocyte function, which persists as a 
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functional kidney (Saxen and Sariola, 1987) (Figure 1.2).  The kidney is formed 
through the reciprocal interaction of the WT1 expressing metanephric mesenchyme 
and a caudal outgrowth from the Wollfian duct (called the ureteric bud) during 
epithelization (Figure 1.2).  
 
At mouse E11, human E34–E35 is possible to find WT1 expression but at very low 
level in uninduced metanephric mesenchyme.  However at E35-36 in humans; E10.5-
11.5 in mice, the ureteric bud arises and invades the intermediate mesoderm. In the 
beginning the Wolffian duct and the metanephric mesenchyme (which are derived 
from intermediate mesoderm) are involved in a restricted regulated manner at E11.5 
in the mouse (E36-37 in humans).  Then the mesenchymal cells condense and form 
the blastema around the uteric bud to from caps that undergo mesenchymal-epitelial 
transition (Figure 1.2, 2). The blastema then develops into the renal vesicle (Figure 
1.2, 3) and matures further via comma and S-shaped bodies into epithelial cells that 
form the proximal tubules, distal tubules and the glomerulous of the nephron. WT1 
expression is low in the developing blastema and increases in the structures known as 
the comma- and S-shaped bodies (Figure 1.2, 4-5). 
 
 In mammals, the pronephric tubules and the anterior portion of the pronephric duct 
degenerate, but the more caudal portions of the pronephric duct persist and serve as 
the central component of the excretory system. Following differentiation, WT1 
expression is generally downregulated, and restricted to the podocytes which form the 
filtration barrier within the mature glomerulous where WT1 expression will persist 
during adulthood. Three genes known to be directly controlled by WT1 in the 
podocyte include podocalyxin (Palmer et al., 2001), nephrin (Wagner, 2004), and 








Figure 1.2 Diagram representing neprhogenesis. Nephrogenic development (1-6) 
and develped nephron structure (7). A, vas afferens; B, vas efferens; C, Bowman’s 
capsule or glomerulous; D, proximal tubule; E, Loop of Henle; F distal tubule; U 
ureteric bud. Yellow cells are developing podocytes. This figure was reproduced with 
permission of the author (Menke ad Schedl, 2003).  
 
The glomerulous is responsible for blood filtration in the kidney. It consists of four 
different cell types: endothelial cells, supporting mesangial cells, and epithelial cells 
of the Bowman’s capsule (Figure. 1.2, 7-C). Coordinated cross-talk between these 
cells is required for the normal development and maintenance of the filtration barrier. 
The glomerulous is made by arrays of capillaries in a looped shape sustained by 
mesangial cells. While blood plasma is filtered through the glomerular capillary, the 
local intracapillary pressures plasma to pass through the glomeruli filtration barrier, 
which consists of three components displayed in layers: the glomerular endothelial 
cells, the basement membrane and the podocyte (Figure 1.3). The glomerular 
endothelial cells are flattened cells that regulate homeostasis and vasomotor tone 
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(Ballermann et al., 2005), and also divides the blood and tissue compartments. At this 
point filtration is not considerably highly permeable to water and small solutes. The 
endothelium completely covers the basement membrane. This second layer is a dense 
cluster of extracellular matrix components which provide local high blood pressure 
for the capillary wall. The recent finding of proteins critical for permeability highlight 
the podocytes as the ideally specialized to perform the main filtration barrier (Zenker 
et al., 2004) and interestingly is where WT1 is highly expressed during life time in 




Figure 1.3 Schematic structure of the glomerular filtration barrier. On the left 
side Bowman’s capsule shown in square. On the right plasma fluid through 
endothelial cells (red arrows) followed by basement membrane and ends up in the 
podocyte barrier (yellow arrows). This figure was reproduced with permission of the 








1.1.8.2 WT1 in gonad development and sex determination 
Typical defects of aberrant reproductive system development and impaired 
masculinisation are well defined for WAGR, Denys Drash syndrome (DDS), and FS 
as urogenital abnormalities associated with mutations in WT1 (reviewed by 
Scharnhorst et al., 2001). Also it has been shown using Wt1
–/– 
mice, that a thickening 
of the epithelium rises toward the gonad primordium at embryonic stage day 11 but 
that gonad development fails to progress further, and is followed by apoptosis. 
Further WT1/–KTS was shown to be required for the survival and proliferation of 
biopotential gonadal cells. In knock-out mice with lacking only the WT1/–KTS  
isoform gonads begin to regress by embryonic day 12.5 (Hammes et al., 2001; 
Kreidberg et al., 1993). 
 
A second role for WT1 during gonad formation occurs at the level of sex 
determination. In mammals during the early development the gonadal system has 
potential to develop either into testes or ovaries independently of external ambient 
factors. The fact that WT1 is already expressed within the undifferentiated gonad and 
lacking of WT1/ +KTS isoforms in
 
gonads specifically exhibit male-to female sex 
reversal indicate a role for WT1 in sex determination (Hammes et al., 2001). Other 
factors are involved, including as the product of the steroidogenetic factor 1 (Sf1) 
gene, and the Lim homoebox protein LHX-9.  Expression of Sry is important for the 
activation of the male differentiation pathway. In vitro experiments suggested that 
WT1 is responsible for transcriptional activation of Sry (Berta et al., 1990). As 
expected, only the “DNA binding” variant WT1/–KTS can transactivate this gene, 
since the WT1/+KTS isoforms showed no effect in cotransfection assays (Hossain 
and Saunders, 2001). Expression of Sf1 and expression of WT1 in the gonad begin at 
roughly the same time and might be dependent. Indeed, Wilhelm and Englert (2002) 
demonstrated that WT1, and more specifically both isoforms (Hammes, 2002) can 
activate the Sf1 promoter in vitro and in vivo. The programmed cell death phenotype 
in Wt1-knockout mice can be explained by a lack of Sf1 expression.  
 
 WT1 expression in Sertoli cells in testes and in granulose cells in ovaries, uterus, 
oviduct and endometrium in adulthood could indicate a third role of WT1 in the 
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maintenance of cellular functions in these reproductive cell types (Hsu et al., 1995; 
Pelletier et al., 1991a; Pritchard-Jones et al., 1990). Using a tissue specific RNA 
interference technique in Sertoli cells it shows that Wt1 expression in the germ cells 
have an anti-apoptotic role proving WT1 to be essential for survival and maturation of 
sperm (Rao et al., 2006).  
 
1.1.8.3 Hematopoiesis 
WT1 expression has been detected in foetal spleen, liver and thymus in which the 
development of blood cells takes place during gestation (Junqueira and Carneiro, 
1995). In addition, WT1 is transcribed in bone marrow, lymph nodes and peripheral 
blood throughout life suggesting that WT1 is involved in erythroid myeloid and 
lymphoid cell formation and also its maintenance (Fraizer et al., 1995; Menke et al., 
1998). Wt1 expression is mainly found in earlier stages but not in mature blood cells 
suggesting its involvement in hematopoiesis. A Wt1 knockout mouse model was 
employed to elucidate the role of Wt1 in haematopoiesis, finding that cells lacking 
WT1 were deficient in hematopoietic stem cell function making only minimal 
contribution to the hematopoietic system. 
 
Alberta et al., (2003) observed a reduction 75% in erythroid blast-forming unit, 
erythroid colony-forming unit and colony-forming unit-granulocyte macrophage-
erythroid-megakaryocyte. It was found that embryonic stem cells lacking Wt1 failed 
to contribute effectively to the developing haematopoietic system in chimeric 
embryos in a competitive situation, providing evidence a role for Wt1 in 
differentiating haematopoietic cells (Alberta et al., 2003).  Furthermore, induced 
expression of Wt1 by retroviral infection activated myelomonocytic differentiation of 
CD34 human hematopoietic progenitors and dominance of a subset of immature 
CD38/CD34 cells (Ellisen et al., 2001). In mouse, expression of Wt1 also resulted in 
an enhanced differentiation, 32D cl3 cells, were differentiated in response to 




The proposed role of Wt1 in murine hematopoiesis was challenged by King-
Underwood et al., (2005), who stated that Wt1 is not required for hematopoiesis given 
that (in experiments similar to results those shown by Alberta et al., 2003) Wt1-null 
murine fetal liver cells are capable of reconstituting hematopoiesis following 
transplantation into irradiated recipients. Also they could not establish any difference 
in in vitro colony-forming ability of wild-type and Wt1-null cells. In a transgenic 
mouse system, WT1 was detectable in adult bone marrow, but undetectable in subsets 
of different hematopoietic cells, finding no differences between the clonogenic 
potential of hematopoietic progenitor cells from the aorta-gonad-mesonephros 
between wild-type and Wt1-null. King-Underwood et al., (2005), conclude that Wt1 
is not essential for hematopoiesis in the mouse. 
 
 Even though the primary role of Wt1 in the murine remains to be resolved, 
worthwhile evidence of the function of Wt1 during hematopoiesis can be elucidate 
from its downstream target genes from hematopoietic precursor cells. 
 
1.1.9 The mouse as a model in comparative physiology 
Due to data obtained by exhaustive research in human and mouse genomes it is 
possible to elucidate their similitude. The mouse genome mouse is 2.5 Gb long only 
~14% smaller than the human genome (Waterston et al., 2002). Among the 30,000 
protein-coding genes 80% of mouse genes, can be identified that have human 
orthologue, and less than 1% appear to be truly unique (Mouse sequencing 
consortium, 2002). Shared regions of synteny (e.g. WT1 gene in human chromosome 
11, and in mouse chromosome 2) have been conserved regardless of over 75 million 
years of evolutionary divergence (Nei et al., 2001). According to the mouse 
sequencing consortium (FANTOM3), 1,022 human genes are involved in disease and 
807 of these are also present in the mouse. There is still much to be done to clarify the 
physiological role of each of these. Functional genomics is still an emerging field 
that, due to the vast amount of candidates still to be functionally defined in vivo. In 
the mouse, only about one third of the genes have been studied at some level. The 
number of homologous genes suggests a transdisciplinary effort including different 




1.1.9.1 Mouse models with WT1-targeted mutation 
Biomolecular and biochemical studies of the WT1 gene have contributed enormously 
to the understanding of transcriptional or post-transcritional roles. All this work gave 
very relevant information of how WT1 isoforms interact how they may function 
within the cell. Nevertheless, understanding the role of WT1 in organogenesis must 
take in account of interactions between a multiplicity of cell types and tissues. WT1 
related mouse models allow us to study in detail the role this gene plays in normal 
and abnormal development that would be impossible to gauge from cell culture 
system alone. Gene modification in the mouse can result in measurable changes in 
morphogenetic and physiological properties that can be attributed to WT1. In this way 
mouse models with modified WT1 expression have confirmed unequivocally that 
WT1 plays a central role in kidney development and maintenance. 
 
 
However, it should be considered that in the mouse model, kidneys are significantly 
smaller and their life-span shorter than the cell population in human kidneys. Also, 
human kidney development occurs over a period of 31 weeks compared with mice 21 
days in mice, during which there might be significantly fewer post zygotic mutations 
resulting in less probability of oncogenesis occurring.  Besides, while in human more 
than one tumour-related genes reside on the same chromosome (11p13 and 11p15), in 
mice these two loci are on different chromosomes (2 and 7). Consequently, in 
humans heterozygosity can be achieved for both of these loci with a single hit, 
whereas in the mouse analogous events must involve independent chromosomes. 
Moreover, differences in urogenital systems between mammals and the rest in the 
animal kingdom (e.g. fish) suggests it must be difficult to make final conclusions 
using model organisms if the final interest is to better understand WT1 molecular 





1.1.9.1.1 The Wt1 null mouse 
One of the key findings to confirm WT1 as a central gene in kidney development was 
phenotype of Wt1
-/-
 knock-out mice in which lethality happened by E12 (Herzer et 
al., 1999; Kreidberg et al., 1993). In the Kreidberg knockout mouse model a 
replacement-type targeting vector with a deletion of Wt1 exon 1 and 0.5 kb of 
upstream sequence was used to knockout Wt1. The most prominent finding was the 
lack of kidneys and gonads in the mutant embryos. Further defects were observed in 
diaphragm, peritoneum, epicardium, and tissues derived from mesothelium as well as 
in heart, adrenal glands (Moore et al., 1999; Kreidberg et al, 1993), and spleen 
(Herzer et al., 1999), olfactory system (Wagner et al., 2005) and neuronal tissues, 
specifically retinal ganglia (Wagner et al., 2002).  
 
In mutant mice, the kidney development was arrested after establishment of the 
metanephric blastema from intermediate mesoderm. Blastemal cells were present 
initially but then soon after underwent apoptosis with embryos becoming oedematous 
after E12 and then reabsorbed between E13 and E15. Metaneprhic mesenchyme that 
undergoes apoptosis never manages to reach the ureteric bud and is unable to be 
formed, which might suggest upregulation of apoptosis-inducing genes (Kreidberg et 
al., 1993). On further analyses it was found that WT1
-/- 
mesenchyme had a different
 
histological appearance and also showed the presence of Pax-2 mRNA but not 
protein, suggesting that Pax-2 may be regulated by WT1 at a post-transcriptional 
stage. Other mouse models with increased mesenchymal apoptosis include Bmp7
–/–
 
(Luo et al., 1995) and Sall1
–/–
(Nishinakamura et al., 2001) knockouts. However, only 
the WT1
-/- 
model also presented gonadogenesis, a reduced and shapeless thorax with 
discontinuities in the diaphragm, and small heart and lungs. 
In contrast, the heterozygous WT1
+/-
 mice survived into adulthood and initially no 
abnormal phenotype was detected. Later studies back crossing the Kreidberg mouse 
model into mixed genetic background revealed that after 400 days post-gestation 40% 
of the mice had died and this was associated with a predisposition to 




In homozygote Wt1 mouse during gonadal development displayed phenotypes similar 
to those found in DDS (Pelletier et al., 1991a). When the mutant mesenchyme was 
examined for the expression of genetic markers for early mesenchyme differentiation, 
Pax-2, Six2, and glial cell line derived neurotrophic factor (GDNF) mRNAs were 
detected at a level comparable to those in wild-type mice. Unlike individuals with the 
WAGR syndrome, which retain only one functional copy of the WT1 gene, mice 
heterozygous for a functional Wt1 allele revealed no predisposition for WT 
tumourgenesis. This is also true of Sey
Dey
 mice (to be discussed in Section 1.1.9.1.5), 
which are heterozygous for a large deletion in the Wt1-aniridia region (Glaser et al., 
1990) and might reflect a distinct initial genetic predisposition in mice and humans or 
distinctive mechanisms for preventing carcinogenesis. 
 






 To make a the DDS mouse model, the DDS mutation named Wt1
tmT396
 truncates zinc 
finger 3 at the codon 396 which was been introduced into embryonic stem (ES) cells, 
(Patek et al., 1999). Targeted ES cells produce wild-type and mutant transcripts of the 
Wt1 gene in equal amounts, but analysis of the protein products revealed that the 
mutant protein was only 5% of the total Wt1 protein produced. As a consequence of 
this truncation mesangial sclerosis in adult heterozygote mice was observed as well as 
male genital defects resembling what it occur in human DDS. Also there was one 
case of WT implying a potential link between WT1 malfunction and WTs. However, 
in this mouse model the mutant allele did not affect the glomerular lineage in early 
nephrogenesis (Patek et al., 1999). This shows two things: First, by some mechanism 
expression from the mutant allele is compensated. Second, a very small proportion of 
mutated Wt1 protein can produce a dramatic disruption in the genitourinary system. 





On a subsequent attempt by Patek et al., (2008) to generate heterozygotes Wt1
tmT396/+
 
which where back crossed with the MF1-N2 strain mice with no abnormal phenotype 
were obtained, male and female heterozygotes were fertile. Sporadic proteinuria and 
glomerulosclerosis was observed but predisposition to WT or male 
pseudohermaphroditism did not occur. So the authors conclude that effects initially 
observed on kidney disease and fertility were genetic background-dependent, or 
possibly the inheritance might be subject of imprinting (parent-of-origin effect), or 
stochastic effects might prevent to set up disease.  Initial observation was probably 
due to WT1-independant alterations in the knockout ES cells used to generate these 
mice. 
 
A more recent mouse knockout was made with the most frequent mutation observed 
in DDS patients that substitutes a tryptophan for an arginine aa 394 affecting the 
DNA-binding domain in WT1 (Gao et al., 2004). The heterozygous mice did not 
show gonadal dysgenesis or male pseudohermaphrotitism, nevertheless mice had 
proteinurea as a consequence of diffuse mesangial sclerosis. WT1 protein levels were 
decreased by 20% from wild type controls. Electron microscopy showed an 
abnormally thickening of the glomeruli, however, no difference in the number of cells  
were observed, corroborating that mesangial proliferation is not how WT1 mutation 
leads to glomerulosclerosis. Although mechanisms of how this mutation start the 
process of disease is still unknown, this study suggest it could involve some 
deregulations of WT1 downstream target genes.   
 
1.1.9.1.3 Fraiser Syndrome mouse model 
 
As mentioned in Section 1.1.2.1, FS is characterized by splicing defects resulting in 
an inability to express from one allele the WT1/+KTS isoform, suggesting that there 
is an important equilibrium maintained between the different isoforms in normal renal 
and testicular development. Based on previous in vitro evidence distinct functions for 
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WT1 +/– KTS isoforms were suggested. Genetically modified mice were generated 
which express either the WT1/+KTS wt1 isoform or only the WT1/-KTS Wt1 
isoform (FS) (Hammes et al., 2001). Homozygote Fraiser mice die at birth due to 
kidney defects specifically affecting the glomerular podocyte layer and also have 
defects in male sex determination. WT1/+KTS mice are more severely affected and 
have hypodysplastic kidneys and streak gonads. Clearly, both isoforms are necessary 
for correct development, although the appearance of normal adrenal glands and 
spleen in both models indicates that there is some functional redundancy between the 
two isoforms, perhaps because WT1/+KTS isoforms are more critical for kidney and 
testis development than spleen. Nevertheless, the authors could consider re-examine 
if there is any differential expression earlier in development at the Wolffian duct 
which gives rise to both kidneys and gonads. 
 
1.1.9.1.4 Wt1 targeted mice with disruption and CUG-initiated translation 
To elucidate the role of the mammal specific exon 5 in vivo the mammal specific 
features of embryonic implantation and lactation, were analyzed in mice in lacking 
Wt1 +exon 5. Mice were generated by gene targeting in a two-step approach to delete 
exon 5 without disrupting Wt1 isoforms (Natoli et al., 2002a). These mice apparently 
were able to develop, grow and breed normally, without a discernable abnormal 
phenotype, indicating that exon 5 is not required in lactation, or embryonic 
implantation. WT1/+exon5 isoforms have also been studied in DDS WT1/+exon5 
transgene experiments (Natoli et al., 2002b). These results showed that WT1 
isoforms lacking exon 5 have a greater role in directing podocyte differentiation. 
Normal urogenital development occurs in the absence of the mammalian specific 
exon 5 and the CUG-initiated translation isoforms, but this redundancy in mice may 










1.1.9.1.5 The Dickie small-eye (Sey) mouse 
The Harwell Dickie’s small eye (Sey) deletion in mouse is another type of Wt1 
knockout model highly comparable to cytogenetic deletions identified at human 11p 
13 in children with WAGR syndrome and Peter’s anomaly which is characterized by 
defects in the cornea (Glaser et al., 1990). The Sey mouse model has a semi-dominant 
mutation that is phenotypically consistent with aniridia, but none of the other 
abnormalities typically found in human WAGR. The Dickie small-eye (Sey
Dey
) allele 
in mice is an interstitial deletion on chromosome 2 encompassing the Wt1, Rcn and 
Pax-6 genes (Glaser et al., 1990). The Rcn gene encodes retiuculocalbin, which is a 
Ca
2+
 -binding protein expressed in the lumen of the endoplasmic reticulum. In both 
heterozygote and homozygous renal neoplasms were absent and kidneys, gonads and 





The interaction of different genes through development can be studied by crossing of 
mutant mice to create double knockout compound mutant mice. P53 and WT1 have a 
reciprocal effect on their own functions (Maheswaran et al., 1998,),  both can induce 
apoptosis (Menke et al., 1997). Therefore, to corroborate if WT1 interacts in vivo 




mutation interbred. The only new 
phenotype, other than inherited glomeruloesclerosis that what was previously 
reported for wt1
+/-
 mice, was earlier onset of lymphoma, the most prevalent tumour 
associated with Trp53
+/-
 mice.  
 
1.1.9.1.7 Wt1:Pax-2 compound mice 
Both WT1 and Pax-2 are expressed during kidney organogenesis suggesting the 
possibility of a regulatory interaction between them. Mouse embryos containing 
targeted heterozygous disruptions and/or sporadic mutations for Pax-2 (Favor et al., 
1996) as well as transgenic mice with overexpression showed structural defects and 
impaired kidney function (Dressler et al., 1993).  Both mouse models exhibit 







 offspring revealed that kidneys were 50% 
smaller than in wild-type controls and 20% smaller than the Pax2
1Neu/+ 
kidneys 
(Discenza et al., 2003). Kidneys in compound mutant animal had an abnormal the 
renal medulla, and reduced development of the calyces and renal pelvis. In 
heterozygote renal cortex development was comparable with that of Pax2
1Neu/-
 cortex. 
The authors conclude that wt1 is a modifier of Pax-2. On subsequent review Discenza 
and Pelletier (2004) conclude haploinsufficiency, as a result diminution of total 
protein to enable heterodimeration on these two proteins.  
  
1.2 Non-protein-coding RNA 
In multicellular organisms diverse phenotypic variation makes it possible to 
differentiate and classify phyla through an evolutionary line. Nevertheless, only 
~1.2% of the human genome is translated to protein (Venter et al., 2001) a feature 
that is similar across the vertebrates and indeed all metazoa, making this genomic 
feature uninformative for discriminating between major groups of organisms despite 
remarkable differences in developmental complexity (Figure 1.4 B). On the other 
hand, sequencing projects have found that the number of protein-coding genes and 
the extent of their sequences remain relatively static. In concordance with this,  
annotations show that the nematode worm Caenorhabditis elegans, containing only 
~1,000 cells, has ~20,000 protein-coding genes (Stein et al., 2003), roughly the same 
number as human (Goodstadt and Ponting, 2006) which has ~100 trillion cells in 
precisely formed tissues, including ~100 billion neurons with an estimated 1014 
synaptic connections in the neocortex (Andersen et al., 2003). In contrast the number 
of intronic, and intergenic sequences does appear to correlate with developmental 
complexity, increasing remarkably along the phylogenetic scale. This suggests that 
these sequences may contain elaborate regulatory information (Figure 1.4 A), 
although the biological relevance of the non-coding sequence is stills a matter of 
debate (Dennis 2002; Brosius, 2005; Struhl, 2007; Pauler et al., 2007). 
 
Recently it has become clear that the majority of the eukaryotic genome is transcribed 
in a developmentally regulated manner to produce a large class of RNAs with little or 
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no protein-coding potential RNAs (ncRNAs); (Carninci et al., 2005; Cheng et al., 
2005; Kaprankov et al., 2007b; Mattick and Makunin, 2006), that are often rapidly 
degraded (Yazgan and Krebs, 2007). Dissecting the mouse genome the RIKEN 
Mouse Gene Encyclopedia project used cell lines and tissues to create a full-length 
cDNA library of 5’-capped and 3’-poly(A) tailed RNAs with many putative RNAs 
without open read frames were identified (Hayashizaki et al., 2003). In 2005 the 
FANTOM3 genome sequencing consortium annotated 103,000 cDNA sequences that 
were classified as non-coding RNA. Sequencing of a large set of these cDNA by the 
FANTOM3 consortium, found that 47% had absent open reading frame (ORFs) so 
were classified as putative ncRNAs (Carninci et al., 2005; Katayama et al., 2005). 
 
To evaluate whether ncRNAs have a functional role a study was undertaken by 
Ravasi et al., (2006). Using a combination of RT-PCR, microarrays and Northern 
hybridization it was shown that ncRNAs are expressed in a tissue-specific manner 
suggesting they have biological function. The FANTOM3 Consortium, 2005 found 
that the extent of ncRNA length does not change across metazoan species, in spite of 
large differences in developmental complexity (Taft et al., 2007). Often, many 
transcripts are expressed from a single locus. Analysis of expressed sequence tags 
(EST) has indicated that an average of 5.6 different transcripts are produced from 
each locus, with protein coding RNAs often capable of producing two or more 
variants, as we could see in Section 1.1.2.1 for WT1 locus. According to the 
ENCODE consortium 90% of the mammalian genome is estimated to be actively 
transcribed (Birney et al., 2007). Due to the frequent occurrence of this ncRNAs in 
species with higher developmental complexity therefore is proposed to be strictly 
regulated during developmentally manner (Mattick, 1994, 2001).  
 
Recent growing evidence suggests that ncRNA transcripts are functional, particularly 
in the regulation of epigenetic processes, leading to the hypothesis that there exists a 
hitherto hidden layer of genomic programming in humans and other multicellular 







Figure·1.4 The fraction of non-protein-coding DNA and megabases of protein 
coding sequence (CDS) per haploid genome in different species. (A) The ratio of 
the total bases of non-protein-coding to the total bases of genomic DNA per 
sequenced genome across phyla (i.e. the fraction of non-protein-coding DNA). The 
four largest prokaryote genomes and two well-known bacterial species are depicted in 
black. Single-celled organisms are shown in gray, organisms known to be both single 
and multicellular depending on lifecycle are light blue, basal multicellular organisms 
are blue, plants are green, nematodes are purple, arthropods are orange, ascidians are 
yellow, and vertebrates are red. Species names are listed below B. (B) The amount (in 
megabases) of CDS per genome for species ranked by fraction of non-protein-coding 
DNA. Original source Mattick et al., (2007). This figure was reproduced with 









1.2.1 Categories of ncRNA 
ncRNAs can be generally classified according to their sizes which may indicate 
specific length-dependent functions. The following section will briefly described the 
three best known types of ncRNAs, long, small and micro, although other types have 
been recently discovered (see Table 1.3). 
 
1.2.1.1 Long non-coding RNAs  >~200 nt  
Tiling arrays tested on the human genome, revealed that the majority of transcription 
occurs as long ncRNAs (lncRNAs) (Kapranov et al., 2007b). Although a small 
number of lncRNAs have been functionally characterized (Prasanth & Spector 2007) 
they seem to exhibit a broad range of functions (Prasanth & Spector 2007,) each with 
restricted expression in specific cell types and localization to specific cellular 
compartments (Clemson et al., 1998; Ginger et al., 2006; Prasanth et al., 2005; 
Willingham et al., 2005). Their functions are extremely diverse comprising events 
such as: DNA demethylation, X-inactivation, modulation of transcription and 
genomic imprinting (Avner et al., 2001), but also in subcellular dynamics, including 
chromatin modification, transcriptional activation, transcriptional interference, 
nuclear transportation, and generation of the other classes of ncRNAs  (Costa, 2005; 
Chen et al., 2010; Storz, 2002). 
 
 LncRNAs are thought to be involved in the regulation of protein-coding genes in 
normal development and also oncogenesis. Some lncRNAs may be precursors of 
smaller RNAs, but many are detected as relatively stable polyadenylated and non-
polyadenylated transcripts (Bartel et al., 2004; Cheng 2005; Kim, 2005; Kiyosawa et 
al., 2007; Mallory & Vaucheret, 2006). 
 
The first mammalian ncRNA that proved to have a gene silencing function was the 
Xist ncRNA, which inactivates one of the two X chromosomes in female mammals 
(Marahrens et al., 1997). The Telomerase RNA is also lncRNA and an integral part of 
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the telomerase enzyme serving as a template for the synthesis of chromosome ends 
(Chen et al., 2000). Even larger transcripts that can be 200->10,000 nucleotides in 
length belong to a group known as medium or large RNAs (reviewed in Storz et al., 
2002). Extremely long ncRNAs >10,000 nt detected in insects and mammalian cells 
have been associated with gene silencing and in modifying chromatin structure along 
large chromosomal regions, e.g. human Xist RNA required for X chromosome 
inactivation and mouse antisense Igf2r (insulin-like growth factor type-2 receptor) 
(Air) RNA required for autosomal gene imprinting antisense Igf2r, of the 108kb Igf2r 
gene (reviewed in O’Neil et al., 2005).   
 
 
1.2.1.2 Small non-protein-coding RNAs ~21-22nt 
Transcripts ~21-22 nucleotides in length are a group which comprise small RNAs 
(sRNAs). These are potent regulators of postranscriptional and transcriptional gene 
expression (Voinnet et al., 2009). The effects of sRNAs gene expression and control 
are generally inhibitory as long as the regulatory mechanisms underlie RNA 
silencing. Control of gene expression of sRNAs was discovered in 1993 while 
analyzing the nematode Caenorhabditis elegans larvae sRNAs were found 
complemented the sense strand of a larger mRNA and bound to its 3' untranslated 
region, thus inhibiting translation (Bartel, 2004; Lee et al., 1993). Since then a 
number of different sRNAs have been found with a variety of mechanisms of 
transcriptional regulation. They also can be divided in two main groups the small 
interfering RNAs (siRNAs) and the micro RNAs (miRNAs).   
 
The siRNAs are double-stranded RNA molecules (~21 bp), generated by the cleavage 
of dsRNA by an enzyme called Dicer, a member of the RNase III family. SiRNA is 
thought to be exogenous in origin derived directly from virus, transgenes trigger or 
transposons, which is excised from fully complementary double stranded, that is not 
encoded in the genome. (Tomari and Zamore 2005). siRNAs regulate the degradation 
by cleavage of mRNA complementary sequences, resulting in the down regulation of 
protein synthesis (Fuchs and Boutros, 2007; Kittler et al., 2003; Mocellin et al., 2006; 
Sledz et al., 2005). They have roles in virtually all developmental processes, 
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including stem cell and germline maintenance, development and differentiation, 
transcriptional and post-transcriptional gene silencing and subcellular localization. 
The 186nt human U2 small nuclear RNA involved in RNA splicing (Will et al., 
2001). siRNAs can also silence gene expression by obstructing the promoter by 
directing gene methylation or chromatin condensation, roles that have been associated 
with involved in transposon control and viral defence. SiRNA sequences can be 
phylogenetically conserved.  
 
The other class of sRNAs are the microRNAs (miRNAs) (~21 bp), these are a diverse 
class of sRNAs molecules (Table 1.3) and typically endogenous gene products, 
miRNAs appear to originate from stem-loop precursors with incomplete double-
stranded hairpins. Like siRNAs, Dicer enzymes excise miRNAs from their 
precursors, and Argonaute (Ago) proteins appears to perform the signature of 
silencing effectors’ function being part of the catalytic components of the RNA-
induced silencing complex (Meister and Tuschl, 2004) (Table 1.3).  
 
miRNAs are involved in a wide variety of biological processes, such as development, 
metabolism and cell cycle (Boehm et al., 2005; Carleton et al., 2007; Harfe et al., 
2005), as well as human diseases, such as diabetes, cancer and neuro- and immune-
degenerative processes (Jin et al., 2004; Poy et al., 2004; Volina et al., 2006). 
miRNAs are a highly conserved between species with diverse functions in the 
regulation of gene expression in multicellular eukaryotes and some unicellular 
eukaryotes (Kato and Slack, 2008). It has been estimated that miRNAs regulate ~30% 
of human genes (Bartel, 2004), and that half of the known miRNAs are inside or next 
to polymorphism hot-spots sites in minimal regions of loss of heterozygosity and 
regions of amplification, near common breakpoints associated with cancer (Garzon et 
al., 2009; Lu et al., 2005; Volinia et al., 2006). In particular miR-15a and miR-16-1 









Table 1.3 Classes of non-coding RNA in mammals 




Long non-coding RNAs (lncRNAs) 
 
The broadest class, encompass all non-protein-coding RNA 
spencies >~200 nt, including, mRNA-like ncRNAs. Their 
functions include epigenetic regulation, acting as a sequence-
specific tethers for protein complexes and specifying 
subcellular compartments or localizations 
 
Small interfering RNAs (siRNAs) 
 
Small RNAs ~21-22 nt long, produced by Dicer cleavage of 
complementary dsRNA duplexes siRNAs form complexes 
with Ago protein and are involved in gene regulation, 
transposon control and viral defense.  
 MicroRNAs (miRNAs) 
 
Small RNAs ~22 nt long, produced by Dicer cleavage of 
imperfect RNA hairpins encoded in long primary transcripts or 
short introns. They associate with Ago proteins and are 
predominately involved in post-transcriptionaly regulations. 
 
Promoter-associated RNAs (PARs) 
 
A general term encompassing a suite of long and short RNAs, 
including promoter-associated RNAs (PASRs) and 
transcription initiation RNAs (tiRNAs) that overlap promoters 
and TSSs. These transcripts may regulate gene expression. 
 
Small nucleolar RNAs (snoRNAs) 
 
 
Recently described classes 
Traditionally viewed as guides of rRNA methylation and 
pseudouirydylation. However, there is emerging evidence that 
they also have gene-regulatory roles. 
X-inactivation RNAs (xiRNAs) 
 
X-inactivation RNAs (xiRNAs) 
 
 
Dicer-dependent small RNAs processed from duplexes of two 
lncRNAs, Xist and Tsix, which are responsible for X-
chromosome inactivation in placental mammals.  
 
Sno-derived RNAs (sdRNAs) 
 
Small RNAs, some of which dicer dependent, wich are 
processed from small nucleolar RNAs (snoRNAs). Some 
sdRNAs have been shown to function as miRNA-like 




microRNA-offset RNAs (moRNAs)  
 
tRNA-derived RNAs  
 
Small RNAs ~20nt, derived from de regions adjacent to pre-
miRNAs. Their function is unknown. 
 
tRNAs can be processed into small RNA species by conserved 
RNase (angionin). They are able to induce translational 
repression. 
 
MSY2-associated RNAs  
(MSY-RNAs) 
 
MSY2-RNAs are associated with the germ cell-specific 
DNA/RNA binding protein MSY2. Like piRNAs, they are 
largely restricted to the germline and are ~26-30 nt long. Their 
function is unknown. 
 
Telomere small RNAs 
(tel-sRNAs) 
Dicer-independent 24 nt RNAs principally derived from G 
rich strand of telomeric repeats. May have a role in telomere 
maintenance 
  
This table was reproduced with permission of the author (Mattick, 2005) 
 
 
1.2.1.2.1 The influence of H19 on Igf2 
The IGF2 and H19 genes are reciprocally imprinted transcripts, both located at 
11p15.5 in human and distal chromosome 7 in mouse. H19 codes for a 2.3 kb spliced 
and polyadenylated RNA product. H19 is a member of the class of genes transcribed 
by the RNA polymerase II that was the first example identified of a non-coding RNA 
(Brannan et al., 1990). Coexpression of H19 and it  IGF2 occurs in parallel in most of 
the same tissues during embryogenic development. IGF2 encodes a potent mitogen, 
transcribed from four promoters P1-4, of which promoters P2-4 are imprinted and 
transcription occurs only from the paternal allele (Ogawa et al., 1993; Rainier et al., 
1993) whereas H19 is expressed from the maternal allele. The modulation of 
imprinting of H19/IGF requires binding of the vertebrate insulator protein, CCCTC 
binding factor (CTCF) a multivalent zinc finger protein whose DNA binding is 
prevented by DNA methylation, CTCF binds to the maternally differentially 
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hypomethylated domain (DMD) and is involved in blocking access of enhancer 
sequences to IGF2 promoters. On the paternal allele, methylation of the DMD blocks 
CTCF binding and repressing H19 transcription while allowing enhancers to interact 
with IGF2 promoters (Figure 1.6). Loss of imprinting of IGF2 and H19 is common in 
WTs, and IGF2, as an autocrine growth factor is an appealing target in playing a 
causal role in tumorigenesis (Arima et al., 1997; McCann et al., 1996).  
 
Recent studies of BWS have found in inherited mutations in WT (Riccio et al., 2009). 
This might be correlated with the LOI mechanism allowing the paternal allele of 
IGF2 to be expressed and H19 to be silenced. Nevertheless, the abrogation of H19 
might also be a factor in tumour progression, as this conserved molecule (Juan et al., 
2000) has been correlated with TS activity (Brannan et al., 1990; Hao et al., 1993). 
Additionally, evaluation of IGF2 peptide levels in WTs with relaxation of imprinting, 
indicate little change in protein levels (Baccarini et al., 1993; Haselbacher et al., 
1987), though this does not exclude a role for elevated IGF2 at early stages of 
tumourigenesis. Interestingly, mice inheriting a truncated maternal H19 allele and a 
deleted paternal IGF2 allele had no discernable phenotype whereas mice inheriting 
only a deleted maternal H19 showed body overgrowth.  
 
 
Figure 1.5 Long noncoding RNA-mediated transcription regulation by enhancer 
competition. The H19 lncRNA is transcribed only maternally from the imprinted 
H19/Igf2 locus, which is controlled by chromatin insulators that lie upstream of the 
H19 gene. On the maternal chromosome, the insulator sequence is unmethylated and 
binds CCCTC-binding factor (CTCF), and thus prevents the enhancers from 
interacting with the Igf2 promoter, but instead activates H19 gene transcription. On 
the paternal chromosome, insulators are methylated and do not bind CTCF, thus 





On the other hand mice inheriting only a deleted paternal IGF2 gene displayed 
somatic undergrowth when compared to control mice. This indicates that the loss of 
H19 is not lethal, H19 expression governs IGF2 repression, and the overexpression of 
IGF2 is responsible for the overgrowth phenotype observed in the maternal 
inheritance of a deleted H19 (Leighton et al., 1995). 
 
1.2.2 Antisense RNA transcripts 
By definition antisense transcripts are RNA molecules that are transcribed from 
opposite strand of conventional (sense) genes. Such antisense transcripts may overlap 
or not with mature sense (Figure 1.6) (Williams and Fried, 1986). Many ncRNAs are 
divergently expressed that overlap protein-coding genes and are a widespread 
phenomenon in mammalian genomes (Table 1.4). In the last several years, 
attention has been addressed to the fact that a considerable fraction of the 
transcriptome comprises endogenous transcripts with inverse orientation 
serving as a template of RNA polymerase II (Goodrich et al., 2006).  
 
Antisense RNA molecules are transcribed from the opposite strand and in the reverse 
direction compared with a sense transcript which commonly is a protein coding RNA 
is translated. They are classified into two groups: One is the natural antisense 
transcript (NAT) which has partial or complete complementary transcript sequences 
shared with a sense counterpart. The second type is non-overlapping with the sense 
transcript but may be complementary to DNA (Figure 1.6). Antisense transcripts can 
be spliced, polyadenylated and imprinted, although it has been reported that they have 
a tendency to undergo fewer splicing events than is typically displayed by their sense 
counterparts (He et al., 2008). 
 
 1.2.2.1 Discovery 
The first NATs were discovered in 1981. These were small plasmid-encoded RNA 
regulators which control the copy number of Escherichia coli plasmids CoE1 and R1 
(Tomizawa et al., 1981; Stougard et al., 1981; reviewed in Brantl et al., 2002). 
Antisense RNAs can be coding or non-coding. An example of a protein coding 
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antisense RNA is mitotic apparatus protein one. It is an antisense transcript of 
Interleukin 18 binding protein and overlaps the 3’ untranslated region (UTR). 
However, naturally occurring antisense RNAs are usually ncRNAs and represent 




Figure 1.6 Schematic representing antisense transcripts. An example of 
complementary “natural” antisense in blue, and “non-overlapping” of a given sense 
transcript in red. At the top double chain showing polymerase enzyme and 
transcription orientation.  
 
 Conventionally, the sense strand is considered to encode the protein since it has the 
same sequence as the mRNA. However, long open reading frames in the antisense 
strand can exist which might encode "antisense" proteins (Meckler, 1969; Merino et 
al., 1994). Yomo et al., (1992), interpreted the discovery of long antisense open 
reading frames in certain plasmid genes as indicating that some "unknown force" is 
protecting the frames from mutations generating stop codons. In later studies, Yomo 
and Urabe (1994) have generalized these arguments taking into account the 
observation that the frequencies of individual codons in sense strands are often 
similar to their frequencies in the antisense strands (when read in the same phase and 
with the correct polarity; Alff-Steinberger 1984, 1987; Yomo and Ohno 1989). 
 
Others have suggested that the genetic code may initially have evolved to enable the 
simultaneous emergence of sense and antisense peptides (Alff-Steinberger, 1984; 
Konecny et al., 1993; Zull & Smith, 1990). Codons for hydrophilic and hydrophobic 
aa on the sense strand may sometimes be complemented, in frame, by codons for 
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hydrophobic and hydrophilic aa on the antisense strand. Furthermore, antisense 
proteins may sometimes interact with high specificity with the corresponding sense 
proteins (Blalock and Bost, 1986; Blalock, 1990; Clarke and Blalock, 1991). The 
interactions involve multiple contacts along the lengths of the polypeptide chains 
(Tropsha et al., 1992). 
 
The presence and abundance of genes with antisense transcripts have been estimated 
by distinct methodological approaches, including bioinformatics analysis of 
expressed sequence tag (EST), Ref Seq and data bases (Zhang et al., 2006), single-
strand RT-PCR (Yeung and Lau, 2002), hybridization techniques (Rosok and Sioud, 
2004), strand specific microarrays (Ge et al, 2008), sequencing (Katayama, 2005; 
Kiyosawa et al., 2003), serial analysis of genomic expression (SAGE) libraries (Ge et 
al., 2006), global run-on sequencing (GRAO-seq)(Core et al., 2008) and asymmetric 
strand-specific analysis of gene expression (He et al., 2008). These techniques 
provide ample evidence that the mammalian genomes code for numerous antisense 
transcripts. At least a 1,000 NATs were have been found conserved between human 
and mouse (Engstrom et al., 2006) However, this information remains limited 
because not all of the mammalian transcriptome has been sequenced fully and more 
information is needed to map antisense elements which are transcribed in low copy 
number. For instance, in the mouse due to large scale sequencing of cDNA clones by 
the FANTOM3 consortium NATs were shown to be associated with 70% of sense 
transcribed transcribed genes, with most lacking protein-coding capacity (Katayama, 
2005). The abundance of non over lapping antisense RNAs has not yet been 
estimated. This suggests that there is a higher prevalence of antisense RNAs in 
mammals and alludes to their importance (Table 1.4). The occurrence of an imprinted 
ncRNA with some an imprinted gene cluster has been observed (Sleutels & Barlow 
2002) however ncRNA, have also been identified in several bi-allelically expressed 
genes such as N-myc, BFGF, Hox11, RPS14 and Kelch-like 1 (Benzow & Koob, 
2002; Krystal et al., 1990; Li et al., 1996; Potter & Bradford, 1998; 1990; Tashev & 
Roufa, 1995). Antisense transcripts identified within imprinting regions so far are 
expressed from the paternal allele only, apart from Tsix, the antisense transcript to 




1.2.2.2 Functional validation  
 As it has been stated before mammalian genomes code for numerous antisense 
transcripts, but their function remain poorly understood. Several authors have 
identified that endogenous expression levels may have a positive reciprocal 
correlation between the presence of sense and antisense transcripts, within specific 
tissues or cell lines (Katayama et al., 2005; Li et al., 1996; Sado et al., 2001,), 
however this interaction may not occur between tissue or cell-type (Alenina et al., 
2002, Okada et al., 2008). Although very little is known about the biological 
functions of NATs (reviewed in Lavorgna et al., 2004), recent evidence indicates that 
antisense transcripts are frequently functional and use diverse transcriptional and 
post-transcriptional gene regulatory mechanisms to carry out a wide variety of 
biological roles (Table 1.4). The biochemical function of NATs has been assessed in 
various organisms, and evidence for RNA interference, RNA editing, RNA splicing, 
transcriptional interference, or direct RNA-protein interaction has been reported. 
These important findings have been reviewed in detail (Faghihi and Wahlestedt, 
2009; Mattick 2005). However, the extent to which these mechanisms contribute to 
the phylogenetic drive to accumulate antisense transcripts in eukaryotic genomes is a 
matter of debate.  
 
Antisense RNAs can cause messenger RNA (mRNA) destruction, repression and 
activation, altered RNA processing (such as editing), effects on transcription, 
inhibition of mRNA transport and alteration in mRNA stability. Antisense RNA 
mechanism of action can be via DNA, RNA or protein-interaction. The RNA may 
affect the DNA level if the sense and antisense promoters compete for shared 
enhancers or the antisense RNA may occlude the promoters directly. At the RNA 
level transcription is clearly important in gene control, but translation is also 
extensively regulated. Translation repression can occur by inhibition of ribosome 
elongation, but only very tight binding antisense agents can also block this 




 Translation initiation can be inhibited by mRNA structure or antisense sequences 
which cover/mask recognition signals. In prokaryotes, trans-encoded antisense 
sequences typically work by binding to the start codon region of mRNA whereas in 
eukaryotes most NATs repress translation by binding sequences within the 3’UTR. It 
may seem surprising that binding to sites in the 3’UTR can repress translation; 
however this region interacts with the 5’UTR where translation begins. Connective 
tissue growth factor (CTGF) exhibits repression of translation mediated by the 
antisense (Kubota et al., 1999).  
 





or disease relevance 
Suggested mechanism Species 
BACE1  and BACE1-
AS 
Alzheimer’s disease Stability H,  M 
APOE  and APOE-
AS1 
Alzheimer’s disease Not known H,  M 









P15  and P15-AS Tumour suppressor Chromatin modification H 
P21  and P21-AS Tumour Suppressor Chromatin modification H 




Not known H 
Zfh-5  and zfh-5AS Transcription factor Not known  
M 
Progesteron 
receptor and PR-AS 




heterochromatin protein 1 
H 
HAR1F and HAR1R Neuro-development Not known H 
WT1 and WT1-AS Kidney 
development 
Methylation H 
BDNF and BDNFOS Neurotrophic  factor RNA duplex formation P 
PINK1 and naPINK1 Mitochondrial 
function 
Not known H 
FMR1 and ASFMR1 Fragile X mental 
retardation 
Epigenetic changes H, M 






Anxiety, depression Not known H 
Rad 18  and NAT-
Rad18 
Apoptosis Post-transcriptional control H, R 
HFE and HFE 
antisense RNA 
Iron storage disorder Translation repression H 
Zeb2 and 




Splicing H, M 
TSP1  and TSP1-AS Platelet aggregation Not known H 
Urocortin, Ucn  and  
Ucn-AS 
Neuro-transmission Post-transcriptional  
Sphk1  and  Khps1 Calcium 
mobilization 
Demethylation H, R 




Msh4 and Hspa5 Meiotic DNA 
recombination 
RNA degradation M 
Pax-6 and Pax-6OS  
Pax-2 and Pax-2OS 
Six3 and  Six3OS 
Six6 and Six6OS 
Otx2 and Otx2OS 
Crx and CrxOS 
Rax and RaxOS 
Vax2 and Vax2OS 
Eye development  Not known M,  H 
Hyaluronan synthase 
2 and HASNT 
Hyaluronan 
biosynthesis  
Not known M,  H 
Msx1 and Msx1_AS  Skeletal terminal 
differentiation 
Splicing, imprinting R,  H 
 FGF-2 and FGF-AS 




translational block, editing, 
stability 
Mm 
p53 Differentiation Transport M 
N-myc Oncogenesis Splicing M,  H 
Tsix and Xist X chromosome 
inactivation 
X inactivation Mm 
HIF-1α and aHIF Poor prognosis 
marker in breast 









Α-Thalassaemia Methylation H 
IGF2R and Air Tumour suppressor Imprinting H,  M 






GNAS Signal transduction Imprinting H, M 
BCMA and BCMA-
AS RNA 
B-cell maturation Translation block, editing H 
Bcl-2 and IgH Follicular B-cell 
lymphoma 





Splicing H, R 
Thymidylate 
synthase 
 and rTSα DNA  
Replication 






Stabilization H, B 
Myelin basic protein 
(MBP and MBP-AS) 
Myelin formation Transport M 
eNOS  and  NOS3AS 
(sONE) 
Vascular disease Inverse S–AS correlation H,  M 
Neuronal nitric 








S, H,  R 
Inducible nitric 
oxide synthase (iNOS  








Inverse S–AS correlation P  






eIF2α T cell mitogenesis RNA degradation H 
ERCC-1, RAF49 
(ASE-1) 
DNA repair Stability, localization H 
α1 collagen Chondrogenesis Competitive transcriptional 
interference  
Ch 
MKRN2 and RAF1 Cancer Polyadenylation Mm 
Hoxa 11 Development Epigenetic Mm 
Cardiac troponin 1 Myocardial function Translation H, R 













TOP1 and TOP1-AS Cell cycle Translational regulation H 
EP1 prostanoid 




Not known M 
EMX2 and EMX2OS Development Splicing, polyadenylation H, M 
Thymidine kinase  
and TK-AS 
Cell cycle Inverse S–AS correlation M 
DIPLA1 and DIPAS Placenta specific Not known H 
GnRH and SH Gonadotropin-
releasing hormone 
(GnRH) 
Not known R 
HLA-J cluster 
HZFw and  HZFc 
HZFw and HCGV 
HTEX6 and  HTEX4 
MHC class I Alternative splicing, 
alternative polyadenylation 
H, M 
MHC IIa, IIx, IIb  
and  antisense aII, xII, 
bII  
Skeletal muscle 
myosin heavy chain 
regulation 
Transcriptional interference 
and/or promoter methylation 
R 
Cardiac βMHC  and 
AS- βMHC 
Cardiac myosin 
heavy chain – gene 
switching 
Transcriptional regulation 
at promoter  
H, R 









Inverse S–AS correlation F 
ORCTL2 and 
ORCTL2S 
Wilm’s tumour Imprinting H 
 Tenascin-X and 
P450c21B 
Adrenal function Post-transcriptional H 




Translation interference M, Z 





















 Species, P: primate, C: canine, Mm: mammal, B: bovine, F: fungus, Z: zebrafish, H: 
human, M: mouse, R: rat, Ch: Chicken. Information modified from Faghihi and 
Wahlestedt, 2009. This table was reproduced with permission of the author. 
 
1.2.2.3 Proposed mechanisms of NATs-mediated regulation of sense mRNA 
The first model to explain NAT-mediated regulation of sense RNA expression  
maintains that RNA duplexes require overlap a region of at least 6- to 8-bp to form 
stable double stranded RNA through complementary base pairing sequences, to result 
in inhibition of the of protein synthesis (Lai 2002; Lewis et al. 2005). The second 
model involves methylation of promoters included in regions transcribed by antisense 
mRNAs repressing the transcription of sense mRNAs (Reik and Walter 2001; 
Tufarelli et al. 2003; Wutz et al. 1997). A third method suggests the usage of 
differential transcriptional regulatory elements. Antisense transcripts participate in 
processes in development, physiology, and responses to external stimuli. Although 
numerous NATs have been predicted in various species the mechanisms they use to 
regulate gene expression remain unclear. To elucidate these mechanisms four routes  
have been proposed (Lavorgna et al. 2004):  
 
A) Mechanisms related to transcription  
B) RNA-DNA interactions 
C) RNA-RNA interactions in the nucleus 
D) RNA-RNA interactions in the cytoplasm 
 
1.2.2.3.1 Mechanisms related to transcription. 
This model centers on transcriptional collision. The RNA polymerase encoding sense 
and antisense transcripts clashes within the overlapping region, stopping their 
transcription. This model was implied from the analyses of the expression levels of 
cis-NATs in yeast (Peterson and Myers 1993; Puig et al. 1999). In more recent 
studies, the collision of Escherichia coli, and  Saccharomyces cerevisiae (Prescott 
and Proudfoot 2002), RNA polymerases were observed by atomic force microscopy 
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(Crampton et al. 2006) showing that RNA polymerases do not displace each other, 
but instead stall in front of each other. Bioinformatic analysis in human and mouse 
reveals that the size of shared regions between sense and antisense transcripts is 
inversely correlated with the level of antisense transcript expression, suggesting a 
putative clash of RNA polymerases. The point of collision increases the length of 
spanning region. In this model, the antisense RNA is not required to be transcribed, in 
order to interfere with transcription of the sense RNA. 
 
1.2.2.3.2 RNA–DNA interactions 
The RNA-DNA model proposes that NATs can have a direct or indirect participation 
in RNA–DNA or RNA–chromatin interactions (Bernstein et al., 2005). This 
comprises genomic imprinting (Kanduri et al., 2008), X-chromosome inactivation 
(Reviewed by Avner and Heard 2001) and random endogenous monoallelic 
exclusion. In each of these cases NAT’s interact with one of the two alleles of a gene, 
enabling monoallelic expression. NAT participate in other forms of epigenetic 
regulation, involving DNA methylation (Tufarelli et al., 2003). Antisense transcripts 
may bind to specific region of DNA strand, resulting in either DNA methylation or in 
histone-modifying enzyme recruitment and subsequent alterations in chromatin 
structure (Yu et al., 2008). These roles for antisense transcripts in epigenetic silencing 
are likely to be independent of Dicer therefore small RNA production. However, 
antisense RNA can be processed by Dicer to small RNA in the cytoplasm. 
Divergently, antisense transcripts stay binding DNA or act chromatin modifications 
in which may interfere with adjacent regions.  
 
 
1.2.2.3.3 Nuclear and cytoplasmic RNA-RNA duplex formation  
Another type of proposed mechanism involves the formation of nuclear or 
cytoplasmic sense–antisense RNA duplexes. Nuclear RNA duplex can produce 
alternative splicing in mRNA by masking the splice sites and there by changing 
isoform ratios. In addition to this mechanism, RNA may act as a substrate enzymes 
altering the localization, transport or stability of the sense mRNA transcript. In the 
cytoplasm, where RNA hairpins can interact with sense mRNA modifying stability 
and/or translation efficiency. The RNA duplex can mask miRNA or create a template, 
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within the hairpin loops, for producing endogenous siRNA. The RNA-RNA hybrid 
can help mRNA stability by preventing mRNA decay. 
 
Interestingly, through these diverse types of mechanisms antisense transcripts in 
human cell lines are not always linked to expression of the sense gene. The function 
of ncRNAs, are not restricted only to antisense transcripts, also it may be dependent 
largely on their interactions with RNP complexes. For example, knockdown or 
blockade of endogenous antisense transcripts can have different outcomes, either 
increasing or decreasing sense transcript expression (Wahlestedt et al., 2006). 
Certainly, there are examples of parallel expression of sense and antisense transcripts 
(Krystal et al., 1990, Moorwood et al., 1998). This indicates the metabolism of sense: 
antisense hybrid is transcript or context-specific, with diverse downstream effects.  
 
1.2.2.4 Antisense RNAs associated with tumour suppressor genes and oncogenes 
Antisense transcripts are present in some tumour suppressor genes and could have a 
role in carcinogenesis as they have been found over expressed in carcinomas. 
Recently a NAT of p53 was characterized and named as Wrap53 that regulates 
endogenous p53 mRNA levels  by targeting the 5’ untranslated region of p53 mRNA. 
siRNA knockdown of Wrap53 results in downregulation of p53 mRNA and 
suppression of p53 induction upon DNA damage. On the contrary, overexpression of 
Wrap53 increases p53 mRNA and protein levels strongly suggesting that Wrap53 
influences p53 via Wrap53/p53 RNA interaction (Mahesharan et al., 1993). 
 
Many ncRNas show abnormal expression patterns in cancerous tissues, including 
miRNAs telomerase RNA, lncRNA. Details of the biogenesis and function of siRNA, 
are still largely unknown especially in mammals. On the other hand, miRNA are 
mostly known to function in differentiation and development as part of a large scale 
of regulatory network of many protein coding genes. Many microRNAs have been 
found in primary human tumours (Calin et al., 2002; Calin et al., 2004; He et al., 
2005; Lu et al., 2005). Moreover, many human microRNAs are transcribed at 
genomic regions linked to cancer (Calin et al., 2004; McManus, 2003). Of particular 
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interest is the mir-17 microRNA cluster, which is in a region on human chromosome 
13 that is frequently amplified in B-cell lymphomas (He et al., 2005). Overexpression 
of the mir-17 cluster was found to co-operate with Myc to accelerate tumour 
development in a mouse B-cell lymphoma model. Further evidence for such a link 
between Myc and the mir-17 cluster has come from microarray expression studies, 
which showed that mir-17 cluster gene expression was induced by the overexpression 
of Myc (O’Donnell et al., 2005). Also for the case of single nucleotide 
polymorphisms have been found in a transcript called rs11614913 that overlaps has-
mir-196a2 has been found to be associated with non-small cell lung carcinoma (Hu et 
al., 2008). Likewise, a screen of 17 miRNAs that have been predicted to regulate a 
number of breast cancer associated genes, were found to be regulated by microRNAs 
miR-17 and miR-30c-1. (Shen, et la., 2009) 
 
1.2.2.5 Antisense RNAs at imprinted genes 
Among the range of non-coding RNAs so far identified, a subgroup can be delimited 
associated with genes regulated by genomic imprinting. By definition, genomic 
imprinting is an epigenetic differential expression of autosomal alleles dependant on 
parent of origin (Reik et al., 2001a). Currently about 100 imprinted genes are known 
in the mouse and human genome (some annotated in Table 1.5).  
 
 NcRNA transcripts have been identified at a number of imprinted loci, which often 
occur as may contain both protein coding and noncoding genes 
(http://www.har.mrc.ac.uk/research/genomic_impriting). Imprinted expression has 
been found in diverse mammals, except in the egg-laying mammals, reinforcing the 
fundament of the proposed relation between genomic imprinting and the maternal 
allele control during gestation (O’Neill et al., 2005; Reick et al., 2003; Wilkins and 
Haig 2003). NcRNAs found at imprinted clusters include two classes of small 
regulatory RNAs. These are snoRNAs and miRNAs. In some cases lncRNAs are 


























































































































































In some cases one or more protein-coding genes are expressed from one allele 
whereas the other allele silences these genes and instead expresses an antisense 
ncRNA gene instead. Thereby, imprinted ncRNAs display discordant expression in 
cis with imprinted protein-coding mRNA genes, indicating that they may act as 
epigenetic silencers. Of the three imprinted ncRNAs so far tested, a silencing function 
has been shown for the Air and Kcnq1ot1 ncRNAs (Mancini-Dinardo et al., 2006; 
Sleutels et al., 2002). The H19 ncRNA, however, does not act as a silencer, despite 
showing a similar discordant expression pattern (Schmidt et al., 1999).  
 
Deletion of the ncRNA promoters in three other imprinted clusters is linked with loss 
of imprinting of cis-linked imprinted mRNA genes, suggesting that these ncRNAs 
may have a role on silencing  (Chamberlain and Brannan, 2001; Lin et al., 2003; 
Williamson et al., 2006). These imprinted overlapping pairs are linked with a wide 
range of pathologies, exhibiting a typical LOI in many cancers. In most of these 
examples except from Igf2 the sense transcript is maternally expressed and the 
antisense paternally expressed in either mouse or human. Igf2 and Igf2as are both 
paternally transcribed in the mouse. Air and also Tsix, have very long continuous and 
unspliced transcripts, however Tsix has also been shown to undergo complex 
alternative splicing (Table 4).  
 
1.2.2.5.1 The antisense RNA transcript AIR  
A nuclear ncRNA antisense transcript called AIR (Air for the mouse), partially 
overlaps with Igf2r. Air is a ~108-kb, capped, polyadenylated, and is transcribed 
exclusively by RNA pol II from the paternal allele (Braidotti et al., 2004; Seidl et al., 
2006; Wutz et al., 1997). The Igf2r/Air transcription at the Igf2r/Air locus (proximal 
chromosome 17) in the mouse genome is maternally expressed and paternally 
methylated. However it has been found overexpressed in WT in human (Vu et al., 
2003). Air is an unusual ncRNA because it has a conserved unspliced structure 
escaping from cotranscriptional splicing and persists as a nuclear transcript (Seidl et 




In this imprinting cluster a bidirectional silencer stops AIR transcription from the 
paternal allele whereas maternal expression persists from three protein coding genes 
Igf2, Slc22a2 and Slc22a3. This  is due to methylation and silencing promoter in cis 
as is expressed through 79 kb upstream the antisense (Rougeulle and Heard 2002; 
Sleutels et al., 2002; Zwart et al., 2001) (Figure 1.7). The silencing of these three 
genes (Igf2, Slc22a2 and Slc22a3) is a consequence of an unmethylated CpG island 
located in IGF2R intron 1 that serves as the AIR promoter. AIR overlaps with only 
one of the three imprinted genes in the domain, IGF2R, but not the other two Slc22a2 
and Slc22a3 suggesting that there might be more than one mechanism of silencing. 
Silencing by Air is also restricted to specific tissues at particular stage in 
development, specifically in the brain and placenta, the fundaments of how still 
unknown (Sleutels et al., 2002; Yamasaki et al., 2005).  Air is expected to act by 
other mechanism than base paring RNA-RNA duplex mechanisms for imprinting 
(Sleutels et al., 2002; Spencer and Lee 2006). The model of Air action involves two 
different steps. First, during Air silencing overlaps Igf2r by RNA interference 
(RNAi). Nevertheless, other work by Barlow and colleagues (Sleutels et al., 2003) 
does establish that when Igf2r expresion is silenced in the mouse model imprinting of 
Slc22a2, Slc22a3, and also Air persists.  
 
In addition to a direct interaction with Igf2r, Air could recruit chromatin modifier 
proteins to specific regions of the imprinted locus in a manner similar to the role 
suggested for Xist RNA, in order to repress Slc22a2, Slc22a3 (Sleutels et al., 2003). 
Consistent with this, Igf2r exhibits allele-specific histone modifications (Fournier et 
al., 2002). However, RNA FISH analysis using specific probes against Air RNA did 
not show coating by Air RNA of the imprinted chromosomal region (Braidotti et al., 
2004).  
 
In the Air knockout the mouse model when the targeted allele was present from the 
maternal allele the phenotype of the mice was not discernible. When the targeted 
allele was inherited from the paternal Igf2r paternal methylation was lost, and 
paternal silencing of two other genes within the same imprinted gene cluster 
divergently expressed in relation to Air. Also was found a 15% reduction in weight in 
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new born animals. This phenotype was reversible in a different experiment where 
male mice with Air truncation were combined with female mice containing a 3cM 
chromosomal deletion spanning the Igf2r locus. In normal conditions maternal 
inheritance of the Igf2r deletion is lethal at embryonic stage between E15.5-17.5. 
After interbreeding with the Air truncated allele mice these double heterozygous were 
of normal size, viable and fertile indicating that the lethal  Igf2r knockout phenotype  
was rescued by the paternal truncation of Air due to Igf2r expression from the 
paternal allele (Sleutels et al., 2002). 
 
 
Figure 1.7 Igf2r/Air imprinted cluster. Figure showing parent-of-origin imprinting 
expression of Air, Igf2r, Slc22a2 and Slc22a3 and non-imprinted genes Slc22a1, Plg 
and Mas. 
 
1.3 WT1 antisense transcription 
 
1.3.1 Identification 
As an additional ingredient to the complexity present at the WT1 locus is the presence 
of RNAs that do not appear to encode protein products. The WT1 antisense transcript 
was first isolated from WT RNA and mapped to the human 11p13 locus showing the 
same temporal expression pattern as WT1 although initially thought to be non-
overlapping. Those transcripts initially identified were between 2.1-2.7kb in length, 
polyadenylated, with three introns as indicated by the identification of four cDNAs of 
dissimilar lengths with common 3’ end. They were thought to be transcribed from a 
bi-directional promoter serving both WT1 and WT1-AS (Bonetta et al., 1990; Huang 
et al., 1990). These antisense transcript was initially called WIT-1 (now known as 
WT1-AS) with a telomeric-to-centromeric direction (antisense to WT1 transcription), 
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without discernable overlapping regions with the sense transcript initially named 
WIT-2 (now known as WT1), that were thought to arise  from a single CpG island, a 
common feature to many promoters regions (Huang et al., 1990). Even though 
transcripts were not cloned and sequenced, it was predicted that these two transcripts 
may span and work as a bidirectional promoter based on the fact of a pair of TATA 
boxes plus a CCAAT box.  The identification of a divergent transcription at the WT1 
locus in the human was observed in the WT1 locus (Gessler and Burns, 1993). Studies 
found more than one splice through exon/intron boundaries in that transcript by RT-
PCR product from human foetal kidney. It was also found in WTs cDNA to have a 
common shared single splice site.  
 
The initially identified WIT-1 antisense transcript does not harbor a long open 
reading frame and is expressed in the opposite sense with regard to WT1. Later 
experiments discovered multiple-spliced RNA isoforms produced from several 
transcriptional start sites, some of which produced antisense transcripts overlapping 
with the 5’end of WT1, exon 1 and intron 1 (Figure 1.8). Using RNase protection 
assays were performed to look for WT1 exon 1-spanning antisense transcripts in 
mouse tissues (Campbell et al., 1994) and strand-specific Northern blot in human 
(Eccles et al., 1994). The WT1-AS promoter has been identified in WT1 intron 1 
(Malik et al., 1995) called antisense regulatory region (ARR). Primer extension was 
used to show the WT1-AS transcriptional start site, within the ARR. However further 
functional analysis indicate the antisense isoform named as AS1 to be a potential 
regulator of WT1 (Dallosso et al., 2004).  
 
 
Figure 1.8 Scheme resuming the WT1 sense/antisense locus in human. The 
antisense transcription elements in red and sense transcription in black. Arrows show 






1.3.2 Functional characterization 
Deregulation of both sense and antisense transcripts was observed in a subset of WTs 
(Yeger et al., 1992). Prompted by this looking the biological relevance of WT1-AS, 
Moorwood (et al., 1998) found by co-transfection analysis with antisense WT1 exon I 
constructs evident a physiological role for the antisense transcript in regulation of its 
sense counterpart (Moorwood et al., 1998). High level of exon of exogenous WT1-AS 
expression led to down-regulation of the endogenous sense transcript. Lower levels 
(more physiological) of WT1-AS actually enhanced sense WT1 expression, resulting 
in increased WT1 protein. Interestingly, parallel expression of WT1 sense and 
antisense RNA, and also protein was observed in both WT and normal tissues from 
human foetal kidneys (Moorwood et al., 1998). In contrast to upregulation of WT1 by 
Wt1-AS found in 293 cells WT1 antisense reduced WT1 protein levels and inhibited 
the growth of several WT1-expressing cancer cell lines (Eccles et al., 1994; Oji et al., 
2002). Using a WT1 intron 1 probe identified a 7-10kb transcript in foetal kidney and 
WT samples. 
   
RNA duplex analysis has revealed that the 5’ regions of WT1 sense transcripts can 
duplex in vivo with overlapping antisense transcripts (Dallosso et al., 2004). This is 
analogous to N-myc sense and antisense transcript expression in neuroblastoma cells, 
which are found as hybridized duplexes in vivo (Krystal et al., 1990). Studies from 
Krystal et al., (1990), found that not every single N-myc sense/antisense duplex 
transcripts match equally, which might suggest being the same behaviour on WT1 
generating more transcripts upstream its major transcriptional starting sites. These 
may play a significant role modulating the splicing pattern on the antisense 
transcripts. In addition to this it has to be taking in account that function may not be 
purely dependent on the sequence properties but also the formation at least on 
secondary structure or in transcription from restricted chromosome spots with a 





A genome-wide screen of hypermethylated loci in breast cancer identified the WT1 
ARR in intron 1 (Huang et al., 1997). A subsequent study (Kleymenova et al., 1998) 
examined Wt1 alterations in rat mesothelioma (a well-established model of the human 
disease) and identified tumour-specific methylation in Wt1 intron 1. Plass et al., 
(1999) used methylation sensitive restriction landmark genomic scanning (RLGS-M) 
to identify WIT-1 as a gene that was specifically hypermethylated in intron 1 and 2 of 
relapsed, similar to AML and complete remission (CR) samples. Malik et al., (2000b) 
discovered that the WT1-AS transcript is imprinted in human adult kidney. In the 
developing kidney WT1-AS transcription is expressed from both alleles (paternal and 
maternal). Differential methylation of the ARR was found in normal kidneys, 
accompanied by monoallelic expression of WT1-AS. In a subset of WT ARR 
hypomethylation was concordant with biallelic expression of WT1-AS suggesting 
incidence of the epigenetic state (Malik et al., 2000). Recent work (Dallosso et al., 
2007) has identified imprinting of WT1-AS in human postnatal kidney, and ARR 
hypomethylation together with loss of imprinting of the WT1-AS as an early event in 
WT tumourgenesis. This suggests an epigenetic deregulation involving WT1-AS in a 
range of cancer types. Therefore the characterization of the WTI-AS transcript and 
elucidation of its function are of increasing significance.  
 
A further WT1-AS transcript was identified from a foetal kidney EST library, and its 
presence was confirmed by real time RT-PCR in adult and foetal kidney, spleen and 
WT tissue. However it was absent in liver or brain, whereas the antisense transcript 
isoforms were also expressed in these tissues (Dallosso et al., 2007). Such tissue 
specificity might suggest that certain aberrations of splicing may play a critical role in 
the etiology of carcinomas. This was supported by the finding that WT1-AS transcript 
isoforms were aberrant in more than 50% of patients with AML and 25% of patients 
with acute lymphocytic leukemia (Dallosso et al., 2007). 
 
In the mouse, Wt1 exon 1-spanning antisense transcripts have been reported very 
similar to Wt1-AS transcripts (Campbell et al., 1994). Other reports have identified 
divergent transcripts upstream of mouse Wt1, but failed to detect Wt1-overlapping 
RNAs (Gong et al., 2001). In the latter case, a  mouse metanephric cell line which 
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expresses wt1 (M15 cells) and  organs from neonatal mouse were analysed by RPA 
using probes to detect either far upstream, exon 1 or the intron 1/exon 1 boundary 
within Wt1. An antisense transcript was identified with a 5’ end upstream of Wt1 in 
the M15 cell line, kidney and spleen, but none that overlapped WT1 exon 1 or intron 
1 (Gong et al., 2001). More recently three alternatively spliced Wt1-AS were isolated 
from neonatal mouse tissue overlapped with Wt1 exon 1 and intron 1, and had a large 
splice of ~25kb, upstream of main Wt1 transcriptional start site (Dallosso et al., 
2007).   
 
1.3.3 A transgenic mouse model for Wt1-AS  
In the last few decades mutant mouse models have proven to be one of the most 
useful tools for collecting details about WT1 gene expression and its role during 
urogenital system development. These models are providing a more comprehensive 
approach, useful for discovering the role of a particular gene looking at the normal 
and abnormal function. Furthermore, they have allowed for the discovery of organs 
other than kidneys whose development is regulated by WT1 (Discenza and Pelletier 
2004).  
 
The analysis of human and mouse sequence data has highlighted two upstream 
conserved regions, termed MCR1 and MCR2 which lie ~12 and 5kb upstream of 
WT1 exon 1 respectively (Figure 1.9). Using a gene-targeting approach, a mouse 
model was created with the aim of comparing the function of MCR2 as an RNA 
species and as a DNA element with respect to regulation of Wt1 expression and 
overall mouse development. Both (MCR1 and MCR2) elements are located at the 3’ 
termini of alternately spliced, non-coding antisense transcripts from human kidney, 
and MCR2 shares 94% sequence identity between mouse and human over 289 bp. 
This high inter-species homology implies a functional role for MCR2. Although it 
might have been more informative to knockout Wt1-AS expression, perhaps by 
mutating the WT1-AS promoter, this may have also directly interfered with Wt1 
expression making it impossible to differentiate the role of Wt1-AS on its own. 
Transient transgenic mice that have been generated with a construct containing the 
298 bp conserved MCR2 region linked to a minimal promoter-lacZ cassette show a 
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subset of WT1 expression (Colin Miles, personal communication) demonstrating that 
this conserved region can have enhancer activity.    
 
Two different animal models were created to analyze the role of WT1-AS, one with  
truncated allele and another one with a deleted allele.  Different data can be recovered 
from each model if WT1-AS has a separate function, respectively either as a DNA 
enhancer element or as an RNA element at the transcriptional level. 
 
The targeting construct incorporates Mcr2 and surrounding Wt1 homologous regions 
(H), a neomycin resistance gene (GKneo) that allows for positive selection within ES 
cells, a transcriptional terminator sequence (TTS) orientated to cause a premature 
termination of WT1-AS transcripts and a diphtheria toxin (DTA) that allows negative 
selection of ES cells those that incorporate the targeting construct at a random 
location. LoxP sites have been strategically introduced to allow a cre-recombinase 
mediated 2-step targeting strategy after introduction into ES cells. Deletion between 
the two LoxP sites flanking the neomycin gene (Δ1) leaves Mcr2 intact, but result in 
transcripts that are terminated before transcription of Mcr2. Deletion between the two 
LoxP sites flanking both the neomycin gene and Mcr2 (Δ2) however, will in result 
the removal of the Mcr2 region as well as premature termination antisense transcripts 
(Figure 1.10).  
 
 
Figure 1.9 Schematic of the WT1 5’ upstream region, showing nucleotide 
identity between human and mouse genes. A percentage of identity plot between 
human (NT-009237) and mouse (AL512584) upstream WT1. The highly conserved 
regions MCR1 and MCR2 are indicated below. Scale is indicated in kb pairs with 
conserved features positioned relative to a major WT1 transcriptional start site 
(Hoffmann et al., 1993). Regions of sequence identity between 50-100% are display 
by continuous lines of alignment (CLIC Sargent Research Group, University of 












Figure 1.10 Targeting constructs upstream at the 5’ region of the WT1 locus. At 
the top shows the construct before genomic rearrangements were made from LoxP 
recombination. In middle Δ2 construct (Trigger) shows Mcr2 flanked by LoxP sites 
and a transcriptional terminator sequence (TTS). These elements are surrounded by 
homologous regions (H). At the bottom Δ1 (Davis) shows the same organization but 
without Mcr2. Image provided by Dr. Kim Moorwood and Dr. Joanne Stewart-Cox. 
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1. To look at conservation of Mcr2 in vertebrates. 
2. To establish whether the WT1 antisense gene is indeed truncated in the 
mutant mouse.  
      3. To characterize the role of an endogenous antisense transcript in the                                
regulation of expression from the mouse Wt1 locus: 
 
3.1 To determine whether the introduced mutation results in any changes in the                             
expression of sense Wt1 and Awt1 at the level of mRNA or protein. 
 






















































2.1.1 Vertebrate conservation analyses 
Multiple alignments of 30 vertebrate species were performed using the NCBI genome 
Browser and the July 2007 (NCBI37/mm9) mouse genome assembly. This was 
provided by University of California Santa Cruz (http://genome.ucsc.edu, 
Rosenbloom et al., 2009). The multiple alignments were generated using “multiz” 
and other tools in the UCSC/Penn State Bioinformatics comparative genomics 
alignment pipeline. The conservation measurements were created using the 
“phastCons” package from Adam  Siepel at Cornell University. 
  
2.1.2 Open Reading Frame search 
The analyses of possible start and stop codons of translational open reading frame 
(ORF) were performed by the Swiss Institute of Bioinformatics (http://www.isb-
sib.ch/). 
 
2.1.3 Protein structure prediction 
The Protein Structure Prediction Server (PSIPRED) aggregates several of the 
structure prediction methods into one location and was used to predict protein 
structure. This was performed using the informatics browser 
(http://bioinf.cs.ucl.ac.uk/psipred) 
 
2.1.4 CpG island prediction 
A CpG island search was made using the public server provided by the European 
Bioinformatics Institute (http://www.ebi.ac.uk/). 
 
2.1.5 QTL 
The Map of Quantitative Trait Loci (QTL) was obtained from Mouse Genome 
Informatics (MGI), annotated by NCBI (http://www.ncbi.nlm.nih.gov) and made by 
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the Mouse Genome Database (MGD): mouse biology and model systems 
(http://www.informatics.jax.org, Bult et al., 1999). 
 
2.2 Mice usage 
 
2.2.1 Animal husbandry 
All animals were maintained in accordance with the United Kingdom Home Office 
Regulations of animal studies. This involves on an artificial light/dark cycle, 
receiving 13 hours of light and 11 hours of darkness (including 30 min of false dawn 
and dusk lightning). Ambient temperature was kept at 21± 2ºC and a relative 
humidity of 55± 10%. Cages were individually ventilated with a housed density of up 
to 6 animals per cage.  Animals were provided with food (CRM formula, Special 
Diets Services; Witham, Essex, UK) and water ad libitum.  
 
2.2.2 Methods of sacrifice 
Animals used during the course of this study were culled according to the Home 
Office Schedule 1 Kill. Embryos were sacrificed by immediate immersion in ice cold 
PBS upon removal from the uterine horns. Neonatal animals were sacrificed by 
decapitation due to the requirement for intact organ tissue. Adult animals were 
sacrificed by cervical dislocation. 
 
2.2.3 Mouse lines with genetically modified Mcr2 
The Mcr2 Davis and Trigger lines used in this study were generated from a gene-
tageted embryonic stem cell line. The gene targeting construct shown in Figure 1.10 
was integrated into a genomic location upstream Wt1 promoter. Chimeras were 
generated by Dr Kim Moorwood and Dr Joanne Stewart-Cox. Mosaic LoxP re-
arrangements were induced by crossing gene-targeted mice with mencre 40 mice. 
Both lines were maintained on 129/C56BL/6/CBA mixed background. 
 
2.2.4 Genotyping of mice 
Genotyping of mice was done by polymerase chain reaction (PCR) (see Section 
2.5.4). Biopsy samples were dependent upon the developmental stage of the whole 
animal, as follows: embryo, tail clip; neonate, tail clip; adult, ear clip.DNA was 
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prepared by boiling tissue for 10 min in 600 µl of 0.1 M NaOH.  Samples were then 
neutralized by addition of 50 µl 1 M Tris-HCl pH8.0 and vortexed for 30 sec. 1 µl of 
each boiled sample was used as template each PCR. 
 
2.3 Histological analyses 
 
2.3.1 Postnatal organ dissections 
Neonatal and adult mice were sacrificed as described in section. Whole body weight 
was recorded. Individual organs were then dissected from the body. Tissues were 
dabbed dry of fluid and their weights recorded.  
 
2.3.2 Fixation and wax embedding of tissues 
Dissected tissues were biopsied and incubated into PBS containing 4% PFA (w/v 
paraformalidehyde, Sigma-Aldrich) overnight at 4ºC. The following day organs were 
washed briefly in PBS then transferred to 70% ethanol and stored at 4ºC until 
processed (no later than 72 hr following fixation). Processing was carried out in a 
Leica TP machine with 2x 2 hour washes in 70% ethanol, 90% ethanol, 100% 
ethanol, histoclear clearing solution, followed by 3x 2 hour washes in 40ºC molten 
wax (Raymond Lamb). Following processing, tissues were embedded in 40ºC molten 
wax within histology cassettes and allowed to cool until solid on a 4ºC cooled 
platform embedding station (Leica, EG1160). 
 
2.3.3 Sectioning of wax embedded tissues 
Sections of 8 um in thickness were cut using a microtome (Leica, RMA2155) and 
placed onto Superfrost plus coated slides (Fisher) (antibody staining) or APTS 
subbed sides (for histological staining), dried at 38ºC overnight then stored a t 4º C.  
 
2.3.4 Subbing slides with APTS 
Slides were initially washed in hot soapy water followed by thorough rinsing in hot 
water and a quick rinse in reverse osmosis (RO) water then in a solution of were then 
placed in to 2% 3-triethokysilpropilamine (APTS) in acetone for 10 min followed by 
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rinsing twice in acetone for 10 sec the twice in RO water for 10 sec. Finally slides 
were baked dry at 37ºC. 
 
2.3.5 Hematoxylin and eosin (H&E) staining of sectioned tissues 
Slides with 8 µm wax sections were washed twice in histoclear clearing solution 
(National Diagnostics) for 2 min to remove wasx. The slides were then hydrated 
though a descending ethanol series for 2x 1 min each in 100% ethanol followed by 1x 
1 min each in 95 ethanol, 90% ethanol, 70% ethanol, 50% ethanol. The slides were 
placed in milliQ water for 1 min before staining in hematoxylin for 15 min. To 
eliminate non-specific binding of haematoxylin, slides were placed under gently 
running tap water for 3 min, followed by 30 sec wash in 1% concentrated ammonia 
(NH3) in 70% ethanol and a final 30 sec wash in 70% ethanol. Slides were then 
dehydrated through an ascending ethanol series for 3 sec and 70% ethanol, 5 sec in 
95% ethanol, 2x 1min in 100% ethanol, washed twice in histoclear solution for 2 min 
each and mounted using DPX mount (Sigma) overlaid with coverslip. 
 
2.3.6 Periodic acid-Schiff (PAS) staining 
Slides with 8µm wax embedded organ sections were washed twice in histoclear 
clearing solution (National Diagnostics) for 2 min to remove wax. The slides were 
then hydrated through descending ethanol series for 2x 1 min in 100% ethanol 
followed by 1x 1 min each in 95% ethanol, 90% ethanol, 70% ethanol, 50% ethanol. 
The slides were placed in milliQ water for 1 min then transferred to freshly prepared 
1% periodic acid for 6 min. Slides were washed by placing them under gently tap 
water for 3 min then into miliQ water for 1 min. Staining was carried out at room 
temperature in Schiff’s reagent (Sigma) fro 15 min. Slides were washed by placing 
them under gently running tap water for 5 min then counter staining in haematoxylin 
for 1.5 min. Finally slides were dehydrated through an ascending ethanol series as in 
section 2.3.5, washed in histoclear twice for 2 min each then mounted using DPX 








2.4 Other analytical methods 
 
2.4.1 Dual X-ray absoptiometry analysis (DXA) 
Body composition was quantified by subjecting whole carcasses of adult mice to 
DXA analysis using a PIXImus scanner (Lunas Maddison; WI, USA) with small 
animal software. Physiological parameters recorded included total area, total weight, 
lean weight, fat weight, bone mineral density (BMD) and bone mineral content 
(BMC) (Samuels et al., 2001).  
 
2.4.2 Urine collection from mice 
Urine samples were collected form mice either by scruffing and holding a 1.5 ml 
microcentrifuge tube under urethra or by individually housing the mice in cages 
without sawdust and using a Pasteur pipette to collect urine from the bottom cage. 
The urine samples were immediately frozen until needed.  
 
2.4.3 Urine Osmolarity 
Urine osmolarity was measured by Micro-Osmometer 3300 (Advanced instruments, 
USA). To measure samples a tip was loaded with 20 µl of sample. Before starting test 
the sampler was within the operating cradle and beneath the cradle top. To start the 
test the entire operating cradle was pushed down until it reached a positive stop. After 
one minute the machine displayed a reading.  
 





) were measured by indirect ion selective electrode (ISE). 
Creatinine was detected and measured by the Jaffe method. Urea was quantified by 
using kinetic UV spectrophotometer. Urine composition analyses were performed by 






2.4.5 Statistical analyses 
All statistical analyses were performed using GraphPad (v3.0 Graphpad Software, 
CA, USA). The exact tests employed for each analysis are denoted in the 
corresponding figure legends in Chapter 5. One way ANOVA non-parametric was 
performed for comparing three groups. This was followed by Tukey test. For 
comparing two groups T-student was employed. 
 
2.5 Molecular Biology Techniques 
All solutions were made according to Sambrook and Russell (2001) with purified and 
deionised water, prepared with the MilliQ water filtration system (Millipore 
Corporation, MA, US) using reagents supplied by Fisher Scientific unless otherwise 
mentioned. 
 
2.5.1 Agarose gel electrophoresis 
Agarose gels were made using between 1 % and 2% weight per volume (depending 
on the nucleic acid expected) by melting agarose (invitrogen) in 1x TAE (0.04M Tris-
acetate, 0.001M EDTA pH 8.0). Before pouring into a gel casting tray, 2.5 ul of 
ethidium bromide (10mg/ml) per 50 ml agarose was added to allow visualization of 
nucleic acids. One sixth volume 6X loading dye (Promega) was added to each 
DNA/RNA sample before loading into the wells of the gel. Samples were 
electrophoresed at 90-100V for 45min or until the DNA ladder was separated. The 
DNA or RNA samples were visualized under uv light. When RNA samples were run, 
the gel tank, gel tray and combs were soaked first with 3% hydrogen peroxide for 30 
min, then rinsed with sterile diethyl pyrocarbonate (DEPC)-treated water (1ml DEPC 
0.1% (Sigma Aldrich) v/v). Nucleic acids were viewed under uv radiation and 
photographed using an Alpha imager 3400. 
 
2.5.2 RNA isolation from tissue samples 
After schedule I Killing (2.2.2). Organs, whole embryos or tissue biopsies were 
isolated and snap-frozen in liquid Nitrogen. RNA was purified from frozen samples 
using TRI reagent (Sigma Aldrich), following the manufacturer’s instructions. 50-100 
mg tissue was homogenized thoroughly in 1 ml ice-cold TRI reagent using a T8.01 
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homogenizer (GMBH and Co., Germany). Samples were stored for 5 min at room 
temperature. After the incubation 0.2 ml chloroform per 1 ml of TRI reagent was 
added, vortexed and centrifuged at 12,000 x g for 10 minutes in a microcentrifuge at 
4ºC. Aqueous phase was placed in a new tube where RNA was precipitated with one 
volume isopropanol v/v and centrifuged at 12,000 for 8 min 4ºC. Washes were made 
with 75% ethanol and subsequent centrifugation at 7,500 g for 5 min. The RNA pellet 
was air-dried for 3-5 min. RNA was resuspended in RNase-free water. 
 
2.5.3 cDNA synthesis 
For semi-quantitative reverse transcription PCR (RT-PCR) 1 µg of DNase I-treated 
RNA using RNA used for cDNA synthesis was first treated using the “DNA-free” kit 
(Ambion) which contains DNAseI, to remove contaminating genomic DNA (as per 
manufacturer’s protocol). Sample was heated to 65 ºC for 5 minutes in a G-Storm 
mark 1 thermal cycler in a total volume of 13 µl. with 1 mM dNTP mix (Invitrogen) 
and 5 uM random primers (Promega). The thermal cycler was paused and samples 
incubated on ice for 1 min. The SuperScript III reverse transcriptase system 
(Invitrogen) was used to synthesize cDNA. A control as set up for each sample, in 
which the reverse transcriptase enzyme was omitted, permitting accurate 
interpretation of subsequent PCR amplification. For strand specific cDNA synthesis 
RNA samples, sense or antisense primer and dNTPs were heated at 65 ºC 
amplification and then placed on ice for one minute. Then all components except 
SuperScript III reverse transcriptase were mixed and centrifuged. The mix of reaction 
was then incubate at 25 ºC for 2 minutes. Immeditly after the  reverse transcriptase 
was added and incubated at 25ºC (10 minutes), 65ºC (50 minutes) and 70ºC (15 
minutes). cDNA samples were then stored at -20ºC.  
 
2.5.4 Polymerase Chain Reaction 
1 µl of template (e.g. 0.1-1 µg purified genomic DNA, 5-50 pg plasmid DNA, cDNA, 
bacterial colony lysates, or ear clip was used for PCR.  Samples were amplified in a 
total volume of 15 µl containing 1X GoTaq Green master mix (Promega, USA) and 
0.6 µM each relevant primer using the following experimental parameters: Initial 
denaturation, 5 min 94ºC followed by 25-40 cycles of 30 sec at 94ºC, 30 sec at 60ºC, 
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30º sec at 50-68ºC and completed with a final extension step of 5 min at 72ºC. 
Conditions for specific primer pairs are described in Table 4.1 Fragments longer 
than1.5 kb were amplified using a high performance polymerase Kod Hot-start DNA 
polymerase (Novagen-Germany), according to the manufacturer’s instructions. 
Amplification of all samples was performed on a G-Storm mark 1 thermal cycler 
(Gene Technologies Ltd., UK). DNA oligonucleotides used as PCR primers were 
purchased commercially (Invitrogen, UK). PCR products were visualized by agarose 
gel electrophoresis (see Section 2.5.1).  
 
2.5.5 Real time quantitative PCR 
Comparative quantification of RNA levels real-time PCR was performed using 
SYBR green technology on an Mx3000P detection system (Stratagene). The 20 mL 
reactions were performed using Platinum SYBR Green qPCR supermix-UDG 
(Invitrogen). Samples were normalized relative to the housekeeping gene Tbp. This 
experiment was performed by Dr. Anne L. Hancock, University of Bristol, UK. 
 
2.5.6 Western blotting 
Whole neonate kidneys were homogenized in 1 ml Igepal CA-630 lysis buffer 
(50mM Tris-HCl pH 8.0, 150 mM NaCl, 1% (v/v) Igepal CA-630 (Sigma Aldrich), 
plus one protease inhibitor cocktail tablet (Roche) per 10 ml buffer). Samples were 
incubated on ice for 30 min to permit cell lyses and passed through a gauge needle 5 
times. Suspensions were centrifuged at 100,000 x g for 30 min (Beckman TL-100 
ultracentrifuge) at 4ºC and the pellet discarded. 
 
Total protein concentration was determined using the BCA protein assay kit (Pierce, 
USA) and samples stored at -20ºC. 20 µg of each sample was mixed with 2x reducing 
sample buffer (250 mM Tris HCl pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol (Sigma 
Aldrich), 10% (v/v) β-mercaptoethanol (Sigma Aldrich), 0.02% (w/v) bromophenol 
blue (Sigma Aldrich), heated to 95ºC for 5 min then kept on ice. Samples were loaded 
onto a polyacrylamide gel (resolving gel: 8% polyacrylamide (National Diagnostics, 
GA, USA), 0.37 M Tris-HCl pH 8.8, 0.1% SDS, 0.05% ammonium persulfate 
(AMPS) (Sigma Aldrich), 0.05% TEMED (Sigma Aldrich); stacking gel: 5% 
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polyacrylamide, 0.12 M Tris-HCl pH 6.8, 0.0% AMPS, 0.1% TEMED) alongside 
pre-stained protein standards (Fermentas, UK), and run at 100 V for 90 min in 
running buffer (0.1% SDS, 25 mM Tris-HCl, 208 mM glycine (Fluka, Sigma 
Aldrich). Protein was transferred onto PVDF membrane (Bio-Rad Laboratories) by 
wet transfer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol (Fisher Scientific) 
Transfer Buffer. All subsequent incubations were performed on an orbital shaker. The 
membrane was blocked in TBS-T (recipe) with 5% powdered skimmed milk (Tesco, 
UK) for 2 hours at room temperature. Primary antibodies were diluted in TBS-T 
(50mM Tris-HCl pH 7.4, 200 mM NaCl 0.01% Tween-20) and %5 powdered milk 
(see Table X.X for antibody concentrations used) and applied to the appropriate 
membranes. Overnight incubation was performed at 4ºC. Membranes were washed 
three times in PBS-T for 15 min per wash, and incubated in peroxidase-conjugated 
goat anti-rabbit secondary antibody (Vector Laboratories, CA, USA) diluted 1/10,000 
in TBS-T with 5 % powdered milk and applied to the membrane for 1 hour at room 
temperature (Table 2.2). Three further washes were performed as before and protein 
detection was achieved using the ECL-Plus system (GE Healthcare), as directed by 




Tissue sections were prepared from wax blocks as in section 2.3.3. Slides were 
prepared as in section 2.3.5. Antigen retrieval was done by boiling slides in urea 
solution (0.8M, pH6.4) for 2 x 10 min in a microwave oven. This was followed by a 
10 min PBS wash. All washes were performed at RT on rocking platform. Each 
section was drawn around section with a wax pen. Incubation with the primary 
antibody was done by dilution in 0.1% BSA/Blocking serum.Non-specific binding 
was blocked for 20 min with 1 drop serum per 3.3 ml PBS. This was followed by 
PBS wash with gentle shaking 2x 5min. Before blocking non-specific binding the 
slide was drawn around the section with a wax pen. Blocking was subsequently done 
for 20 min (1 drop blocking serum 3.3ml 1XPBS) overnight at 4C. After incubation 
washes were done with PBS/0.25% Triton X-100 wash 1x 5 min then PBS with 
gentle shaking 1x 5 min. Biotinylated secondary antibody was incubated for 30 min 
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(3 drops serum in 10ml PBS with 1 drop 2 antibody) at RT. Washes from incubation 
were performed using PBS/0.5% Triton X-100 1x 30 min then PBS 1x 5 min. In 
order to quench endogenous peroxidase activity sections were incubated 5 min with 
3% Hydrogen Peroxide (H2O2 (Sigma Aldrich) (w/w) solution. This was followed by 
a wash in PBS 1x10 min. Pre-formed AB complexes (vector) were applied to the 
sections for 30 min at RT then washed in PBS with gentle shaking 1x 10 min. DAB 
staining was used to detect anybody complexes, this was applied for 5 min (DAB 
peroxidase substrate kit (Vector). Excess stain was removed by washing in running 
tap water for 5min. Haematoxylin counterstain was applied as in then slides were 
dehydrated, cleared and mounted under a coverslip as in section 2.3.5. 
 























































































Primary Antibody Secundary Dilution 
α-Tubuline α-mouse 1:30,000 
C-19 α-rabbit 1:100 




























Chapter 3: Insights into Mcr2 sequence 














































In mouse as well in human transcription upstream of WT1 is abundant and has 
not fully described in the literature and has unknown function. In order to elucidate 
their biological function we set out find conserved elements within this region which 
we predicted might fulfill this putative functional role.  
 
As described in Section 1.3.3 two genomic sequences were previously discovered in 
human and mouse with a high level of sequence conservation named Mcr1 and Mcr2 
both within 20 kb upstream of WT1 exon 1 (Figure 1.6). Mcr1 was longer in length 
with a lower overall sequence identity and further upstream from WT1. Therefore the 
present work was focused on Mcr2 (sequence shown in Figure 3.1). Due to the high 
level sequence identity between human and mouse Mcr2, was of interest to extend the 
conservation analyses to other vertebrate species. This was also carried on for other 
relevant sequences such as Mcr1, reported neighbouring transcripts, Wt1 exonic 
sequences and known ncRNAs. 
In the case of Mcr2 we also looked at ultraconserved sequences which are defined as 
DNA fragments of at least 100 bp with 100% sequence identity between mouse, 
human and rat (Bejarano et al., 2004). These may have functional roles, particularly 
as transcriptional enhancers (Pennachio et al., 2006). However ultraconserved 
elements represent a class of genetic elements whose functions and evolutionary
 
origins remain to be determined. In order to predict other possible functional features 
of Mcr2, its sequence was analyzed for putative open reading frames (ORF). Protein 
coding sequences are more highly conserved than sequences expressed as ncRNA. 
Therefore we wished to establish whether Mcr2 might have protein coding capacity. 
All six possible translational ORF were tested. Start codons were not considered 
necessary because Mcr2 could represent a single exon belonging to a longer spliced 
mRNA. Thereby using software analysis we were able to look at protein structure 






Previous evidence showed that untranslated conserved regions have a role as a 
transcriptional enhancers (Pennacchio et al., 2006). Due to the high identity between 
Mcr2 in mouse and human it has been previously tested and shown to be an enhancer 
element in lacZ reporter transgenic mice (unpublished observations, Colin Miles, 
personal communication). In a recent study an element comprising part of Mcr2 was 
also identified as a zebrafish transcriptional enhancer. This element was found to bind 
members of the retinoic acid receptor family factors and to mediate responsiveness to 
retinoic acid (Bollig et al., 2009). However this sequence has not previously been 
functionally characterized in any mammalian model. In a different aspect we also ran 
CpG island predictions for Mcr2 and its local genomic sequence environment and 
looked in to Quantitative Trade Loci shown to map to Mcr2 on the NCBI database. 











Figure 3.1 Mcr2 sequence.  The mouse Mcr2 DNA sequence is shown in capitals 
(Total length 298 bp) in C57BL/6 strain flanked by contiguous sequence in non-
capitals. The mouse Mcr2 (5’-3’) sequence in capitals sequence and highlighted in 
red showing total length of 298 bases in C56/B6 strain flanked by contiguous 
fragments in non-capitals. 
 
3.2 Results 
 3.2.1 The Wt1 antisense locus 
Upstream from the mouse Wt1 promoter a number of spliced and unspliced (see 
Figure 3.2) antisense transcripts have been reported in testis, spleen and ovaries (See 
Appendix, Supplementary Table 1). From these only the unspliced AK172697 
overlaps with Wt1 promoter (by 15 nucleotides). AK165089 and also AK161318 
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appear to initiate immediately upstream of the Wt1 promoter, being transcribed in the 
opposite direction to Wt1 mRNA. These two transcripts are spliced to sequences very 
far upstream from Wt1 (about 30 and 50 kb from Wt1 promoter respectively) (Figure 
3.2), so that none of these two reported RNAs include the Mcr2 sequence. In fact 
Mcr2 is not present in the Genbank database as an expressed sequence at all (Figure 
3.2). In case of the human locus Mcr2 is present in transcripts, some of which overlap 
Wt1 exon1, been originated in intron1 (Malik et al., 1995) (Figure 3.3).  
 
 
Figure 3.2 Transcripts reported within 55 kb of mouse Wt1. Mcr2 is marked in 
red, and is positioned 4.613 kb from Wt1. Far left, Wt1 gene; middle, blue boxes: 
cDNA exons from specific tissue; green boxes: from mRNA without described 
source. For full description of source of all those cDNAs and mRNA see Appendix, 
Supplementary Table 1. Far right, chromosome 2 sale bar (kb). Highlighted 






Figure 3.3 Transcripts reported within 8 kb upstream of human WT1. Scheme 
shows transcription reported within 8 kb of human WT1. MCR2 is marked in red. Far 
top left blue box is WT1 (exon 1) followed down by WIT1 (WT1-AS). Middle blue 
boxes: cDNA exons from specific tissue; green boxes: from mRNA without 
described source. For full description of source of all those cDNAs and mRNA see 
Appendix Supplementary, Table 2. Far right, chromosome 2 scale bar (kb). Figure 
adapted from NCB1 screen-dump. 
 
 
3.2.2 Predictive analyses of functional properties of the Mcr2 sequence  
3.2.2.1 Open reading frames at Mcr2 
All six possible translational reading fames were interrogated in order to elucidate the 
protein coding capacity of Mcr2 (Figure 3.4). This was performed by using the public 
server provided by the Swiss Institute of Bioinformatics (http://www.isb-sib.ch/). The 
longest ORF was found on the sense 5'-3' translation frame 3, with a total of 65 amino 
acids including start and stop codons (4 kDa of predicted protein mass), 40 amino 
acids within Mcr2, then continuing towards WT1. Due to the minimal length of each 
96 
 
ORF it seems unlikely that Mcr2 is translated into a peptide. The lack of predicted 
translation of Mcr2 suggests that it may exist as a part of the ncRNA class.  
5'-3' Frame 1 
L S F L G Stop K H K N T N T L K E F S K V R R L K S L S Stop V L L L L L L L L F F F F F F F L F F 
S P P P PL F A K L N L G S G V L I V T S D W N S R W C A L D W K Q L S V H Q F H G L P Y L L 
W P R P G L H P H C G I N A E Q I E T Y P L Y N Stop F Q N L K R F T G Stop Stop Stop K Q R C 
Stop I L S L V A L G E L G N P V V W R Q N T A A P G T R N W G K G K I C I S H Q A V L G G L G 
G F S P L T R P G R R V Stop S P D G R  
5'-3' Frame 2 
Y H F Stop V K N I K T Q I L Stop K N F L R Stop E D Stop S L C H K F S S S S S S S S S S F S S S 
S F F F H R P H P C L Q S Stop I W G Q E F Stop L Stop P Q T G I P D G A L W T G S N S Q F I N 
F Met G F H I C S G H G L V S I P T V A L Met Q N K L R H I L Y I I S S R I Stop K D L R D N N R S 
S A A E S F H W W L L G S W G T P W C G V K T L R L Q A P G T G G R A K F A S R T R Q C Stop 
V V Stop V V L A P Stop P G Q G G E F E A Q Met E G  
5'-3' Frame 3 
I I S R L K T Stop K H K Y F E R I F Stop G E K I K V S V I S S P P P P P P P L L L F L L L P F F F T 
A P T L V C K V E S G V R S S N C N L R L E F Q Met V R S G L E A T L S S S I S W A S I S A L A 
T A W S P S P L W H Stop C R T N Stop D I S S I Stop L V P E F K K I Y G I I I E A A L L N P F I G 
G S W G A G E P R G V A S K H C G S R H Q E L G E G Q N L H L A P G S A R W F R W F Stop P L 
N Q A R E E S L K P R W K V  
3'-5' Frame 1 
N L P S G L Q T L L P G L V K G L K P P K P P S T A W C E Met Q I L P F P Q F L V P G A A V F 
Stop R H T T G F P S S P R A T N E R I Q Q R C F Y Y Y P V N L F K F W N Stop L Y R G Y V S I C 
S A L Met P Q W G W R P G R G Q S R Y G S P Stop N Stop Stop T E S C F Q S R A H H L E F Q S 
E V T I R T P D P R F N F A N K G G G G E K K R K K K K K K K R R R R R R R R T Y D R D F N L L 
T L E N S F K V F V F L C F Stop P R N D  
3'-5' Frame 2 
T F H L G F K L S S L A W L R G Stop N H L N H L A L P G A R C K F C P S P S S W C L E P Q C F 
D A T P R G S P A P Q E P P Met K G F S S A A S I I I P Stop I F L N S G T N Y I E D Met S Q F V L 
H Stop C H S G D G D Q A V A R A D Met E A H E I D E L R V A S S P E R T I W N S S L R L Q L E 
L L T P D S T L Q T R V G A V K K K G R R R K R R R G G G G G G G E L Met T E T L I F S P Stop 
K I L S K Y L C F Y V F N L E Met I  
3'-5'Frame3 
P S I W A S N S P P W P G Stop G A K T T Stop T T Stop H C L V R D A N F A L P P V P G A W S R 
S V L T P H H G V P Q L P K S H Q Stop K D S A A L L L L L S R K S F Stop I L E L I I Stop R I C L 
N L F C I N A T V G Met E T R P W P E Q I W K P Met K L Met N Stop E L L P V Q S A P S G I P V 
Stop G Y N Stop N S Stop P Q I Q L C K Q G W G R Stop K K K E E E E K E E E E E E E E E E N L 
Stop Q R L Stop S S H L R K F F Q S I C V F Met F L T Stop K Stop Stop 
Figure 3.4 Mcr2 ORF prediction. Scheme showing predicted translation of the 
mouse Mcr2 region marked in grey and bold characters flanked by continuous 
neighbouring sequences. The largest possible translated region is given by the sense 
orientation 5’-3’ on frame 3 shown underlined. 
 
3.2.2.2 Secondary structure prediction 
Because most of the ORFs were considered too short to encode proteins, the 
PSIPRED secondary structure prediction method (Bryson et al., 2005) was employed 
to elucidate if any discernable protein structural features were present on the longest 
ORF 5'-3' Frame 3. The PSIPRED Protein Structure Prediction Server aggregates into 
one location under several of the structure prediction methods. No metal response 
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elements were found or transcription factor motifs were found. However, its predicted 
amino acid sequence is expected to form a coil-helix-coil (Figure 3.5 B). Also a MAR 
motif was found by looking at possible matrix attachment region it also comprises 
amino acid 3 until 22 (Figure 3.5 A). 
 
 
Figure 3.5 Schematic descriptions of secondary structures. (A) position of matrix 
attachment region; (B) position of helix domain; (C) legend related to B. Figure 
adapted from PSIPRED screen-dump. 
3.2.2.3 CpG island prediction near Mcr2 
Many developmental and in particular antisense ncRNAs genes have been found 
silenced due to hypermethylation. So that has been speculated that about half of 
mammalian genes, and, possibly every mammalian house-keeping gene have a CpG-
rich region near by their 5' end (Bird, 1986). In WT1 a CpG island cause 
hypermethylation associated with imprinting. In neoplasia occurs a different 
methylation pattern, aberrantly methylated region occurs in the first intron of the WT1 
gene in breast cancer (Laux et al., 1999) and ovarian cancer in WT1-AS (Kaenushi et 
al., 2004). To search for CpG islands software was used to define isochore plots GC 
content within 2 kb from Mcr2.  After CpG analyses an island was found 481 bp from 




Figure 3.6 Map of Mcr2 including QTLs and CpG island spots. Scheme adapted 
from NCBI. Map viewer showing the positions of Mcr2 (red bar), contiguous CpG 
island (grey bar). Followed towards left by part of chromosome 2 from mouse strain 
C57BL/6. Far left, reported QLT (Lvrq1, Splq1, Hrtq1, Dntcs2, Tlq1, Tlq1 in blue) 
within Mcr2. Figure adapted from NCBI screen-dump.  
 
3.2.2.4 Phenotype association for Mcr2 sequence. 
Blast search of the mouse genome with Mcr2 identifies several QTLs annotated by  
Mouse Genome Informatics (MGI): Lvrq1, Splq1, Hrtq1, Dntcs2, Tlq1, Tlq1 (Figure 
3.6). QTLs are large genomic sequences (several Mbp) linked to particular 
phenotypic traits in mice in this case. QTL markers called Hrtq1, Lvrq1 and Splq1 
were discovered in heart, liver and spleen respectively by a linkage analysis 
performed on 552 10-week old male animals from a (M16i x L6) F2 intercross to 
identify QTLs associated with measurements of growth such as organ weight, growth 
rate, and adiposity. In heart, liver, and spleen weight differences were identified. L6-
derived alleles conferred recessively inherited decrease in organ weight in the 
presence of these markers (Rocha et al., 2004).  
 
More evidence was also found in studies of dental caries susceptibility using QTL 
analysis in mice. For this experiment genetic crosses of C3H/HeJ (caries-resistant) 
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and C57BL/6J (caries-susceptible) mice inoculated with Streptococcus mutants 
serotype C were performed. A region called Dntcs2 was identified as responsible for 
dental caries susceptibility (Nariyama et al., 2004). As suggested by the blast hit, 
variations in the Mcr2 sequence could be responsible for these traits. However the 
QTLs are very large and Mcr2 very small, so this is not very likely. In both cases 
organ weight difference (heart, liver, spleen) and susceptibility to dental caries have 
not been mapped to a gene so it remains plausible that these traits may map to Mcr2.  
 
In a further QTL study to clarify the role of genomic elements associated with 
specific telomere length, two inter-fertile mice species were used, both harbouring 
dissimilar telomere length, Mus musculus (telomere length >25 kb) and Mus spretus 
(telomere length 5-15 kb). It was found that a QTL, Tlq1, for this trait which maps to 
chromosome 2 (Zhu et al., 1998). However subsequent work found that Tlq1 maps to 
a gene called RTel which is not very close to Mcr2 so in this case is confirmed to be a 
“miss mapping” (Ding et al., 2004). 
 
3.2.3 Phylogenetic analysis of Mcr2 
Conservation analysis of the WT1 gene shows its presence throughout vertebrate 
genome evolution with some features specific to mammals as described earlier in 
Section 1.1.2.1. Other features such as the zinc fingers and the transregulatory 
domains are conserved between all gnathostome classes including the chick, alligator, 
Xenopus laevis and zebrafish. However, the WT1+KTS isoform is found throughout 
the vertebrates whilst the 17 aa (+/-exon 5) deletion event is exclusive to mammals 
(Miles et al., 1998; Kent et al., 1995). Between mouse and human WT1 polypeptides 
an extremely high level of amino acid sequence conservation is observed (> 95%). 
 
Functionally important elements are thought to be more likely to experience purifying 
selection pressure so that key regulatory domains involved in development are 
retained. Given that the genitourinary system has evolved considerably during 
vertebrate radiation, it has been speculated that the complexity of mammalian WT1 
isoforms may be associated with changes to the genitourinary system. In contrast 
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alternative +/- KTS splicing might be linked to basic function conserved throughout 
vertebrate evolution.  
 
The conservation of antisense RNAs at the WT1 locus has not been fully studied. As 
stated in section 1.2.2.1 antisense RNAs were first discovered in prokaryotes but are 
now recognised as being of great importance in the regulation of mammalian gene 
expression, in particular covering most of the transcription units of the mouse 
transcriptome, many of which appear to be lncRNAs, localized within the nucleus 
with or without polyadenylation (Lehner et al., 2002, Cheng et al., 2005). Many 
ncRNAs are of unclear significance and lack strong sequence conservation, 
prompting suggestions that they might be non-functional. Wang et al., (2004) stated 
that ncRNAs identified in a mouse cDNA library were poorly conserved, and 
therefore predicted to be non-functional. However, certain functional lncRNAs such 
as Air and Xist are also poorly conserved, which suggests that lack of conservation 
does not mean lack of function (reviewed in Pang et al., 2006). Nevertheless, 
miRNAs and snoRNAs are widely conserved among a diverse range of species 
(Huttenhofer, 2001; Lagos-Quintana, M. et al. 2001). Therefore, it might be that 
different types of ncRNAs can exhibit different patterns of sequence conservation, 
which can be expected as they are thought to play a variety of functions. Evolutionary 
conservation of sequences upstream of WT1 could indicate novel functional 
regulatory domains. WT1-AS transcripts have been shown to be expressed in parallel 
to WT1 in developing and paedriatic kidney in vitro WT1-AS levels affect WT1 
expression (Moorwood, et al., 1998). 
In order to evaluate the conservation patterns of Mcr2 or other antisense elements 
upstream of WT1, alignments were performed using the genomes of 30 vertebrate 
species. The degree of sequence identity with the mouse genome was then calculated. 
Pair wise alignments with Mcr2 were generated using BLAT on DNA which is 
designed to find sequences of 95% and greater similarity (Kent, 2002) through the 
UCSC Genome Browser (http://genome.ucsc.edu, Rosenbloom, et al., 2010).  
Multiple alignments were generated using Multiz and other tools in the UCSC/Penn 
State Bioinformatics comparative genomics alignment pipeline. The conservation 
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measurements were created using the phastCons package from Adam Siepel at 
Cornell University. Details of the alignment parameters are noted in the genome wiki 
Mm9 multiple alignments. The evolutionary relationship used for conservation 
analysis is shown in Figure 3.7. Track displays of multiple alignments show three 
measures of evolutionary conservation across them all in one set. The vertebrate 
species tested were the placentals and euarchontoglires given below plus: Opossum, 
Platypus, Chicken, Lizard, Frog, Tetraodon, Fugu, Stickleback, Medaka, Zebrafish. 
Two more restricted groups were also tested to the euarchontoglires subset (10 
species plus mouse): mouse, rat, Guinea Pig, Rabbit, Human, Chimp, Orangutan, 
Rhesus, Marmoset, Bush-baby, Tree Shrew. The euarchontoglires above plus: Shrew, 
Hedgehog, Dog, Cat, Horse, Cow, Armadillo, Elephant, Tenrec. The placental 
mammal conservation helps to identify sequences that are under different 
evolutionary pressures in mammals and non-mammal vertebrates. At the top of each 
alignment graphs resume mammal, euarchontoglires and vertebrates conservation. 
Gap annotation for all Figures shown (3.8-3.18) were used as follows: Blank, no 
bases in the aligned species. Possibly due to a lineage-specific insertion between the 
aligned blocks in the mouse genome or a lineage-specific deletion between the 
aligned blocks in the aligning species. Double line: aligning species has one or more 
unalignable bases in the gap region. Possibly due to excessive evolutionary distance 
between species or independent deleted regions between the aligned blocks in both 
species. Pale yellow coloring: aligning species has Ns in the gap region and reflects 
uncertainty in the relationship between the DNA of both species, due to lack of 
sequence in relevant portions of the aligning species. This description applies for all 
graphs. 
Mcr1 was found to be mammalian specific (Figure 3.10) whereas Mcr2 was found to 
have partial conservation from medaka to rat (Figure 3.8). Mcr2 has a specific 
domain that is conserved from medaka to rat (except for the chicken) and another 
domain that is exclusive to non-fish vertebrates. In order to verify the limits of the 
conserved region up and downstream Mcr2, a wider sequence was analyzed.  A 
preliminary PIPLOT (Figure 1.9) graph shows high conservation between human and 
mouse Mcr2 (98%), therefore it was expected that Mcr2 should appear as a plateau on 
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the alignment graph. Indeed this was confirmed to be the case. No further 
conservation was found outside the previously identified Mcr2 sequence (Figure 3.9). 
The genomic sequences of Wt1 exon 1 and exon 1 A (codes for AWT1) were also 
analyzed (Figure 3.13 and 3.14).   As expected Wt1 exon1 shows a quite conserved 
pattern all across vertebrates. In contrast exon 1 A has a more conserved pattern 
within mammals plus the Lizard (Figure 3.14. Interestingly, exon 1 A shows more 
conserved region towards AWT1 code region, which is translated to protein. 
However exon 1 A did not show any conservation in Teleostei. In human it is known 
that WT1-AS and AWT1 transcription originates in intron 1.  Exon 1 A shows a poor 
conservation of its sequence outside of mammalian genomes. Indeed there is no 
conservation in aquatic vertebrates. This shows for the first time that AWT1 is 
mammal+lizard-specific. In the case of euarchontoglires there is a more similar 
pattern of conservation of AWT1 than the rest of mammals (Figure 3.14). 
In Mcr2 two ultraconserved domains were identified, one of 112 bp and a second 
domain which of 111 bp (Figure 3.11 and 3.12). Phylogenic conservation of a 
transcript antisense to wt1, the cDNA isolated from 2 day mouse neonate ovary with 
an accession code AK165089 was also performed, and shown in figure 3.2 and 3.16. 
This transcript is spliced and includes exons up to 35 kb upstream of Wt1. Mcr2 itself 
is spliced out of AK165089. It contains significant ORFs with a maximum coding 
capacity of 86 amino acids. This element was found to share synteny with other 
murines but not with other vertebrates (Figure 3.16) Exons are more widely 
conserved than introns which suggest a function for the transcript. Traces of 
conservation appear to be from lower vertebrates becoming more extended in 
euarchontoglires. A more consistent pattern of conservation is observed in the 
unspliced antisense transcript that overlaps the Wt1 promoter and was identified in 
spleen with accession number AK172697 (Figure 3.17).  In this case it appears not 
well conserved in lower vertebrates, on the contrary is exhibit a more define pattern 
in euarchontoglires . This transcript also does not include Mcr2 sequence. 
Additionally conservation of two well known ncRNA transcripts conservation was 
analyzed. These were Wrap53 and H19. For the ncRNA H19, displays a wide 
conservation in mammals. In contrast Wrap53 has conserved domains at the 
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beginning and until the end of the transcript. Wrap53 has more synteny with the rat 
than all the rest of organisms (Figure 3.17 and Figure 3.18). 
 
 






Figure 3.8 Alignments of vertebrate sequences with mouse Mcr2 (289 bp). 
Vertebrates conserved domain in which retinoic acid response element shown by the 
black square. Non-fish conserved domain vertebrates in red box.  
 
Figure 3.9 Mouse Mcr2 extended sequence alignment (599 bp).  At the top Mcr2 




































Figure 3.14 Alignments of vertebrate sequences with mouse exon1 A (181 bp). 
 
 
Figure 3.15 Alignments of vertebrate sequences with mouse AK165089 




Figure 3.16 Alignments of vertebrate sequences with mouse AK172697 
transcript (1677 bp). 
 
 
Figure 3.17 Alignments of vertebrate sequences with mouse Wrap53 noncoding 









Mcr2 has not favorable prediction of active translation to protein because of 
the many stop codons which would terminate its translation. The ORF present are 
unlikely to encode protein with functional structure. Finding between 3 to 7 stop 
codons for each frame analyzed in both sense and antisense orientation it would be 
unlikely to encode a Mcr2 protein. On the other hand some structural protein 
properties have been found in terms of secondary structure and MAR. No other 
structural properties or predicted DNA-Protein binding were found. It is more likely 
that Mcr2 exerts its active role as a RNA transcript. Also a putative CpG island was 
found through at 481 bp from Mcr2 towards WT1 direction.  
 
In terms of RNA expression GenBank displays diverse spliced and unspliced 
transcripts upstream the Wt1 gene in mouse and human. The vast majority of them 
are expressed in the antisense orientation. Most of them do not overlap with Wt1 
except from the transcript AK172697 that overlaps the Wt1 promoter by just 15 
nucleotides. Mouse Mcr2 is not previously reported as an expressed transcript in  
110 
 
GenBank, or as part of one. In fact transcripts AK165089 and AK161318 splice out 
Mcr2 far upstream. In human, MCR2 forms part of the WT1-AS-1 (accession code 
L25110.1) transcript which shows the same structure as the one reported by Huang et 
al., 1990. Also, in the human several transcripts overlap the WT1 promoter except 
from the transcript reported by Eccles et al., (1994), which starts at intron 1 and spans 
exon 1 and continues upstream WT1 now known as WT1-AS.  
  
Mcr2 was recently reported to contain a retinoic acid response element (Bollig et al., 
2009). An alignment of this was published showing conservation in 5 vertebrates 
showing homology between zebrafish and human. Differently to other vertebrates 
(Kent et al., 1995), fish possess two wt1 genes wt1a and wt1b, which each show 
similar but non-identical spatial and temporal patterns of expression in nephrogenesis 
(Bollig et al., 2006). The retinoic acid response element was found to be involved in 
the regulation of development of intermediate mesoderm implying that the conserved 
element is an enhancer of wt1 a transcription. Although they found responsiveness to 
retinoic acid receptor in zebrafish, the percentage of identity between the whole 289 
bp of Mcr2 in human and zebrafish is only 22%, whereas between mouse and human 
is 94%. Mcr2 contains different conservation domains, one that shares homology 
with most vertebrates, and another one that is exclusive of non-fish vertebrates. 
Thinking on a functional role for Mcr2, due to the fact that has two patterns of 
conservation within vertebrate domains, might be the case of having specific 
functions on aquatic or non-aquatic vertebrates. Interestingly another ncRNA, H19 
was also only conserved in euarchontoglires. Also ultraconserved domains and MAR 
were found which suggests a possible transcriptional role. In the case of the 
ultraconserved domains might provide more evidence to support its role as 
transcriptional enhancer proposed by Bollig et al., (2009). Interestingly, other 
sequences were found to be widely conserved in mammalian organisms. This was the 
case for Mcr1 and exon 1 A. On the other hand, dissimilar pattern of conservation 







Supplementary Table 1 Full description transcripts annotated in Figure 3.2 
 
Identification code Description 
BB683964.1 BB683964 RIKEN full-length enriched, 12 days 
embryo female 
mullerian duct Mus musculus cDNA clone 
6820409P12 3-, mRNA sequence 
BB553293.1 BB553293 RIKEN full-length enriched, 2 days 
pregnant adult 
female ovary Mus musculus cDNA clone 
E330005F08 3-, mRNA sequence 
 
BB093804.1 BB093804 RIKEN full-length enriched, 12 days 
embryo, embryonic 
body between diaphragm region and neck Mus 
musculus cDNA clone 9430043P12 3-, 
mRNA sequence 
 
CK329643.1 H8179B10-3 NIA Mouse Unique Gene Set 
Version 2 Mus musculus 
cDNA clone H8179B10 3-, mRNA sequence 
BM220120.2 C0935D05-3 NIA Mouse 12.5-dpc Male Genital 
Ridge/Mesonephros 
cDNA Library (Long) Mus musculus cDNA clone 
NIA:C0935D05 IMAGE:30037960 3-, 
mRNA sequence 
 
AI785414.1 uj41f10.x1 Sugano mouse kidney mkia Mus 
musculus cDNA clone 
IMAGE:1922539 3-, mRNA sequence 
AI314831.1 uj31h06.x1 Sugano mouse kidney mkia Mus 
musculus cDNA clone 
IMAGE:1921595 3-, mRNA sequence 
BB553297.2 BB553297 RIKEN full-length enriched, 2 days 
pregnant adult 
female ovary Mus musculus cDNA clone 
E330005F21 3-, mRNA sequence 
BB046170.2 BB046170 RIKEN full-length enriched mouse 
cDNA library, C57BL/6J 
testis male 13 days embryo Mus musculus 
cDNA clone 6030498F17 3-, mRNA sequence 
BY101868.1 BY101868 RIKEN full-length enriched, pooled 
tissues, adult 
spleen, etc. Mus musculus cDNA clone 
K630140O08 5-, mRNA sequence 
AK031729.1 Mus musculus 13 days embryo male testis 
cDNA, RIKEN full-length 
enriched library, clone:6030498F17 
product:unclassifiable, full insert sequence 
AK032905.1 Mus musculus 12 days embryo male wolffian 
duct includes surrounding 
region cDNA, RIKEN full-length enriched 
library, clone:6720470H10 
product:unclassifiable, 
full insert sequence 
BB621534.1 BB621534 RIKEN full-length enriched mouse 
cDNA library, C57BL/6J 
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testis male 13 days embryo Mus musculus 
cDNA clone 6030498F17 5-, mRNA sequence 
 
BQ552026.1 H4013A02-5 NIA Mouse 7.4K cDNA Clone Set 
Mus musculus cDNA 
clone H4013A02 5-, mRNA sequence 
AK165089.1 Mus musculus 2 days pregnant adult female 
ovary cDNA, RIKEN 
full-length enriched library, clone:E330005F21 
product:hypothetical protein, 
full insert sequence 
 
AK033125.1 Mus musculus 15 days embryo male testis 
cDNA, RIKEN full-length 
enriched library, clone:8030442G15 
product:cytosolic 5' nucleotidase, type 1A, 
full insert sequence 
 
BB624191.1 BB624191 RIKEN full-length enriched, 15 days 
embryo male testis 
Mus musculus cDNA clone 8030442G15 5-, 
mRNA sequence 
CF169579.1 B0815E12-5 NIA Mouse Newborn Kidney cDNA 
Library (Long 1) 
Mus musculus cDNA clone NIA:B0815E12 
IMAGE:30468923 5-, mRNA sequence 
BI076695.2 L0209E12-3 NIA Mouse Newborn Ovary cDNA 
Library Mus musculus 
cDNA clone L0209E12 3-, mRNA sequence 
AK161318.1 Mus musculus adult male testis cDNA, RIKEN 
full-length enriched 
library, clone:4930402L07 
product:unclassifiable, full insert sequence 
AK134414.1 Mus musculus 13 days embryo male testis 
cDNA, RIKEN full-length 
enriched library, clone:6030473K11 
product:unclassifiable, full insert sequence 
BQ418218.1 ik54e02.x3 Kaestner ngn3 wt Mus musculus 
cDNA 3-, mRNA sequence 
BI076674.2 L0080C05-3 NIA Mouse E12.5 Female 
Mesonephros and Gonads cDNA 
Library Mus musculus cDNA clone L0080C05 3-
, mRNA sequence 
AK143272.1 Mus musculus 2 days pregnant adult female 
oviduct cDNA, RIKEN 
full-length enriched library, clone:E230026E04 
product:unclassifiable, full 
insert sequence 
BQ418043.1 ik54e02.y1 Kaestner ngn3 wt Mus musculus 
cDNA 5-, mRNA sequence 
AK172697.1 Mus musculus activated spleen cDNA, RIKEN 
full-length enriched 
library, clone:F830301H19 
product:unclassifiable, full insert sequence 
BY223054.1 BY223054 RIKEN full-length enriched, 
activated spleen Mus 
musculus cDNA clone F830301H19 5-, mRNA 
sequence 
CJ066977.1 CJ066977 RIKEN full-length enriched mouse 
cDNA library, C57BL/6J 
ovary female 2 days pregnant adult Mus 





BY719503.1 BY719503 RIKEN full-length enriched, 12 days 
embryo female 
mullerian duct Mus musculus cDNA clone 




Supplementary Table 2 Full description transcripts annotated in Figure 3.3 
 
Accession code Description 
L25110.1 Human Wilms tumor 1 (WT1) mRNA, exon 1 
DA952652.1 DA952652 SPLEN2 Homo sapiens cDNA clone 
SPLEN2030350 5-, mRNA 
sequence 
 
NR_023920.1 Homo sapiens Wilms tumor upstream neighbor 
1 (WIT1), non-coding 
RNA 
DA961425.1 : DA961425 SPLEN2 Homo sapiens cDNA clone 
SPLEN2042186 5-, mRNA 
sequence 
 
DA704288.1 DA704288 NT2RI2 Homo sapiens cDNA clone 
NT2RI2007592 5-, mRNA 
sequence 
 
CR737788.1 Description: CR737788 Homo sapiens library 
(Ebert L) Homo sapiens cDNA 
clone IMAGp998B065082 ; IMAGE:2063141 5-, 
mRNA sequence 
 
CA430691.1 UI-H-FL1-bgb-l-21-0-UI.s1 NCI_CGAP_FL1 
Homo sapiens cDNA clone 
UI-H-FL1-bgb-l-21-0-UI 3-, mRNA sequence 
BX394943.2 BX394943 Homo sapiens NEUROBLASTOMA 
COT 25-NORMALIZED Homo 
sapiens cDNA clone CS0DC026YK15 5-PRIME, 
mRNA sequence 
AI803567.1 BX394943 Homo sapiens NEUROBLASTOMA 
COT 25-NORMALIZED Homo 
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sapiens cDNA clone CS0DC026YK15 5-PRIME, 
mRNA sequence 
DB247341.1 : DB247341 UTERU1 Homo sapiens cDNA clone 
UTERU1000235 5-, mRNA 
sequence 
 
DA950905.1 DA950905 SPLEN2 Homo sapiens cDNA clone 
SPLEN2028049 5-, mRNA 
sequence 
 
DB192632.1 DB192632 TOVAR2 Homo sapiens cDNA clone 
TOVAR2000753 5-, mRNA 
sequence 
 
BX110205.1 : BX110205 Soares_NFL_T_GBC_S1 Homo 
sapiens cDNA clone IMAGp998O063860 
; IMAGE:1524701 5-, mRNA sequence 
BC100673.1 Homo sapiens Wilms tumor upstream neighbor 
1, mRNA (cDNA clone 
IMAGE:40023097) 
 
AW604794.1 QV4-CT0363-010200-099-g09 CT0363 Homo 
sapiens cDNA, mRNA sequence 
AW028595.1 wv33a08.x1 NCI_CGAP_Ov18 Homo sapiens 
cDNA clone IMAGE:2531318 
3- similar to SW:WIT1_HUMAN Q06250 




BE394437.1 601311703F1 NIH_MGC_44 Homo sapiens 
cDNA clone IMAGE:3633024 
5-, mRNA sequence 
 
AI648530.1  tz55a03.x1 NCI_CGAP_Ov35 Homo sapiens 
cDNA clone IMAGE:2292460 
3- similar to SW:WIT1_HUMAN Q06250 




BX390192.2 BX390192 Homo sapiens NEUROBLASTOMA 
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COT 25-NORMALIZED Homo 
sapiens cDNA clone CS0DC026YK15 5-PRIME, 
mRNA sequence 
AI951613.1 wv37d03.x1 NCI_CGAP_Ov18 Homo sapiens 
cDNA clone IMAGE:2531717 
3- similar to SW:WIT1_HUMAN Q06250 




AA912908.1 ol27f03.s1 Soares_NFL_T_GBC_S1 Homo 
sapiens cDNA clone IMAGE:1524701 
3- similar to SW:WIT1_HUMAN Q06250 




BC002734.2 Homo sapiens Wilms tumor upstream neighbor 
1, mRNA (cDNA clone 
IMAGE:3633024) 
 
BC098290.1 Homo sapiens Wilms tumor upstream neighbor 
1, mRNA (cDNA clone 
IMAGE:40023096) 
 
BF058864.1 : 7k35f06.x1 NCI_CGAP_Ov18 Homo sapiens 
cDNA clone IMAGE:3477634 
3-, mRNA sequence 
BC096708.1 Homo sapiens Wilms tumor upstream neighbor 
1, mRNA (cDNA clone 
IMAGE:40023095) 
 
BF434735.1 Description: 7p03g11.x1 NCI_CGAP_Ov18 
Homo sapiens cDNA clone IMAGE:3644757 
3-, mRNA sequence 
 
M60614.1 Human Wilms' tumor (WIT-1) associated 
protein mRNA, complete 
cds 
 
BF515320.1 UI-H-BW1-anl-g-07-0-UI.s1 NCI_CGAP_Sub7 
Homo sapiens cDNA 
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clone IMAGE:3082932 3-, mRNA sequence 
BF059076.1 7k37e06.x1 NCI_CGAP_Ov18 Homo sapiens 
cDNA clone IMAGE:3477610 
3-, mRNA sequence 
BU633051.1 UI-H-FL1-bgt-g-19-0-UI.s1 NCI_CGAP_FL1 
Homo sapiens cDNA clone 
UI-H-FL1-bgt-g-19-0-UI 3-, mRNA sequence 
 
T54801.1 yb42d04.s1 Stratagene fetal spleen (#937205) 
Homo sapiens 
cDNA clone IMAGE:73831 3-, mRNA sequence 
CB267195.1 1006101 Human Fat Cell 5--Stretch Plus cDNA 
Library Homo sapiens 
cDNA 5-, mRNA sequence 
T54965.1 yb42d04.r1 Stratagene fetal spleen (#937205) 
Homo sapiens 
cDNA clone IMAGE:73831 5-, mRNA sequence 
BQ436800.1 AGENCOURT_7769032 NIH_MGC_92 Homo 
sapiens cDNA clone IMAGE:6069449 
5-, mRNA sequence 
CR604547.1 full-length cDNA clone CS0DC024YP12 of 
Neuroblastoma Cot 25-normalized 

























Chapter 4: Mcr2 expression in the 









































In order to elucidate a role in vivo for Mcr2 different transgenic mice strains 
were generated previously in our lab by Dr. K. Moorwood and Dr. J. Alsop. E14C4 
ES cells were transfected with the Mcr2 targeting construct and targeted clone 
isolated. Targeted ES cells clones were selected and expanded. By blastocyst 
injection this ES cells clone was used to generate Mcr2 gene-targeted strains and then 
maintained on a C57xCBA genetic background. Two different strains were derived 
one with the Mcr2 sequence in the genome and another without this sequence. 
However, both strains have a transcriptional terminator sequence to abrogate through 
Mcr2 transcription so that even the strain with Mcr2 was designated to have truncated 
antisense expression. The strain with Mcr2 intact was named Trigger (for truncation 
only) and Davis (for deletion and truncation). Trigger and Davis were made in order 
to compare if Mcr2 could have a role at either at the DNA or RNA level or both. To 
characterize Mcr2 expression in the Trigger and Davis mouse models wild type (+/+) 
heterozygous (-/+) and homozygous (-/-) animals were compared. First, this Mcr2 
expression was analyzed in wt kidney and Trigger 
-/-
 and Davis 
-/-
 strains were 
assessed to confirm whether correct truncation or deletion had occurred, respectively. 
Also to characterise if there were antisense, antisense expression or both (Mcr2) in 
Trigger and Davis models. For this, the expression in Trigger and Davis mouse 
models siblings was analyzed by RT-PCR using cDNA synthesized from a specific 
strand (sense or antisense). As discussed in Section 3.2.1, most of the transcription 
reported upstream Wt1 occurs in the antisense orientation. Indeed the mouse kidney 
has several antisense transcripts which have been reported (Dalloso et al., 2007), 
however we did not know if that was the case for Mcr2. Also by RT-PCR has been 
performed to detect the common splicing contained by AK165089 and AK161318 in 
order to analyze its expression in our Mcr2 knockout model (Davis 
-/-
). For 
description of this splicing site see Figure 4.1. Particularly, this was tested to look if 
the expression of AK165089 and AK161318 might be disrupted. These predicted 
transcripts have been reported previously of mRNA, from ovary (AK165089) and 
testis (AK161318) (see Appendix, Table 1). The AK165089 transcript was shown to 
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be highly expressed in the developing kidney, suggesting that it might have an active 
role in development (Dallosso et al., 2007) (Figure 4.2). In a different aspect by 
looking at wild type mouse expression of Mcr2 it is of interest to see whether its 
allele-specific expression pattern parallels the pattern seen in the human. In human, 
WT1-AS is disrupted in WT and leukaemia had a potential oncogenic role due to loss 
of imprinting expression (Hancock et al., 2007). Although in the mouse there is no 
evidence of imprinting in some WT1-AS transcripts that have been analyzed, this 
epigenetic mechanism has not been analyzed at Mcr2.  
 
 
Figure 4.1 The mouse Wt1 locus in the region of Mcr2 showing spliced 
transcripts AK165089 and AK161318.  Splicing of about 21 kb occurs around 
Mcr2 in transcripts AK165089 and AK161318. Both transcripts splice out Mcr2 
(dotted line). The position of Mcr2 (vertical red line) is shown with respect to Wt1. 
Primers designed for amplifying the firs splicing are shown. 
 
Figure 4.2 Graph showing q-PCR results displaying the expression of sense and 
antisense transcripts present in various tissues. P) placenta, S) spleen, B) brain, L) 
liver and K) kidney. Different stages were analyzed E17.5 and postnatal day (P) 3, 7, 









4.2.1 Detection of truncated and deleted alleles  
 
4.2.1.1 Genotyping 
To verify Mcr2 allele identity, specific primers were used to generate a product able 
to differentiate the truncated (Trigger) or deleted (Davis) allele from the wild type 
allele. PCR genotyping proved to be reproducible and consistent using ear biopsies as 
a DNA source and using TF/S primers (Figure 4.3). These primers amplified bands of 
1.002 kb (wild type), 1.46 kb (Davis homozygous) and 1.9 kb (Trigger homozygous) 
that really distinguish the three possible alleles. 
 
 
Figure 4.3 Illustration of TF/S primers used for genotyping. On left: structure of 
the Trigger (A) indicating Mcr2 in red and Davis (B) homozygous genomic structures 
indicating TF/S primer biding sites. On right: examples of typical PCR data (right 




4.2.1.2 Mcr2 expression in the mouse kidney 
In human, it has been documented that WT1-AS and WT1 might functionally interact 
because they have been found coordinately expressed, and in co-transfection assays 
WT1-AS can affect WT1 expression (Moorwood et al., 1998). Interestingly, it was 
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found that Wt1-AS reaches its highest expression in the developing kidney, 
suggesting a functional role in development (Dalloso et al., 2007).  
 
Although there is evidence of WT1-AS expression in human foetal kidney and also in 
mice it was of interest to detect Mcr2 expression in the mouse kidney. To do this, RT-
PCR assays on kidney tissue were performed using CNL-B primers (Figure 4.5). 
RNA samples from Davis strain were used as negative controls. As expected agarose 
gels show a band of 243 bp in length, only when RT was present in wt sample. RNA 
from the Davis strain did not amplify a band using these primers (Figure 4.4) 
 
Figure 4.4 RT-PCR analysis of Davis wild type and homozygous mutant 
samples. Lane: 1) 100 bp ladder (Promega), 2) Davis 
+/+ 
-RT, 3) Davis 
+/+
 +RT, 4) 
Davis 




Figure 4.5 Illustration of CNL/B primers used for genotyping. Mcr2 is marked in 







4.2.1.3 Analysis of Mcr2 expression from the truncated allele in Trigger mutant 
mice strain using random primers. 
The knock-in mouse model Trigger contains a transcriptional terminator sequence 
which was designed for truncating antisense transcripts from Mcr2 sequence. To 
evaluate whether abrogation of Mcr2 occurs in this particular model, RT-PCR 
analysis from kidney (E17.5) RNA was perform under similar conditions to those 
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used to detect Mcr2 expression previously in the wild type samples (See previous 
section 4.2.1.2). Using CNlong/B primers evidence of Mcr2 transcription was found, 
suggesting that the transcriptional terminator sequence was not working properly and 
this strategy of knock down could not efficiently stop transcription though the Mcr2 
sequence (Figure 4.6). However, since RT-PCR is not quantitative, additional 
experiments were performed to further evaluate Mcr2 expression in Trigger mutant 
mice. 
 
Figure 4.6 RT-PCR of Mcr2 expression in Trigger mutant mice. Lane: 1) 100 bp 
ladder (Promega), 2) +RT Trigger
+/+
 Mcr2, 3) –RT Trigger+/+ Mcr2, 4) Actin, +RT 
Trigger
+/+
, 5) Actin, -RT Trigger
+/+







 , 9)  –RT Trigger-/- Actin.  
 
4.2.1.4 Analysis of Mcr2 expression using strand specific cDNA 
To address whether Mcr2 is transcribed in the antisense or the sense orientation, or 
both, single strand RT-PCR was performed. To do this, cDNA samples were first 
synthesized either sense or antisense (using A/B primers see Table 2.1 and Figure 
4.7) and subsequently used as a template for amplification of the Mcr2 product 
region. RNA samples were kidney E17.5. Thus, specific primers were used, instead 
of random primers, to synthesize strand-specific cDNA. Primer A was used to copy 
sense RNA and primer B to copy the antisense RNA. When used in PCR, products 
derived from cDNA synthesis with primer A represent sense transcripts and products 








Figure 4.7 Illustration of A and B primers used for genotyping. Mcr2 is marked in 







Figure 4.8 Strand-specific RT-PCR of Mcr2 expression in mouse kidney. Lane:  
1) Antisense, Trigger 
+/+
 + RT; 2)Antisense, Trigger 
+/+
 –RT; 3)Sense, Trigger +/+ 
+RT; 4)Sense, Trigger 
+/+ –RT; 5)Antisense, Trigger -/- +RT; 6)Antisense, Trigger -/- 
–RT; 7)Sense, Trigger-/- +RT ; 8) Sense, Trigger-/- -RT; 9) Antisense, Davis -/- +RT; 
10)Antisense, Davis 
-/- 
 -RT; 11)Sense, Davis 
-/-
 +RT; 12) Sense, Davis 
-/-
 –RT; 13) 
100 bp ladder (NEB). 
 
A comparison was made between wild type (Mcr2 transcription is known to occur) 
and homozygous mutant kidneys from Davis and Trigger neonates. In wild type RNA 
amplification of Mcr2 was seen in the antisense orientation and not in the sense. 
Mcr2 was also expressed in Trigger 
-/-
 mutant mice but not in Davis
 -/-
 mice which 
were employed as a negative control (primer binding sequences are deleted in the 
Davis mutant allele). This confirms that the transcriptional terminator sequence is not 







4.2.1.5 Measuring levels of transcription by qPCR in Davis and Trigger strain 
mice. 
To estimate the levels of Mcr2 expression at E 17.5 from kidney total RNA, including 
in the Trigger strain quantitative PCR (qPCR) was performed by Dr. Hancock at 
Bristol University. The result of this experiment was comparable to those from the 
RT-PCR. In this assay two different homozygous mutant samples were employed for 
both Davis and Trigger and compared to wild type using A and B primers.  
 
 
Figure 4.9 Quantitative PCR analysis of Mcr2 expression in Trigger and Davis 
mice. Graph displaying folds of PCR product. Blue bars indicate antisense 
transcription and red bars indicate sense transcription. This graph shows 1 wild type 
and 2 homozygous for each Trigger and Davis mutants. All samples were taken from 
kidney E17.5. Error bars show the range of triplicate measurements.  
 
 
As expected, very little sense transcription at Mcr2 was detected in the analised 
kidneys. However abundant expression was seen in the wild type but also in Trigger 
-
/-
 homozygous mutant sample. Levels of expression were measured and expressed as 
fold-changes. The Tbp housekeeping gene was used to normalize samples (Figure 
4.8). A slight reduction in both Trigger homozygous with no expression was seen in 






4.2.1.6 Analysis of transcriptional terminator sequence function by testing the 
contiguous spliced WT1-AS transcript.  
In the mouse kidney transcription at the WT1 locus has been shown in the antisense 
orientation for spliced transcripts containing two exons (accession code AK165089 
and AK161318). These transcripts have been reported in ovary and testis 
respectively. In both cases signal was only seen using cDNA made from the antisense 
transcripts (Dalloso et al., 2007). Specific primers Lox2x2-5P/MWTPro-R were used 
to detect transcript expression of these transcripts (Table 2.1; Figure 4.1).  
 
Following a hypothesis in which Mcr2 could act as an enhancer of other antisense 




 kidneys were 
assessed from total RNA made from E17.5.  In order to validate if the abrogation of 
the Mcr2 DNA sequence affects the expression of neighbouring transcripts 
AK165089/AK161318 expression was assessed at E17.5. After amplification PCR 
bands were amplified of the expected size but there was no change in expression of 
the spliced antisense transcript (Figure 4.10) although, perhaps a small decrease in 
antisense expression when the TTS is present. 
 
Figure 4.10 Expression of the spliced antisense transcripts. Detection of splicing 
present in AK165089/AK161318 transcripts. Expected fragment size: 270bp) Lane 
















4.2.3 Imprinting study 
 
4.2.3.1 Allele-specific expression of Mcr2. 
As discussed earlier, (Section 1.2.2.5) in contrast to most of the transcriptome, a 
minority of genes are monoallelically transcribed in a parent-of-origin dependant 
manner. This is known as genomic imprinting and requires DNA elements to display 
allele-specific epigenetic modifications, such as differential DNA methylation. 
Intragenic CpG islands may serve as promoters of allele-specific antisense transcripts 
(Hutter et al., 2006) and as we have seen in Section 3.3.3 Mcr2 is located next to a 
CpG island.  
 
To address the possibility that Mcr2 expression might be regulated by imprinting in 
Mcr2. Heterozygous mice (with deleted allele present in Davis 
+/-
) were generated 
and analyzed immediately after weaning at 22 days old. Two different groups of 
offspring one with Mcr2 deleted from the paternal allele (Davis 
+/p
) and the other one 
with Mcr2 deleted from the maternal allele (Davis 
m/+
) were generated by breeding 
homozygous male and female respectively with wild type mates (Figure 4.11). 
 
Figure 4.11 Crosses to obtain heterozygous mutant Davis mice with Mcr2 
deleted from the paternal or maternal allele. Blank boxes are wild type strain (with 
Mcr2 intact) and filled boxes Davis homozygous mutants (with both Mcr2 alleles 
deleted). Half-filled boxes represent heterozygous offspring. Offspring with the half-
filled box on the right represent Davis 
p/- 










 After RT-PCR amplification of RNA from kidney using CNL-B primers (used to 
detect the presence or absence of Mcr2; Figure 4.5) no evidence of parent-of-origin 
transcription (imprinting) was found. Amplification of Mcr2 sequences was seen in 
wild type and also both heterozygous (Davis 
p/-




Figure 4.12 Analysis of Mcr2 allele-specific expression in (post-natal day 22) 
kidney samples. An RT-PCR product of 243 bp represents amplification of 
transcribed Mcr2 sequences were:  Lane 1) Davis 
p/m
  -RT; 2) Davis 
p/m
 +RT; 3) Davis 
p/-
 -RT; 4) Davis 
p/-
 +RT; 5) Davis 
p/-
 -RT; 6) Davis 
p/-
 +RT; 7) Davis 
-/m
  -RT; 8) 
Davis 
-/m
 +RT; 9) Davis 
-/m
  -RT; 10) Davis 
-/m
  +RT. 
 
 
As a result of this experiment heterozygous expression from Mcr2 Mats and Pats 
(Figure 4.12) was not conditional of the allele from were derived and all band signal 
had the same electrophoretic pattern as the Wt on lane 1 used as positive control. At 





4.2.3.2 Investigation of the allele specificity of expression in wild type mice using 
a naturally occurring sequence polymorphism. 
Around 250 base pairs downstream from Mcr2 (between mcr2 and Wt1 exon 1) a 
polymorphism was found and sequenced by Dr. Kim Moorwood. This polymorphism 
gave a different length PCR- fragment in three different inbred mouse strains (CBA, 
C57 and 129) (Figure 4.13). Using a pair of primers designated SF-VR, products of 
346 bp (C57) and 334 bp (CBA) were distinguishable on acrylamyde gel 






CBA uni 373 bp 
C57 rev 346 bp 










ATAAATAAATAAATA                                                    TTTTTTTAAAAGGAGAAAGAA 
ATAAATAAATAAATAAATA                                         TTTTTTTAAAAGGAGAAAGAA 
AAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAACTGAGATAA 
AAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAA                                           CTGAGATAA                 













Figure 4.13 Alignment of sequences amplified by SF-VR primers. 129 is at the 




4.2.3.3 SF-VR polymorphism imprinting analysis. 
In order to look for evidence of imprinting in the region proximal to Mcr2 RT-PCR 
amplification was done using RNA from strains C57 and 129 (experiment  performed 
by Dr. Kim Moorwood). Offspring were generated by crossing either C57 females or 
129 females with C57 males or 129 males. Kidney RNA analysed at fetal stage 
(E17.5) and several post natal stages (P), however, no evidence of imprinted 




Figure 4.14 Allele specific expression by RT-PCR in an expressed polymorphism 
sequenced near to Mcr2 PCR products in polyacrylamide gels showing the 
polymorphism between C57 and 129. Genomic (G) DNA was used as a positive 
control for PCRs (left panel). RNA expression (R) was analysed by RT-PCR of 
kidney RNA containing either a C57 and 129 mother and C57 father (right panel). 
Ages of analyzed offspring are indicated (E=embryonic day and P=postnatal day).  
 
 
Figure 4.15 Illustration of SF/VR primers used for genotyping. Mcr2 is marked in 















4.3 Discussion  
 
By using a conventional PCR way it is possible to discriminate between wild 
type, heterozygous and homozygous mice in consistent, reduced time and expense 
compared with other methods. An alternative methodology to detect Wt1-as would 
have been strand-specific Northern blots. However, when strand-specific Northern 
hybridization was attempted in our laboratory was not possible to detect transcripts 
containing Mcr2 transcript because there was a strong signal from non-specific 
binding of the probe to 18S and 28S ribosomal RNAs that would have make it 
binding (Allsop, 2008). Perhaps because Wt1 antisense transcription level is 
relatively low, has not been successfully detected on Northern blot. 
 
A genotyping method was established that allows positive identification of wild type, 
deletion (Davis) and truncation (Trigger) Mcr2 alleles, allowing discrimination. It 
was previously shown that Wt1-as transcripts are highly expressed in the developing 
kidney (Dallosso et al., 2007) RT-PCR amplification using primers specific for Mcr2 
has shown that this conserved genomic region is expressed in the E17.5 mouse 
kidney. No expression was seen in Davis which carries only the Mcr2 deleted alleles. 
Therefore Davis 
+/+
 and Davis 
-/-
 mice could be used as a positive and negative 
controls, respectively, for comparison with transcription in the Trigger strain. 
Consistent results were obtained by conventional RT-PCR using both random 
priming and strand specific priming of cDNA synthesis, as well as in quantitative 
PCR reactions in each case, Mcr2 was detected in kidney samples from Trigger
 -/-
 
mice, indicating that the transcriptional terminator sequences were not operating 
efficiently at all. By qPCR it was possible to see that Mcr2 expression in Trigger 
-/-
 
mice perhaps was slightly diminished. Sequence analysis of the engineered mutation 
in both Trigger and Davis transgenic strains showed that the regions inserted by the 
gene targeting remained intact suggesting the transcriptional terminator sequences 
were not working as planned. In addition, looking at the expression of neighbouring 
transcripts there was no evidence they were disrupted when Mcr2 was deleted from 




In contrast to what has been found in human (Hancock et al., 2008) Mcr2 transcripts 
in the mouse showed no evidence of imprinted expression. Imprinting of Mcr2 
transcripts therefore, differ in human and mouse due to variability in the evolution of 
imprinting control elements, or could occur only at specific stages in the mouse. 
However, when looking at neighbouring elements (defined by the SF-VR primers) 
were not possible to find any evidence of imprinting at different stages in two 





























Chapter 5: Phenotypic screening of 







































Wt1 antisense transcription has been detected in several wt mouse tissues 
during both the embryonic stage (E17.5) and also postnatally (Figure 4.2) (Dallosso 
et al., 2007). In an effort to elucidate any relevant physiological role of Mcr2 in the 
biology of the mouse heterozygous and homozygous Trigger and Davis mice with 
genetically modified Mcr2 were monitored for any signs of morbidity or mortality in 
comparison to wt mice. Mortality was followed until adulthood but also this was 
evaluated by checking genotypes after birth and comparing allele frequency with 
Mendelian ratios to find if there was any lethality during gestation. Morbidity studies 
were carried out to observe any early sign of kidney disease by looking at the 
presence or absence of proteinurea which might indicate kidney malfunction (Menke 
et al., 2003; Lahiri et al., 2007). Analysis of the organs of these mutant mice was also 
carried out in adulthood to look for differences from wt siblings. A way to understand 
the physiological effect of a genetic modification is by comparing modified model 
organisms against the unmodified experimental controls quantitatively and 
qualitatively. Specifically weight, appearance and histological parameters were 
analyzed to define any potential phenotype. 
 
Due to the polygenetic background of Trigger and Davis mice the most closely 
related animals as possible were used to maintain the most similar genetic 
background for the genetic model mice and the control wt mice. This was possible by 
inter-crossing heterozygous littermates to obtain wt, heterozygous and homozygous 
siblings. The cohort of animals studied was made up of individuals as closely related 
to each other as possible to enable any potential phenotype, especially a subtle one to 
be revealed. In the case of subtle effects or very variable wt phenotypes, successive 
cohorts were followed increasing the number of animals to enable reach statistical 





At 7 months old, various tissues were analyzed from adult mice to look at organ 
morphology through histological analysis. Contrary to what was expected the Trigger 
strain did not display correct truncation of Mcr2 antisense expression that would 
allow us to analyze the role of Mcr2 at the RNA level (see designed of Trigger 
genetic modification Figure 1.10). Therefore although the Trigger strain was used for 
preliminary analysis it was not studied as completely as the Davis strain. Therefore 
the Davis strain became the main focus of our experimental interest. As described in 
Chapter 4 much of our analysis has specifically focused on the kidney because of the 
involvement of Wt1 in kidney development and function. However in this Chapter 
the whole animal was studied in different way to enable discovery of the potential 




 5.2.1 Allelic inheritance study 
Following previous reported transfection studies which show that WT1-AS 
transcription of WT1-AS can elevate Wt1 levels (Moorwood et al., 1998) we might 
have expected disruption of Mcr2 in the mouse we might have expected disruption of 
Mcr2 in the mouse to affect Wt1 protein levels. Since Wt1 has been shown essential 
for the organization of other organs from the kidney, we also expected that 
developmental defects might occur in for example heart and kidney as in the case of 
the Wt1 null mouse model (Kreidberg et al., 1993). In contrast to these expectations 
only occasional, apparently random morbidity features were detected at post natal 
stage which may have contributed to occasional mortality of individuals in Trigger, 
Davis and wt mice (Table 5.4). Trigger and Davis strain line heterozygotes and 
homozygotes, both males and females were able to generate offspring and viable 
through adulthood.In order to test the possible influence of truncation or deletion of 
Mcr2 in Davis and Trigger heterozygotes and homozygotes, heterozygotes inter-
crosses were counted and compared to expected Mendelian ratios. Genotyping was 
performed after weaning by PCR amplification from an ear clip biopsy as described 
on Figure 4.1.  During inheritance, alleles at a single locus segregate according to the 
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second law of Mendel’s inheritance (Mendel, 1866). Any variations from Mendel’s 
ratio might be indicative of segregation dependant on a particular strain specific 
polymorphism or genomic imprinting or interestingly, if there is a decreasing number 
of homozygotes might be indicative of embryonic lethality. Genotype ratios were 
compared to the expected Mendelian ones using the Chi-squared test to determinate 
whether obtained values were significantly different from the expected ones. Whether 
or not the difference was classified as significant from one another relies upon the 
cutoff point called probability value (P). For the present study the cutoff point was 
P<0.05. The results for Davis mice genotypes were analyzed under the Chi-squared 
test with a total of 257 adult mice and shown in 5.1.  With 2 degrees of freedom, 
X
2
=18.94, indicated that two-tailed P value is less than 0.0001. By conventional 
criteria, this difference is considered to be extremely statistically significant 
indicating that the observe ratios are unlikely to occur by chance if Mendelian rules 
apply. In the Davis strain, wt offspring predominate, at the expense of both Davis 
heterozygotes and homozygotes (Table 5.1). According with the number of wt 
animals (94) versus the number of homozygotes born (52) nearly half of the Davis 
homozygous is reduced (41%). In the case of the Trigger strain (Table 5.2), there was 
no significant difference (P>0.05) between observe and expected ratios, the 
conclusion being that pups of all three genotypes were born. For Trigger X
2
= 5.34 
with 2 degrees of freedom, therefore the P value was 0.0693. By conventional 
criteria, since 0.0693 >0.05 any differences between observed and expected values 
are not statistically significant.  
 
Table 5.1 Frequency of genotypes obtained from Davis mice. A total of 257 Davis 
mice were obtained from heterozygous intercrosses. Table shows also expected 
number and percentage according to Mendelian inheritance. Wt= wild type, he= 
heterozygous, ho= homozygous. 






wt 94 64.25 25% 
he 111 128.5 50% 
ho 52 64.25 25% 
Total 257  
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Table 5.2 Frequency of genotypes obtained from Trigger mice. A total of 100 
mice born were obtained from Trigger heterozygous intercrosses. Table shows also 
expected number and percentage according to Mendelian inheritance. Wt= wild type, 
he= heterozygous, ho= homozygous 






wt 33 25 25% 
he 39 50 50% 
ho 28 25 25% 
Total 100  
 
Due to these results is possible that (on the contrary of the normal values in the 
Trigger strain) Davis homozygous mice may experience lethality at gestational stage. 
However, this phenotype is incompletely penetrant, because, clearly, homozygous 
Davis mice are able to be born, viable and fertile, yet arise at a lower than expected 
frequency. This leads to the assumption that Davis homozygous intercrosses may 
give rise to smaller litters than wt intercross counterparts. To test this hypothesis 
further analysis was performed by looking at the number of offspring produced by 
intercrosses of each possible Davis genotype, wt, heterozygote or homozygote 
breeding pairs. If Mendelian laws apply, we might expect equal litter sizes for all 
genotypes as shown in Table 5.3 there is a reduction from an average litter size of 7.1 
for the heterozygous intercrosses and 6.7 for homozygous intercrosses.These results 
suggest the possibility of embryonic lethality associated to some degree the Davis 
allele. Consistent causes of adult morbidity associated with the Davis allele (see 
Table 5.4) might have pointed to an incompletely penetrant embryonic lethality 
phenotype. However, no consistent features were found. Similarly some lethality if 
mice happened neonatally, before genotyping is possible and the dead pups are 
cannibalised. Thus, at this point the reason for the unexpectedly low number of Davis 
heterozygotes and homozygotes born to heterozygous intercrosses, and the smaller 




Table 5.3 Average litter size produced by each intercross. 
Intercross  type No. Litters counted Total offspring Average (No. Pups 
per litter) 
wt 6 48 8 
he 36 257 7.13 
ho 14 94 6.7 
 
 







































Genotype Sex Reason Age at 
death 
Clinical 








Wt Unknown FDC Neonate Unknown 
He Male FDC Neonate Unknown 
Wt Female FDC Neonate Unknown 
Het Female FDC 3 months Unknown 
Ho Female Cull 3 months Apparently 
intestines 
blocked  
Wt Male Cull 3.5 months Small and 
thin 
apparently ill  
Ho Male FDC  4 months Unknown 
He Female Cull 4.5 months Necrotic 
brain, 
sclerotic liver 
Ho Female Cull 5 months Prolapsed 
 
 
Het Male Cull 5.5 months Hyperactivity 
Wt Female FDC 6 months Unknown 
Ho Male Cull 8 months Enlarged 
stomach with 




5.2.2 Allometric scaling analysis   
Allometric scaling is the term used to describe the mathematical relationship between 
similar organisms of different sizes. This principle can be used to predict differences 
in both metabolism and structural function between living organisms because size 
influences the rates of biological function from the level of the cell to population 
dynamics of plants and animals (West et al., 1997). Since the body function is related 
to size, there are many implications for the use of allometric scaling in medical 
research. Allometric principles have been applied to physiologic function such 
glomerular filtration rates (GFR) (Singer, 2001). In order to define any abnormality in 
organ growth the total size in terms of area, length and weight of each animal was 
measured as well as the weight of individual organs. For this a cohort each of Davis 
and Trigger of mice were sacrificed at 7 months of age and measured individually by 
sex and genotype. Organs where Wt1 is known to be expressed (at least during 
development) were dissected weighed and fixed in paraformaldehyde and embedded 
in wax blocks for subsequent analysis. These organs include Brain, Eye, Heart, 
Spleen, Kidneys, Testis Thymus, Liver and Abdominal and Renal fat pads. Because 
of intrinsic gender  difference of weights were analyzed separately for males and 
females, this also would give us a confirmation in case if a difference appears, so that 
the observed dissimilarity might or not be able to be present in both genders. The 
values were analyzed using the statistical tool one-way analysis of variance 
(ANOVA) was performed to corroborate the values obtained and avoid redundancy 
with Tukey’ Multiple Comparison (Tukey’s test). Tukey’s post hoc to see differences 
between three groups, this test can be used to compare all groups to each other to find 
where the differences lie. One way ANOVA looks for differences between three or 
more classes. This test is completed by Gaussian distribution by given P value that 
the groups are sampled within the same population. Whether differences between 
groups are valid or not is dependent upon the P value. The P values was defined as 









5.2.2.1 Trigger weight analysis 
From a cohort of 24 mice including equal numbers of male and female mice divided 
into same numbers of wt, heterozygotes and homozygotes. Organs were dissected and 
weighed. Graphs displaying average weights of whole carcasses and organs of male 
or female Trigger mice, comparing homozygotes, heterozygotes and wt’s are shown 
in Figure 5.1 (i-xx). None of these weight measurements showed any statistical 
significant differences between the genotypes for each sex shown in Table 5.5 except 
only for sporadic cases as male eye and female left kidney. This could be explained 
by the finding that the terminator sequence, designated to truncate Wt1-AS RNA 
upstream of Mcr2 was not very effective, resulting in continued Mcr2 expression in 


























Figure 5.1 Graphs representing total body and individual organ weights in 
grams of 7-8 month old Trigger mice (i-xxi). 
 
 
Table 5.5 Summary of the data presented in Figure 5.1 Data showing deviation 
from Wt controls. </> addressed the difference in size between groups, p values were 
categorized according to standard consensus *P<0.05, **P<0.01, *** P<0.001, ns= 










5.2.2.2 Davis weight analysis 
The same analysis was made for the Davis strain with two consecutive cohorts with a 
pooled total sample number of 48. Graphs of the average weights are shown in Figure 
5.2 (I-XXV). Cohorts of 4 animals for each sex, and genotype (n=24). Most of the 
measurements employed 2 cohorts (n=48). For a few of the measurements more or 
less animals were used. For the total weight analysis at 7 months (n=60), and a single 
cohort was used for recording total weight day 1, abdominal and renal fat paths only  
one cohort was raised (n=24). In the case of the total body weight a statistically 
significant difference was found with 17% difference between the wt and both 
heterozygotes and homozygotes, which were heavier (Figure 5.2 I and II). However 
this difference in weight is not reflected by body length (Figures 5.2 III and IV). To 
discover whether Davis homozygotes were already heavier than their wt and 
heterozygous littermate at birth, the total body weight of neonates was measured 
(Figure 5.2 V). No significant difference was observed at that stage suggesting that 
this phenotype develops with age.   
 
By looking at the individual organs weights, a significant contribution to the 
increased total body weight of Davis homozygotes compared to wt’s is not obvious 
for any particular organ. In some cases (e.g. male spleen, both genders left and right 
kidneys, male liver) there is a slight trend towards increased weight in Davis 
homozygotes compared with the wt counterparts. However, these differences are very 
slight and contradicted by opposite founded in trends towards some heavier organs in 
wt’s compared to Davis homozygous (e.g. male and female heart, thymus, male 
testes, male abdominal fat and both genders of renal fat). In the case of the male brain 
weight this was difficult to reconcile, particularly as the apparent phenotype is not 
shown in females. This might have been an artifact due to the procedure of killing 
adult mice which has to be done by dislocation of the neck, sometimes damage the 
brain and is difficult to biopsy and weight integrally. The right and left kidneys were 
weighted separately due to the fact that in normal circumstances the right is bigger 





However no differences between right and left kidney weight were found in this 
study. In summary no statistically significant increase in organ size in Davis 
homozygotes, compared to wt’s was found. In fact the only case of statistical 
significance involves homozygotes showing decreased rather than increased weight. 
Therefore, the increased total body weight of Davis homozygotes is not due to 






























Figure 5.2 Graphics representing body and individual organ weights in grams of 












Table 5.6 Summary of the data presented in Figures 5.2. Data showing deviation 
from Wt controls. </> addressed the difference in size between groups, P values were 













5.2.3 Urine analysis of Davis and Trigger 
Proteinurea is a frequent and early manifestation of glomerulonephritis mouse 
(Hoffstein et al., 1975). It can indicate functional disruption of the kidney. WT1 is 
essential for glomerular the maintenance of podocytes which perform glomerular 
filtration in the kidney (Guo et al., 2002; Menke et al., 2003). For this reason, we 
analyzed Davis and Trigger mouse urine for proteinurea. In fact proteinurea has been 
detected in transgenic mice expressing extra copies of a single isoform of Wt1 (-KTS) 
disrupting the Wt1 allele (Lahiri et al., 2007).  
 
Urine samples were collected from cohorts of Davis and Trigger mice (n=24) at 6 
months of age. Cohorts contained equal numbers of males and females of each 
genotype. 7 µl samples were analyzed by SDS-PAGE and protein visualized by 
staining with Coomassie Brilliant Blue staining. This method is sufficient to detect 
protein at >20 µg. As can be seen in Figure 5.3 no mice in the Trigger cohort had 
proteinurea, regardless of genotype. In the case of the Davis line, three mice 
displayed protein urea. (Lanes 9, 10, 11).  
 
However, this phenotype did not correlate with genotype. The three positive samples 
were from females of the same single litter and were genotyped wt, wt and he 
respectively. Therefore proteinurea is not caused by the presence of the Davis allele 
in these particular mice. Kidneys from these two cohorts were not included in the 
weight study, but were studied hystologically. 
 
Only 3 samples were detected with protein in the urine counting for 2 wt and one ho 
(Figure 5.3). This 3 individuals were littermates been born from the same parents. 









Figure 5.3 Urine analyses for early detection of proteinurea in Davis and Trigger 
mice. SDS-Polyacrylamide gel of Davis  (1 to 27)and Trigger (28 to 54) urine 
samples. Lanes 1, 19 and 37: molecular weight ladders (Fermentas). Lanes 18, 36 and 




5.2.4 Segregation of polymorphic alleles in mice with abnormal kidneys. 
As shown in section 4.2.3.2, by using SF-VR primers is possible to amplify strain-
specific polymorphisms. During analysis of mouse wt1 antisense transcript 
expression by q-PCR in embryonic kidney, it was noticed that primers amplifying a 
sequence transcriptional upstream of the transcriptional terminator in Trigger 
homozygote mice gave rise to two different side peaks (personal communication). 
Subsequently by cloning and sequencing genomic PCR products, it was discovered 
that parental mouse strains combining to Trigger and Davis, namely C57BL/6, CBA 
and 129 had strain specific length polymorphism at the repetitive sequence between 
primers SF and VR. Due to proximity of the SF-VR sequence and Mcr2, if Mcr2 has 
any association with the formation of cystic kidneys of SF-VR might segregate with 
this pathological phenotype. A whole litter in which three females had kidney failure 
(Figure 5.3) was analysed including parents and grandparents. The SF-VR alleles are 
shown in Figure 5.10 including cystic individuals (2, 3 and 4), parents (5, 6) 
grandparents (7, 8), CBA and C57BL/6 genomic DNA as markers (10, 11) (Figure 
5.4). Although no correlation between mice with abnormal kidneys was observed, 
mice inheriting the mother’s C57BL/6 allele had cystic kidneys, whereas those that 
inherited the mother’s CBA allele did not.   
 
Figure 5.4 PCR showing distribution of SF-VR alleles in mice with abnormal 
kidneys. (1) He cystic littermate, (2) wt cystic littermate, (3) Ho cystic littermate, (4) 
heterozygote father,  (5) heterozygote mother, (6) wt  grandfather, (7) homozygote 
grandmother, (8) normal littermate,  (9) normal littermate, (10) pure CBA, (11) pure 






5.2.5 Histological analysis of Davis organs 
To look for any abnormal organ morphology kidney, testis, liver, heart, spleen and 
thymus were dissected and histologically examined in a cohort of 24 (4 animals of 
same sex and genotype). The developmental expression of Wt1 in these tissues has 
been reported (Kreidberg et al., 1993), so an effect due to Mcr2 disruption was 
anticipated. A representative of each organ was sectioned from a wild-type, 
heterozygous and a Davis homozygous mouse. Organs were embedded in the same 
orientation and also stained in the same time in order to equalize conditions as much 
as possible. Most of the staining was done by haematoxylin and eosin (H&E) except 
in the kidney which was done by Periodic Acid Schiff (PAS) staining. All samples 
were males unless otherwise stated.  
 
Kidney histology 
Wt1 is expressed in the podocyte in the glomeruli of the adult kidney where it has a 
role in kidney function (Guo et al., 2002). For the case of the kidney PAS staining 
was used to visualise proximal and distal convoluted tubules were glycoproteins 
become visible with this staining. Proximal tubules show of pink staining within 
brush borders whereas distal tubules should not. A representative sample was 
analysed. Homozygote and wt kidneys were undistinguishable by histological 
analysis, showing that no obvious morphological kidney abnormality was associated 
with the Davis allele. All structures of the kidney were present in homozygous as 
well as in the wild-type kidney, displaying normal distribution. Within the kidney 
from the cortex (Co) to the capside (Ca) was possible to find glomeruli (G). They 
were present and appear normal, with a radial distribution surrounded by distal (D) 
and proximal (P) convoluted tubules (Figure 5.5). an example of a heterozygote 
kidney with no presence of peripheral tubules is shown  in Figure 5.5 E. Protein in the 














Figure 5.5 Histological analysis of Davis kidney. PAS stainining of sagittal sections 
in wt (A) and homozygous (B) kidney (20X) showing capsid (Ca), distal convoluted 
tubules (D); proximal convoluted tubules (P)and cortex(C). Below is shown the 
glomeruli (G) displaying the podocytes (Po) present wt (C) and homozygote (D) 
(40X). (E) Sagittal dissection of abnormal heterozygote kidney showing no presence 











As seen in the weight section (5.2.2.2), homozygous Davis testes were consistently 
found to be lighter than the testes of wt counterparts. H and E staining of a wt and 
homozygotes testes sections shown that although the size and number of the 
seminiferous tubules appeared to be the same, the distribution was not equal. 
 
However, the number sertoli cells and mature sperm did not reveal any significant 
difference. On the histology analysis gaps were found between those tubules (Figure 
5.6). No other parallel between testes pathology were discern. Although this 
genotypic dimorphism is consistent in the population, ho mice are able to generate 
offspring. So because of this mild feature we did not proceed to any further research 
about this particular subject. Sections of testes from 9-month-old mice were stained 
with Mayer’s hematoxylin (Figure 5.6).   
 
Seminiferous tubules were counted as well as the spermatozoa within those tubules. 
An arbitrary line in the middle of sagittal sections was draw in order to look at the 
number of tubules. The average of tubules in the testis for homozygous was 16.3 for 
the wt and 16.6 for the homozygote (P= 0.0869). The amount of mature sperm 
counted was also not significant between these two groups (P= 0.0611). No 
differences were noticed between wt and homozygous Davis mice which seemed to 









 Figure 5.6 Histological analysis of Davis Testis. Sagittal dissection stained with H 
& E., comparing seminiferous tubules distribution in wt (A and C) and  homozygous 
(B and D) (4X); below, wt (E) and homozygote (F) sections indicating Sertoli cells 










This organ did not statistically change in weight between genotypes. Consistent with 
this no difference in thymus morphology was found between Davis homozygotes and 
wt controls. Also no pathology was noted.  Features of the thymus such as thymic 
corpuscles medulla and cortex were indistinguishable between wt and homozygotes 
as shown in Figure 5.7.  
 
Figure 5.7 Histological analysis of Davis thymuses. (A) Sagittal sections of thymus 
from Davis wt and (B) homozygote stained with H & E (20X) showing capside (Ca), 
medulla (M) and cortex (C). 
 
Liver and spleen histology 
No observable differences were found by histological analyses of homozygous livers 
and their wt counterparts (Figure 5.8). Hepatocytes had an apparently similar 
distribution across wt and homozygous liver sections and no difference in number or 
shapes was obvious in the collected images. Heterozygous male mouse was found to 
have a sclerotic liver with apparently fat in the tissue (Figure 5.8 C).  Abnormalities 
in livers were found in 3 males and 2 females (3 wt females; 1 male heterozygote and 
1 female homozygote). The same mice with liver abnormalities also had spleen 
abnormalities. However, histological analysis of Davis homozygous and wt spleen 
did not reveal any feature exclusive to either genotype (Figure 5.8). Spleen cells did 
show common distribution between white and red pulp.  Abnormal spleens displayed 
thickened and sometimes enlarged shapes with uneven epithelium surrounding the 
external area of the organ. However as was the case for livers, these abnormalities did 




Figure 5.8 Histological analyses of Davis liver and spleen. Liver sections stained 
with H & E. (40X). Wt (A) and homozygote (B) liver sections show distribution of 
hepatocytes (H). (C) wt with apparently abnormal fat (F) content (20X). Longitudinal 
section of spleen organs stained by H & E. Wt (C), homozygote (D) and (F) 
displaying white (W) and red pulp (R) distribution and abnormal heterozygote with 







Wt1 is needed for heart normal heart development. Wt1 is expressed in the 
epicardium of the developing heart which is the external layer of tissue in the heart. 
In the homozygous Wt1 knock-out mouse model (Kriedberg et al., 1993) the failure 
of the heart has been determined to be the cause of embryonic lethality at mid-
gestation. In the weight study (see section 5.2.2.2) Davis homozygote male heart 
weight was significantly lower than wt; however this weight difference was not 
apparent in females. Sex-dependent differences were not expected for heart defect. 
Davis homozygote mouse heart has apparently undistinguishable from wt heart in 
terms of shape and distribution of cardiomyocites. No heart abnormality of pathology 
was found (Figure 5.9). 
 
      
Figure 5.9 Histological analysis of Davis hearts. Stained sections with H & E show 
epicardum (E) tissue in wt (A) and homozygote (B) sections (40X). 
 5.2.6 Body composition of Davis mice. 
The Davis weight study found that homozygotes had significantly higher weight than 
wt siblings (average of 17% higher, Section 5.2.2.2) even though, parallel increases in 
organ weight were not found. Indeed some organs of homozygous Davis mice were 
lighter were lighter than their wt siblings. Therefore, the analysis was extended to 
include a comparison of body size (area) and components such as bone, muscle and 
fat. 
 For this a new cohort of Davis mice 4 each per genotype including equal numbers of 
males and females (n=24) was analyzed at 7 months of age. Whole cadavers of Davis 
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mice were subjected to dual X-ray absorptiometry (DXA) which gives an estimate of 
fat mass, fat-free soft tissues mass and bone mass (Jabb et al.,1998; Zotti et al., 
2008).  As shown in Table 5.7 no statistically significant differences between Davis 
wt, heterozygous, homozygous were found. Therefore the increased body weight of 





Figure 5.10 Average body composition of male and female Davis mice. Graphics 
show levels of lean, BMC, BMD, fat, fat% and areas values are expressed in g/cm
2
. 











Table 5.7 Summary of P values obtained by using DXA measurements of body 









5.2.7 Davis dry weight study 
After ruling out individual organs, bone, lean, fat as contributory factors to the 
increased total body weight of Davis homozygous to wt’s, a remaining factor that 
could account for weight difference was water content which is controlled by the 
kidney. This was evaluated by comparing the weight of a mouse organ with the 
weight of the same organ after desiccation. 12 females (4 per genotype) at 7 months 
of age were used for this study. The liver was chosen for this analysis as a 
representative tissue because it is a suitable size to allow a difference in dry and wet 
weight to be measured using a fine balance.  
 
After recording fresh (wet) weight, the livers were dried in an oven until no further 
decreasing in weight occurred indicating that a totally desiccated stage had been 
reached. Comparison of the average water content of organs from each genotype 
showed that liver water content was significantly higher (Figure 5.12) in 
heterozygous and homozygous Davis mice compared with wt counterparts. This was 
indicative of water retention in the tissue associated with the Davis allele. An average 







Figure 5.11 Average percentage of fresh organ weight lost from livers after 
desiccation. Graph shows the values obtained of water in the liver after desiccation 
expressed in percentage; wt= wild type, het= heterozygous and ho=homozygous.    
 
5.2.8 Davis urine osmolarity 
The body has a complex regulatory system which balances the water intake and 
losses to maintain the osmotic equilibrium. This system involves primarily hormones 
on the kidney. Thus normal renal function is crucial to maintenance of normal plasma 
concentration. An abnormal plasma concentration is likely to be reflected by 
excretion of urine with abnormal osmolarity level as well as causing abnormal fluid 
levels in the tissues of the body.  
 
Given the significant difference in water content of Davis homozygous organs 
compared to wt, we sought further difference of altered excretory function in Davis 
homozygotes. To do this we examined urine osmolarity of 8 homozygous and wt 
female mice (n=16). Urine samples were collected and frozen after collection to 
avoid decomposition. In normal conditions urine osmolarity and concentration in the 
urine varies depending on the time lag between water and food consumption and 
sample collection. To reduce variability samples were taken on repeated occasions at 
the same time of the day having a collection of three samples per animal that were 
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pooled together. Osmolarity was measured twice per pooled sample and the average 
was recorded as the final value. 
 
The values obtained from the wild type mice fitted within normal range reported 
previously (Ma et al, 1997). This result shows that Davis
 
homozygotes had a 
significant increase in urine osmolarity compared with the wt control (P=0.0285) 
(Figure 5.13). This suggests that the abrogation of Mcr2 contributes to abnormal 
osmolarity in the urine. Thus, because the urine osmolarity is abnormally high the 
body increases due to the retention of water seen in Davis homozygous livers. Thus, 
urine osmolarity could indicate an excretory defect that could potentially explain the 
difference in total weight     
 
 
Figure 5.12 Graph showing urine osmolarity in Davis mice. Graph displays the 
result of urine osmolarity expressed in mOsm/L in Davis mutants and controls. 
Wt=wild type, ho= homozygous. A statistically significant difference was found 




5.2.9 Davis urine composition 
Abnormal salt excretion has been associated with human disease (Gutkowska et al., 
2009). For example, some types of nephrogenic diabetes insipidus are associated with 
significant natriuresis which is defined as the process of excretion of sodium in the 
urine via action of the kidneys. Previous studies have revealed an increased urinary 
sodium excretion on AQP3 protein null mice as well (Sasaki et al., 1998). The kidney 
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has a vital role in water excretion, transporting solute through the renal collecting 
duct system responsible for the final regulation of urinary sodium excretion (Kwon et 
al., 1999; 2000; Nielsen and Frokiaer, 2003).  
 
The glomerular filtration rate (GFR) is the standard measure of renal function and 
considered the best index to measure renal disease. The clearance of creatinine is 
commonly used to estimate GFR, but this method has limitations. Mice have levels of 
noncreatinine chromogens, which make it hard to interpret. Instead in the mouse GFR 
is estimated by measuring electrolyte, creatinine and urea levels. In order to elucidate 
which factors might contribute to the increased osmolarity of homozygous mice, 




, creatinine and urea. 
 
 The set of samples used in the osmolarity analysis served also to perform this 
analysis (see section 5.2.8). By comparing wt and homozygous levels trends in all of 
the readings indicate an increased concentration in homozygous compared to wt 
(Figure 5.13). However no significant differences between wt and homozygous were 





Figure 5.13 Graphics concentration of urine components in Davis mice. In 
analysis of urine components values expressed mmol/L indicate concentration levels 














5.2.10 Water ingestion by Davis mice 
A study using 28 strains of mice concludes that size is not the main factor that affects 
water ingestion (Bachmanov et al., 2002). Water consumption can be affected by 
salinity, sugar concentration, food availability, temperature, humidity, and stress of 
the environment, however all those factors were fully controlled. To measure 
drinking habits of Davis homozygous and wt mice, 6 months old mice were housed in 
separate cages provided with measured quantity of water in their usual drinking 
bottles. The cages were left untouched for 15 days to minimize water leakage from 
the drinking bottles. At the end of the experiment the final volume of water remaining 
in the bottles was measured and the differences between start and final volumes taken 
as the volume drunk by each mouse.  As a control, an empty cage was provided with 
water bottle in the same conditions. In this case if a considerable amount of liquid 
was lost, presumably through leakage.  The value obtained from the negative control 
was subtracted from the drinking values. The results of this study indicate that there 
is a statistically significant difference (P=0.0195) between the water intake of Davis 
homozygotes and their wt littermates, with homozygotes drinking more (Figure 5.14). 
On average the values obtained of water intake during the experiment account for 82 
ml in wt and 127 ml in homozygous. This is consistent with the finding of liquid 
retention in Davis homozygote organs. Further, given that this increased drinking is 
associated with more concentrated rather than more dilute, urine in Davis 
homozygous mice, compared with wt controls, suggests that an excretory abnormality 
is associated with deletion of Mcr2. In a single case it was found a Davis homozygote 
mouse with the stomach inflated and filled with water this might be a the case of an 







Figure 5.14 Measurement ingested water in Davis mice.  Graphic shows the 
amount of ml of ingested water after 15 days. A statistically significant difference 
















Figure 5.15 Davis male homozygote mouse with excessive liquid in the stomach. 

























5.2.11 Effect of altered Mcr2 on Wt1 gene 
 
5.2.11.1 Levels Wt1 and AWt1 expression in Davis 
-/-
 and Trigger 
-/-
 at embryonic 
stage. 
Wt1-AS is highly expressed at E 17.5 (see Section 4.1). At this embryonic stage we 
measured levels of expression of Wt1 promoter and Awt1. The experiment was done 
in triplicates per sample were the media gave the error bar. Three samples from 
kidney littermates were assessed using two homozygous and one wt. Levels of 
expression were highly variable in Trigger 
-/-
 and Davis 
-/- 
compared to the wt controls 
(Figure 5.16).
 
However the levels of AWt1 expression were diminished in both 
Trigger and Davis homozygous (Figure 5.17). This qPCR experiments were 
performed by Dr. Anne Hancock. 
 
 
Figure 5.16 Quantitative PCR analysis of Wt1 expression in Trigger and Davis 
kidney. Graph displaying folds of PCR product of strand specific RT-PCR. Blue bars 
indicate antisense transcription and red bars indicate sense transcription. Error bars 






Figure 5.17 Quantitative PCR analysis of expression in Trigger and Davis 
kidney. Graph displaying folds of PCR product of strand specific RT-PCR. Blue bars 
levels of Awt1 expression of Trigger and Davis mice. Error bars show the range of 




5.2.12 Effects of altered Mcr2 on WT1 protein 
 
5.2.12.1 Western blot analyses from total kidney protein 
Samples from Davis kidneys were analyzed at the day one of birth.  Wt1 was detected 
using 6FH2 anybody against Wt1.  Consistent with what we have found  by looking 
at Wt1 expression levels, no any changes of Wt1 protein were observed in Davis 
homozygous compared to the wt control. Cells expressing WT1 were used as a 
positive control (Figure 5.18).  
 
Figure 5.18 Western blot analysis of Davis kidney. Top panel shows detection of 
Wt1 using 6FH2 antibody. Panel below shows α-Tubulin that served as loading 









5.2.12.2 C-19 immunohistochemistry in Davis kidney 
 
As explained in section 1.3.2, parallel expression of WT1 sense, antisense RNA, and 
also protein was observed in tissues from human foetal kidneys (Moorwood et al., 
1998). Kidney sections form 7 months old homozygous and wt were analyzed in 
order to detect WT1 protein in the Davis glomeruli. This was performed by using C-
19 antibody against Wt1. After performing this experiment not any discernable 
differences between Davis homozygous and wt were observed (Figure 5.19). 
 
 
Figure 5.19 Detection of Wt1 by immnunohystochemistry in Davis kidney.  
Immunoperoxidase staining using C-19 antibody against Wt1 on kidney from wax 
section slides counterstained with methyl-green from 7 months kidney sections 







 Consistent with RT-PCR data shown in Section 4.2.1.3 indicating that the 
transcriptional terminator sequence was inefficient on the Trigger strain, Trigger 
homozygote mice did not show any significant phenotype by analysis of body (organ 
weight, proteinurea), or effect upon Wt1 levels in the kidney (5.11). Therefore, we 
have not observed any phenotype resulting from loss of Mcr2 RNA. Davis mouse 
histology shows that Mcr2 is not necessary for completing the normal development of  
 
the kidney as well as the other vital organs elsewhere than testis (Section 5.2.5). 
Probably due to defects in testis might be explained that heterozygous and 
homozygous intercrosses had a reduced number of pups born per litter (Table 5.3). 
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Also, nearly half of the expected numbers of Davis homozygous pups expected from 
a heterozygous intercross born which might indicate embryonic lethal. However after 
birth Davis mutants are viable and fertile. 
  
During the time of study Davis and Trigger mice reached more than a year of age 
without presenting any health issues except from the case of the mouse with liquid in 
the stomach (Figure 5.15). The lack of obvious or dramatic phenotype made this 
study difficult since any differences between these genotypes were subtle. 
Pathologies found were independent of the genotype e.g. cystic kidneys, enlarged 
spleens and sclerotic livers, the latter two frequently in conjunction with each other. 
In the case of the case of cystic kidneys, we were able to detect proteinurea but again 
those cases did not correspond to a particular mutant genotype (Section 5.2.3). Davis 
brain and heart showed a significant difference in weight but only for males which 
proved not to be consistent as it would be expected to be found in both. For the case 
of the brain the deviation would be unlikely to be related with Mcr2 bias Wt1 given 
that the later is only expressed in a prominently small part of the brain called 
postrema within the fourth ventricle. 
 
So any brain phenotype would be expected to be independent of Wt1. In the case of 
the testis, there was a clear difference in weight between all 3 genotypes (see section 
5.2.2.2) may be explained by an aberrant distribution on the seminiferous tubules. 
One of the most striking phenotypes found in this study was that both Davis 
heterozygous and homozygous were heavier of 17% on average, compared to wt 
controls (Section 5.2.2.2). These heavier animals were not longer and did not have 
increased area or increased individual organ weights (Section 5.2.6). However Davis 
homozygote mice had increased levels of water in the tissue (Section 5.2.7). DXA 
data, although not statistically significant shoes a tendency for fat to be more 
abundant in wt mice and for muscle to be more abundant in homozygote mice. Indeed 
water in the muscle is present in patients with edema (McMahon et al., 2010), which 
might indicate the bigger muscle volume in Davis homozygous. Urine osmolarity and 
concentration measurements (Section 5.2.8) did suggest excretory defect that indicate 
a functional abnormality in the kidney possibly linked to the abrogation of Mcr2. This 
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maybe a key piece of evidence to indicate a functional deficiency in the kidney 
despite the fact that proteinurea was not present in Davis homozygotes and kidney 
histology appear normal. Although electrolytes in the urine shown insignificant 
deviation from the controls however the tendency in all of them was to be more 
concentrated in homozygous mouse urine. Also the water intake results may indicate 
that Davis homozygous mice should not been dehydrated since they drink more that 
the wt mice. Nevertheless their urine is, surprisingly, not more dilute. This suggests 
an excretory defect.  
 
 Finally to elucidate if Mcr2 has any effect on Wt1 expression by 
immunohistochemistry and western blot indicates that there is no correlation between 
presence of Mcr2 and Wt1 protein.  As reviewed in section 1.1.9.1.1 has been 
reported that changes in Wt1 levels are lethal due to incomplete development 
(Kreidberg et al., 1993), in contrast our Davis Mcr2 mutant display more subtle 
phenotypes which is consistent with the fact that no changes in levels of Wt1 protein 


























































Mcr2 did not have the role that we expected in the kidney in terms of affecting 
Wt1 levels. Because we found no changes in levels of Wt1 RNA or protein the role of 
Mcr2 as an enhancer of Wt1 could not be proved. However, we found other 
interesting features that suggest a role Mcr2 function in the mouse. In this Chapter an 
overview will be presented discussing what the results might suggest. 
 
 
Initially, we considered intrinsic features of the Mcr2 sequence to help explain its 
potential functional roles. Due to shortness of its longest ORF was considered more 
likely to be a DNA regulatory element or as a part of a ncRNAs. This is not 
surprising taking in account that it has been estimated that most of the mammalian 
genome does not code for protein. Although the study of ncRNA is a rising field in 
the literature there are very few examples with ascribed roles and exact mechanisms 
of action in development or organ function remain speculative (Dennis, 2002; 
Brosius, 2005; Struhl, 2007; Pauler et al., 2007). Many expressed DNA sequences in 
the genome without protein coding capacity have an active function as RNA 
elements, with diverse biological roles (Table 1.4). New classes of ncRNA are still 
being described as in the case of RNA enhancers. This recently discovered group of 
ncRNAs can be defined as DNA sequences that bind the transcriptional co-activator 
p300/CBP, that bind histone H3 monomethylated at lysine 4, both located distally 
from transcriptional start sites (Heintzman et al., 2007, Visel et al., 2009). 
Interestingly as mentioned in Section 3.2.2.2 we have found a MAR that might 
involve attachment to histones. In a recent report Bollig et al., (2009) propose that at 
least part of the Mcr2 sequence acts as an eRNA which is responsive to retinoic acid 
in zebrafish. This retinoic acid responsive element controls wt1a expression in the 
zebrafish pronephros. As mentioned in Section 3.5 part of the sequence of Mcr2 has 
this retinoic acid element. Using PIPLOT (Figure 3.8) we found wide conservation of 
Mcr2 sequence in vertebrates which can be divided in two contiguous domains. One 
domain is present in most vertebrates (except from the chicken). Mouse Mcr2 
conservation progressively extends its length of conservation from Medaka to X. 
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Tropicalis where remains well conserved in all non-fish vertebrates making a “bell 
curve” of conservation across non-fish species (Figure 3.9). Tacking in to account 
that Mcr2 is expressed in the kidney may lead to the following hypothesis: The fact 
that this novel region of conservation is present exclusively among the non-fish 
animals analyzed suggests that it may confer some kidney function which is distinct 
from that required in aquatic vertebrates which have a different excretory system. We 
also found a sequence exclusively conserved in mammals as in the case of Mcr1 
suggesting that they may function in mammal-specific tissues.  
 
By random priming we found Mcr2 expression in Trigger 
-/- 
neonate kidney cDNA 
despite the presence of a transcriptional terminator sequence inserted between Mcr2 
and Wt1 exon1. This opened three possibilities: one that sense expression might 
account for transcription of Mcr2 given that the TTS is further downstream WT1 
sense exons. The second scenario was having only antisense transcription but with 
liking of the construct designed to truncate Mcr2 transcription. The third option was 
to be bidirectionally expressed. To elucidate the direction of expression through Mcr2 
cDNA was performed using strand-specific oligo primed RNA. In this case, 
expression was exclusively found in the antisense orientation, confirming the TTS 
sequence was not stopping Mcr2 expression in Trigger 
-/- 
neonate kidney cDNA. In a 
previous report by Dalloso and et al., (2007) the EST AK5089 was also found to be 
exclusively expressed in the antisense orientation by RPA. This evidence suggested 
that the orientation of transcription might be the same for Mcr2 due to the fact that 
they are both in the same locus relatively close to each other. Using a third approach, 
a qPCR reaction gave similar results, negligible sense expression. We can state that 
poor efficiency of premature transcriptional termination TTS was in the antisense 
orientation. Therefore we could conclude that the poor efficiency of TTS sequence 




Although the absence of Mcr2 in the knockout model could not correlate with up or 
down regulation of Wt1 sense, we were able to detect change in levels of Awt1. Davis 
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and surprisingly also Trigger homozygous mutant appear to have reduced Awt1 
levels of expression (Section 5.2.11.1). As seen in Section 1.3.2 levels of Wt1-AS are 
able to modulate Wt1 sense. In the future it would be necessary to prove this 
experimentally by looking Awt1 protein levels.  
 
Other examples have been described to display “concordant regulation”. In some 
cases NATs augment the level of sense RNA or protein levels of other genes. Some 
examples as aHIFI (Faghihi, 2008), asEPO-R (Zahng, 2008) and Zeb-AS (Beltran, 
2006). This could probably also be the case for Mcr2 and Awt1. Also if this result is 
confirmed might indicate that lower levels o Awt1 do not affect Wt1 expression. In 
addition to this in human we have spotted MCR2 to be part of WT1-AS (Figure 3.3). 
Also in human both AWT1 and WT1-AS have been proved to originate in intron 1 
possibly its mechanism of transcription might be structurally linked due to the fact 
that abrogation of Mcr2 caused reduced levels of Awt1.  
 
Loss of imprinting has been detected in WT1 antisense transcripts in WT (Malik, et 
al., 2000, Dalloso, et al., 2004) and ovarian carcinoma (Kaneushi, et al., 2005). 
Because WT1-AS is imprinted in the normal pediatric kidney, therefore we looked at 
the pediatric mouse kidney and other stages (Figure 4.13). However, imprinted 
expression was not seen in the mouse. In a separate approach strain specific genomic 
polymorphism was found expressed but also could not corroborate any evidence of 
imprinting. This was done by Dr. Km Moorwood using kidney RNA from embryos 
(E17.5), juvenile (P2, 3) and adults (P19, 20). Nevertheless evidence of Mcr2 
imprinting might depend on examining different stages than the ones analyzed. 
 
Davis and Trigger mutant mice were examined for phenotypic changes that could 
indicate a function for Mcr2. At the histological level aberrant organization of 
seminiferous tubules was observed in Davis homozygous testes, however no  
differences in amount of the seminiferous tubules and number of mature sperm was 
found. Infertility has been reported in number mouse knockout models, as in the case 
of mice lacking the Cstf2t gene, a paralog of the 64,000 Mr subunit of the cleavage 
stimulation factor (CstF-64). In this model male infertility was observed, however, 
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this did not relate to changes in weight that were found between mutants and wt mice 
(Das et al., 2001). In a conditional Wt1 knockout mouse Gao et al., (2006), reported 
disruption of seminiferous tubules. However, this was not the same defect seen in 
Davis homozygous mutant mice.  
Statistical analyses of 257 Davis mutant mice a deviation was seen in the expected 
number of homozygous mutants. This was the most significant phenotype observed in 
the present study, indicating lethality in Davis genetically modified mice. Viability 
was lost in a significant proportion of homozygous and heterozygous embryos in 
relation to wild type littermates. This might also be linked with abnormal liquid 
homeostasis which may have perturbed viability of the mutant embryos. In a similar 
analysis of genotype number for the Trigger strain no significant result was observed, 
implying that the effect seen in the Davis line has been something directly associated 
with mcr2 DNA function. However it was not possible to uncover the cause of loss 
viability associated with Trigger mutant genotypes.  
 
Because of the normal variability in weight between individual mice a study of the 
association of body weight with genotype required a large cohort of mice. Analyzing 
total body weight in 7 month old mice gave the first clue of body proportion 
abnormality in the Davis strain. The Davis homozygotes or heterozygotes were 17% 
heavier compared to wild type litter mates. None of the organs where Wt1 is shown 
to be expressed were found to be increased in weight and in fact, some of the, some 
were decreased, as in testes and heart. The next step was to define if this was due to 
animal size. After measuring body length and bone mineral content, density (BMC, 
BMD) it was clear that these variables were not altered between Davis homozygote 
mutant and wild type animals. Also, no difference was detected by in fat pad weight 
and actual fat content measured by DXA, perhaps due to a small number of animals 
analyzed. We only analyzed 4 males and females per each genotype (n=24). The 
weight component remaining after considering these analyses was the amount of 
water in the tissue. Liquid retention was commonly has an effect on body weight in 
cases of edema (Manley et al., 2000). A crude diagnostic test for edema simply 
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involves pressing the abdomen, and observing whether if recovers its normal shape. 
Using this test edema was not evident.   
 
It was possible to find a difference when measuring the water content of the liver 
representative organ from mutant and wild type Davis animal, comparing liver 
weights pre- and post- desiccation. After measuring dried livers the Davis 
homozygote liver was found to retain on average 5.6% more water than their wt 
counterparts. If the deregulation of liquid homeostasis was the reason for this 
phenotype we might expect to obtain significantly different values for urine 
osmolarity between Davis homozygotes mutants and wild-type siblings. 
Measurements of liquid retention in the liver, urine osmolarity and total body weight 
in small cohorts of mice suggested that indeed this was the case. 
  
 
This suggested that urine in the Davis homozygous mutants was more concentrated 
than in wt possibly because of kidney dysfunction. However no differences in 
morphology were seen upon histological staining of kidney tissue sections with PAS. 
Also, although proteinurea was not observable on polyacrylamide gels the 
presumptive kidney defect might have been too subtle to be resolved by these 
methods. The most common method for measuring functional kidney efficiency is by 
linking metabolite concentration with creatinine levels, a compound that generally 
has a relatively constant clearance rate. However, some studies have shown 
variability even no related with of water intake and diet (Chilcott et al., 1985). 
However we could not detect evidence of kidney malfunction by measuring levels of 
GFR. This may be because there are other chromogens that might mask the actual 
creatinine in the urine making measurement redundant. Possibly a better way to 
measure this might be supplying intravenous doses of creatinine and subsequently 





 and urea) readings showed that the urine concentration 
tended to be higher in Davis homozygous than in wt siblings. Although this might 
change if the sample size were increased (for example in the case of Na
+
), it can be 




However it is worthwhile to taking into account that the observed differences are very 
mild and did not provoke a significant level of mortality in Davis homozygous 
mutants to expect worse effects at older ages. In just a single case a Davis 
-/-
 mouse 
was found with water retained in an enlarged stomach in an 8 month old mouse 
(Figure 5.15). Possibly more cases would have appeared if had been possible to study 
an older Davis. Davis 
-/-
 not only had higher urine osmolarity but also appeared to 
drink more water than controls, therefore, behaving as if they were dehydrated.  
 
Due to abnormal concentration of the urine, liquid retention within tissues and 
heavier weight in total body it appears that Davis homozygous mutant mice could 
have excretory defects. These mice drink more water but could possibly control high 
osmolarity in tissues through hormonal regulation (Figure 6.1). Liquid retention 
might have been  by measuring the total amount of urine produced, however this is 
difficult to measure accurately due to small sample volumes.  
 
 
Figure 6.1 Hypothetical model of mechanisms in water homeostasis in Davis + 
and – Mcr2. Left panel indicates how water loss is compensate by thirst and 
hormonal and salt components (Arginine vasopressin and Na). On the Right panel 
exemplifies how loss of Mcr2 produces less water reabsorption and possible augment 




Also if would have been of interest to measure the urine concentration with 24 hours 
of water depravation to see the effect on ADH levels in wt control and also 
homozygous counterparts Also other peptides that are expressed in the membrane 
should be looked at as for example aquaporins which are involved in liquid 
homeostasis in the kidney (Nielsen et al., 2002). However, mice deficient with in 
aquaporins exhibited proteinurea and other abnormal phenotypes from those seen in 
Davis mutant mice (reviewed by Verkman and Yang, 2002). 
 
Furthermore lethality due to edema has been detected in mice at E14.5 following 
disruption of the gene encoding Peptidylglycine alpha-amidating monooxigenase 
(PAM) which  catalyzes the COOH-terminal amidation of peptide hormones (Czysyk 
et al., 2006). Homozygous mutants die in utero between E14.5 and E15.5 with severe 
edema. In a different mouse model Yang, et al., (2005) found embryonic lethality of 
homozygous knockout Dicer
ex1/2
 mice occurred at E14.5. As described in Section 
1.2.1.2 dicer is protein that produces short interfering RNAs (siRNAs) out of long 
double-stranded RNAs during RNA interference. Yang et al., (2005) postulate that 
Dicer might exerts its function on mouse embryonic angiogenesis possibly by 
processing of microRNAs. Interestingly, this embryonic stage is similar to the one 
that Czyzyk et al., (2006) detected. This might suggest E11.5 to look at edema in 
Davis transgenic mice due to the fact that potential lethality due to reduced levels 
heterozygous and homozygous animals were obtained. Although some homozygous 
and heterozygous were born, lethality might be explained as a matter of incomplete 
penetrance by this means that in some individuals the phenotype possibly as aberrant 
water homeostasis occurs. 
 
The ability to detect a relevant function for Mcr2 was not a straight forward process. 
It would be that a Mcr2 ncRNA causes a subtle phenotype that would be missed in 
further superficial genetic screens, but might still be strongly disadvantageous in the 
wild. Similarly, modifications in ultraconserved enhancers produced no discernable 
abnormality (Poulin et al., 2005). In this case, Poulin et al (2005) made knock-out  
mice with a deletion of an ultraconserved enhancer element named Dc2. This did not 
show any phenotypic observable differences. Authors previously have stipulated that 
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ncRNAs may give a milder phenotypic effect and more on the side of regulatory 
defects not been primarily source of protein “building” cell components (Mattick and 
Makuning, 2006). We do not know if the lack of more obvious phenotype was due to 
the fact the Davis mutation was studied in a mixed genetic background. For this 
reason at the moment Davis mouse model is being backcrossed to a different strain 
background. Initial screening performed by Dr. Kim Moorwood and Dr. Joanne 
Stewart-Cox has confirmed the difference in weight observed in Davis mutant mice 
described in the present study. 
 
Initially we thought that with such high degree of sequence conservation, suggesting 
severe evolutionary constraint, would predict a lack of tolerance to mutation on Mcr2 
function. Although still far from elucidating the exact mechanism, this work indicates 
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